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  I 
Abstract 
Norovirus is one of the most common agents associated with acute gastroenteritis. Despite its 
discovery 50 years ago, as of now there is no cure or treatment, and knowledge about the 
infection cycle of norovirus is still limited. 
Using cryo-electron microscopy, we determined the structure of different clinically relevant 
GII.4 genotype virus like particles (VLPs), and an engineered version of GII.4 that is in use as 
vaccine candidate. Unexpectedly, we found that these empty particles were composed of 240 
copies of the capsid protein instead of the typical 180. We could show that this conformation 
is only adopted by GII.4 VLPs, and that norovirus virions most likely assemble into T=3 
icosahedral particles. Conversely, the capsid protein of GII.17, another genotype that has 
become clinically relevant in the last years, assembled into the characteristic T=3 icosahedral 
capsid. 
Moreover, we characterized a panel of GII.4 specific Nanobodies and determined their 
binding sites and influence on particle integrity using cryo-EM. Several Nanobodies had a 
strong inhibition potential in surrogate assays against GII.4 VLPs, but cross-reactivity to other 
genotypes was low. Structures of Nanobody/VLP complexes revealed that the Nanobodies 
bound to a similar site on the lower part of the P domain. The structures showed that the 
P domains were flexibly rotated to distinct positions, but generally particle conformation 
remained intact.  
Likewise, we worked on three GI.1 specific Nanobodies and found two Nanobodies with high 
inhibition potential. Importantly, we found that combination of Nanobody with the human 
milk oligosaccharide 2’FL was able to synergistically improve attachment inhibition of VLPs 
to histo-blood group antigens, suggesting the use of combinational treatment against 
norovirus infection.  
In another study, we found that murine norovirus, which is commonly used as a model system 
for human norovirus, was undergoing severe structural rearrangements after incubation with 
ions, such as Mg2+ and Ca2+. The normally extended P domains were collapsing onto the shell, 
accompanied by a rotational movement. Most likely, this movement is important to facilitate 
infection. Importantly, we also characterized a Nanobody that was binding to the lower part of 
the P domain, effectively inhibiting MNV infection by blocking this movement.  
  II 
Taken together, these results gives insight on general norovirus structure and how noroviruses 
are interacting with antivirals and cofactors. Our research broadens the understanding of 
norovirus-internal differences and capsid flexibilities, and can ultimately aid in the 
development of a more effective treatment for norovirus infections. 
  
  III 
Aims and objectives 
Our main aim was to broaden the understanding of norovirus on a structural level. Here we 
focused on different targets:  
 
1) Comparison of structures from different genotypes, based on intact VLPs. 
 
2) Determine the structure of norovirus VLPs in complex with potential antivirals to 
characterize the influence the binding in context of the intact particle. 
 
3) Solve the structure of norovirus capsids in complex with potential binding factors to 
shed light on how noroviruses are interacting with host cells. 
 
  
  IV 
Zusammenfassung 
Norovirus-Infektionen sind eine der häufigsten Ursachen für akute Gastroenteritis. Trotz der 
Entdeckung des Norovirus vor fast 50 Jahren, gibt es bisher keine zugelassenen Impfungen 
oder Medikamente, und viele Fragen zum Infektionszyklus des Norovirus sind noch offen.  
Mittels Kryo-Elektronenmikroskopie konnten wir die Struktur virus-ähnlicher Partikel des 
klinisch relevanten Stammes GII.4, sowie einer gentechnisch veränderten Variante (GII.4c) 
die derzeit als Impfstoffkandidat in klinischen Studien getestet wird, bestimmen. 
Überraschenderweise wurde hierbei festgestellt, dass die Partikel aus 240 Untereinheiten des 
Kapsidproteins VP1 bestanden, die Kapside wiesen somit eine T=4 ikosaedrische Symmetrie 
auf. Diese Morphologie wiederspricht der typischen Norovirus-Struktur, die aus nur 180 
Untereinheiten assembliert und damit T=3 Symmetrie aufweist. Wir konnten zeigen, dass 
diese vergrößerte Struktur nur in Isolaten des GII.4 Stammes vorkommt und über einen 
weiten Zeitraum hinweg konserviert ist. Im Gegensatz dazu deuteten Versuche mit intakten 
GII.4 Viren darauf hin, dass diese in ein T=3 ikosaedrisches Kapsid assemblieren. 
Weiterhin untersuchten wir Viruspartikel des GII.17 Genotyps, der in den letzten Jahren 
klinische Relevanz entwickelte. Hierbei fanden wir, dass dessen Kapsidprotein in Partikel mit 
der Norovirus-typischen T=3 ikosaedrischen Symmetrie assemblierte.  
In einer weiteren Studie analysierten wir GI.1 spezifische konventionelle Antikörper sowie 
Einzeldomänenantikörper (Nanokörper). Interessanterweise konnten wir zeigen, dass eine 
Kombination aus einem inhibierenden Nanokörper und dem humanen Milchzucker 
2’Fukosyllaktose synergistisch inhibierend wirkte. Dies könnte einen neuartigen 
Therapieansatz gegen Norovirus darstellen. 
In einer weiteren Studie charakterisierten wir GII.4 spezifische Nanokörper. Viele der 
getesteten Nanokörper waren in der Lage, die Bindung von Viruspartikeln an 
Histo-Blutgruppenantigene zu unterbinden, jedoch war die Kreuzreaktivität zu anderen 
Genotypen nur gering. Mittels Kryo-Elektronenmikroskopie wurde die Struktur von mehreren 
Nanokörpern im Komplex mit GII.4 Kapsiden gelöst, um deren Bindestelle zu bestimmen und 
den Einfluss der Bindung auf das Kapsid zu untersuchen. Interessanterweise banden alle 
Nanokörper an die untere Seite der P Domäne, trotz verschiedener Kreuzreaktivitäten. 
Weiterhin zeigten die Strukturen, dass die Affinität der Nanokörper stark genug ist, um die 
P Domäne in verschiedene Positionen zu bringen, die die volle Belegung aller Bindestellen 
erlaubten.  
  V 
Das fünfte Kapitel beschäftigt sich mit strukturellen Variationen des murinen Norovirus, 
welches als Modellsystem für das humane Norovirus genutzt wird. Wurden diese Viren mit 
Kationen inkubiert, kollabierte die normalerweise gestreckte Verbindungsregion zwischen P- 
und S Domäne. Es gibt Hinweise dass diese Konformationsänderung notwendig ist, um eine 
effiziente Infektion zu ermöglichen. Weiterhin konnten wir einen Nanokörper identifizieren, 
der an der unteren Seite der P Domäne band und somit eine Infektion in vitro verhindern 
konnte. Unsere Ergebnisse deuten darauf hin, dass die Bindung des Nanokörpers den Kollaps 
der P Domäne verhindert, was eine Infektion unterdrückt.  
Allgemein tragen die Ergebnisse dieser Studien dazu bei, strukturelle Variationen in der 
Norovirus Familie aufzuzeigen. Variationen können durch die Unterschiede zwischen den 
Stämmen oder auch durch die Interaktionen mit Bindungsfaktoren oder antiviralen Molekülen 
auftreten. Strukturelle Modifikationen des Kapsids innerhalb der Norovirus-Familie wurden 
bisher nur wenig untersucht; Informationen über Unterschiede und infektionsrelevante 
Konformationsänderungen können daher dazu beitragen, das Wissen über Norovirus-
Infektionen zu erweitern und letztendlich effektive Prophylaxe- oder Behandlungsstrategien 
gegen Norovirus-Infektionen zu entwickeln. 
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1. Introduction 
1.1. Norovirus pathogenicity and symptoms  
Noroviruses are non-enveloped viruses belonging to the Caliciviridae family that are the 
major cause of non-bacterial gastroenteritis outbreaks. Norovirus was first described after an 
outbreak in a school in Norwalk, Ohio in 1968 (1) and identified in 1972 (83). Norovirus is 
transmitted mainly through the fecal-oral route. Environmental transmissions also occur, via 
contaminated food, water or surfaces (4, 37, 215). Following a short incubation, the infection 
causes nausea, severe diarrhea, vomiting or fever (1). The illness can affect all age groups but 
is usually self-limiting, with symptoms resolving within three to five days (125). 
Nevertheless, norovirus infections are a severe threat for the young, elderly and 
immunocompromised. Moreover, it has been shown that patients can shed virions for more 
than two months after infection (4), and also asymptomatically infected individuals can shed 
virions (156). The virus is highly contagious, with only a few particles (<100) needed to cause 
the disease (205). Combined with its remarkable environmental stability, this makes the virus 
challenging to control, particularly in confined environments such as hospitals, nursing homes 
and cruise ships (138). Approximately 20% of all reported gastroenteritis cases are caused by 
norovirus (10). With 200,000 deaths per year, mainly due to complications caused by 
dehydration and malnutrition, human norovirus-associated infections are recognized as the 
most common cause of death from foodborne gastroenteritis (8, 32, 155). 
 
1.2. Genome organization and variability within the Caliciviridae 
Next to Norovirus, the Caliciviridae family contains 10 other genera that can infect a wide 
range of different species. Mammals can be infected by seven different genera, namely 
Sapovirus, Lagovirus, Vesivirus, Nebovirus Valovirus, Recovirus and Norovirus (217). 
Norovirus and Sapovirus are the only genera known to infect humans and cause outbreaks of 
acute gastroenteritis (149). Other genera have been shown to infect fish (Minovirus and 
Salovirus) or bird species (Nacovirus and Bavorirus). 
The most studied non-human calicivirus is the murine norovirus (MNV). MNV was 
discovered in 2003 (85) and since then several genotypes have been described. MNV is 
classified in the Norovirus genus and shares several characteristics with human noroviruses, 
i.e. fecal-oral transmission; and certain strains caused mild diarrhea in mice (143). As a 
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pathogen, MNV has been detected in various research institutions and is one of the most 
prevalent viruses in mouse facilities (75, 142). One of the major differences between mouse 
and human norovirus is the genetic variability. MNV are more genetically stable than human 
noroviruses, with all genotypes segregated into a single genogroup (206). Due to the 
availability of well-established tissue culture and reverse genetics systems, MNV has become 
the main model system to study norovirus infection (223, 224). 
Caliciviridae have a linear, single stranded positive sensed RNA genome of 7.3-8.5 kb with a 
5’ VPg (genome linked viral protein) cap and a polyadenylated tail at the 3’ end (59). 
 
Figure 1-1 | Schematic representation of the norovirus genome. The genome is connected to VPg at the 
5’ end, and is polyadenylated at the 3’ end. Usually, caliciviruses have 3 ORFs: ORF1 encodes six non-structural 
proteins as a polyprotein that is post-translationally cleaved. ORF2 and ORF3 encode for the major and minor 
capsid protein, respectively, termed VP1 and VP2.  
 
The calicivirus genome usually contains three open reading frames (ORFs), designated as 
ORF1-3 (Figure 1-1). MNV contains an additional ORF4, which encodes for a virulence 
factor (137). ORF1 encodes for a polyprotein that is post-translationally cleaved into six 
nonstructural proteins [p48, NTPase, p22, VPg, 3C-like protease (3CLpro) and RNA 
dependent RNA polymerase (RdRp)] (70). ORF2 encodes the major capsid protein VP1 that 
forms the capsid and ORF3 encodes the minor capsid protein VP2. VP2 is expressed in 
substoichiometric proportions of ~2-8 molecules per virion. So far, the role of VP2 has not 
been fully defined, but there is evidence for its involvement in capsid assembly and genome 
encapsidation (218). Moreover, studies suggested that the presence of VP2 enhances capsid 
stability and homogeneity in size (12), and in feline calicivirus (FCV), presence of VP2 was 
necessary to establish infection (32, 193). 
Noroviruses undergo a high degree of genetic drift and new strains are emerging every other 
year (187). Currently, the Norovirus genus is divided into seven genogroups. Noroviruses are 
further classified into different genogroups and based on their capsid protein and polymerase 
sequence. To increase its genetic diversity, norovirus is known to recombine genetic segments 
from different genotypes and genogroups (47, 126). 
Genogroup I (GI), GII and GIV can cause infections in humans. GI is only contagious to 
humans, but GII and GIV comprise genotypes that can also infect cats, dogs and pigs (216) 
(Figure 1-2). 
ORF 1 ORF 2 ORF 3 VPg 
p48  NTPase VPg Pro VP1 VP2 RdRP p22 
5’  3’  AAA 
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Figure 1-2 | Phylogenetic tree of Norovirus, based on the VP1 sequence. Most genogroups target distinct 
hosts, except GII and GIV, which target humans as well as pigs, cats and dogs, respectively. Figure adapted from 
(34). 
 
Genogroup II is the most predominant group of noroviruses and is responsible for most 
reported cases all over the world. Within this genogroup, GII genotype 4 (GII.4) has caused 
multiple epidemics and therefore has been recognized as the most prevalent and clinically 
important genotype (42, 165). One reason for the predominance of this genotype could be the 
high genetic diversity of GII noroviruses, and in particular GII.4, that evolve much more 
rapidly than GI noroviruses, which exhibit a comparably stable genome (154). However, 
another GII genotype, GII.17, was found to cause major outbreaks, in mainly Asian countries 
(135, 151). Although GII.17 has already been discovered in 1978 (164), only in the last years 
this genotype has become prevalent. A single amino acid substitution permitted GII.17 
variants to bind to histo-blood group antigens (HBGAs), which might have contributed to its 
high infectivity today (188). Moreover, one study suggested that the number of mutations in 
the GII.17 capsid gene per site and year was one order of magnitude higher than in other 
strains, which could support their fast emergence and spread (23). Recently, GII.17 outbreaks 
have been reported in regions outside Asia and epidemiologists speculate that the GII.17 
genotype could become more predominant than GII.4 in the future (36, 146). 
 
1.3. Structural organization of caliciviruses 
Several structures of Caliciviridae members have been solved using X-ray crystallography 
and cryo-EM (13, 24, 31, 69, 162). These studies revealed a common overall architecture of 
the capsid. In general, calicivirus capsids are composed of 180 copies of the ~58 kDa major 
capsid protein VP1, and exhibit T=3 icosahedral symmetry. 
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Figure 1-3 | Ribbon model of GI.1 VP1, colored by domains. The N-terminus (aa 1-49) is colored green, the 
S domain (aa 20-225) is colored in blue, and the P domain, separated in P1 (aa 226-279 and 407-520) and P2 (aa 
280-406) is colored in red and yellow, respectively. 
 
VP1 can be divided into two different domains, a shell (S) domain and a protruding (P) 
domain (162) (Figure 1-3). The S domain is the N-terminal part of the protein (aa 1-225 in 
GI.1 numbering) and forms a continuous scaffold surrounding the RNA genome (129). The 
S domain is relatively rigid and exhibits the lowest sequence variability between the different 
genotypes. Structurally, the S domain adopts an eight-stranded β-barrel fold. It is connected to 
the P domain by a flexible hinge region that is typically 12-14 amino acids in size. In the 
assembled capsid, the P domain is the outermost part of VP1, forming dimeric, arch-like 
protrusions (Figure 1-4). These characterize the typical norovirus shape and are even visible 
in negative stain EM images (84). The protrusions are arranged in a symmetrical manner on 
the capsid, giving the impression of 32 cup-shaped depressions that gave the virus family their 
name (calyx, lat.: cup) (62). The P domain can be further subdivided into the P1 and P2 
subdomains. P1 is the lower part of the P domain, and P2 is an insertion into P1 and 
constitutes the outermost part of the capsid that contains cofactor and receptor binding sites 
(19, 21, 29, 66, 90). Most amino acid variations are occurring in this surface exposed 
subdomain under the pressure of herd immunity, which contributes to the high antigenic 
variability of noroviruses. The general fold of the P domains is conserved among the 
Caliciviridae and is unique for this virus family (162). The P1 domain forms three β-strands 
at the N-terminal part, followed by an antiparallel four-stranded β-sheet, and a single α-helix. 
The P2 domain is formed by a β-barrel composed of six antiparallel β-strands. These are 
connected by loops that are varying in size between the different genotypes. Isolated 
S	 P1	 P2	 P1	N
1-49 20-225 226-279 280-406 407-520 
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P domains can be expressed in E. coli, where they retain biological functions, such as binding 
to HBGAs (199). 
To adopt T=3 icosahedral symmetry, VP1 forms three quasiequivalent conformers that are 
termed A, B and C. These give rise to two different kinds of dimers, A/B and C/C. 60 A/B 
dimers are located at the quasi two-fold icosahedral symmetry axes, whereas the C subunits 
assemble into 30 C/C dimers, positioned at the strict two-fold axes. Usually, the S domains of 
the A/B dimer are bent, whereas the S domains of the C/C dimer are in a flat conformation. 
This difference in packing is commonly observed in other T=3 viruses and is thought to 
enable the virus to form a contiguously closed shell. 
 
Figure 1-4 | Model of the calicivirus structure, using the example of norovirus GI.1. The major capsid 
protein VP1 dimerizes, which leads to the formation of the typical arch like structures. 90 dimers assemble into 
an intact T=3 icosahedral capsid. The figure was generated from the crystal structure of the GI.1 VLP (1IHM). 
 
Remarkably, there is evidence that this T=3 icosahedral form is not the only conformation in 
which the virus capsid can exist. In different studies, smaller VLPs have been reported, 
presumably of T=1 icosahedral symmetry, and composed of only 60 VP1 copies. Such 
particles have been observed in human stool samples (202), as well as in a recently developed 
enteroid cell culture system for norovirus propagation (49). 
Despite the similarity in the general structure, there are still several differences observable 
between structures of different calicivirus genotypes (Figure 1-5). The first high-resolution 
structure of a human norovirus VLP, GI.1, was solved in 1999 (162). In this model, the hinge 
region formed a loop and the P domain was located in close vicinity to the S domain. In 
contrast, the P domains of GII.10 VLPs are rotated in respect to the GI.1 P domain, and 
floating 15 Å over the shell, raised by an extended hinge region (69). Elevated P domains 
appear to be common in caliciviruses, as MNV, FCV and rabbit hemorrhagic disease virus 
(RHDV) share this conformational arrangement (86, 87). 
x2 x90 
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Figure 1-5 | Capsid structure of GI.1 (left) and GII.10 (right). The P domains (dark blue) of GI.1 are lowered 
onto the shell (turquoise), whereas the GII.10 P domain dimers (blue) are floating above the shell. The figures of 
the particles were generated from the crystal structure of the GI.1 VLP (PDB: 1IHM) and the cryo-EM structure 
of the GII.10 VLP (EMDB-5374). 
 
Recently it has been shown that MNV P domains are structurally rearranging from the 
elevated form to a collapsed form after incubation with bile acid, a binding cofactor known to 
enable efficient infection (183). This suggests that the raised and lowered conformations 
could be interchangeable and are not characteristic features for certain genogroups. 
Nevertheless, it is yet undetermined why this collapse is crucial for infection. Moreover, 
structural information on human noroviruses is still scarce and it is not known, whether these 
conformational changes are occurring in human norovirus as well, or if this is a specific 
feature of MNV. 
 
1.4. Norovirus infection cycle  
So far, not all steps in the norovirus cycle of infection have been elucidated (Figure 1-6). As 
only recently a human norovirus cell culture system has been developed (49), most studies on 
the life cycle have been done on related surrogate systems, such as MNV or FCV. What is 
known, is that the virus uses HBGAs and bile acids as cofactors for attachment (49, 200). Bile 
salts are cholesterol derivates that are produced in the liver and secreted into the 
gastrointestinal tract. They are involved in regulation of cellular metabolism, maintenance of 
intestinal homeostasis or facilitation of lipid absorption (27). For several caliciviruses [MNV 
(150), FCV (128) and Hom-1 Calicivirus (194)], proteinaceous receptors have been identified. 
Therefore, it is likely that human noroviruses similarly engage a protein receptor, which 
remains to be identified.  
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Figure 1-6 | Model of the norovirus infection cycle. The virus is attaching to the cell, using either 
proteinaceous receptors or cofactors, such as HBGAs. MNV attaches to sialic acids and CD300lf, human 
norovirus attaches to HBGAs. Cell entry and uncoating mechanisms are so far unknown. The genome linked 
protein VPg initiates RNA translation. The viral RdRp replicates RNA and the replicated genomes are either 
used for further translation in the replication complex or packaged into the newly forming capsids. Figure 
adapted from (71). 
 
The virion is internalized though a presently unknown mechanism, and subsequently uncoated 
and disassembled. FCV has been shown to have a both clathrin- and pH-dependent entry 
pathway (186, 197). Conversely, MNV cell entry is dependent on cholesterol and dynamin, 
but independent of pH (57, 158). Only for FCV, a model of genome release is available so far. 
Cryo-EM studies revealed that upon receptor binding, 12 VP2 molecules assemble at a single 
three-fold axis to form a portal vertex (32). Further structural rearrangements lead to the 
formation of a pore in the shell, and the hydrophobic tip of the VP2 molecules is thought to 
facilitate membrane penetration, to allow subsequent release of the RNA. VPg, an RNA-
attached, nonstructural protein, recruits host translational factors to initiate the translation of 
the viral RNA that takes place in the cytoplasm of the host cell. Genomic RNA is used as the 
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template for initial translation of the nonstructural proteins (207). After synthesis of the 
nonstructural proteins, the replication of the genome occurs via the RdRp in replication 
complexes. Thereby, also subgenomic +RNA is produced that is utilized for translation of the 
structural proteins VP1 and VP2 (168). VP1 and VP2 are encapsidating the accumulated 
genomic RNA to form new virions, which are released in a yet unknown manner. 
 
1.5. Histo-blood group antigens and their role in norovirus infections 
The attachment of a virus to its host cell is a crucial step in the infection cycle. HBGAs serve 
as binding cofactors for human noroviruses and this interaction was shown to be necessary to 
establish norovirus infection. HBGAs are carbohydrate-based antigens that include the ABO- 
and Lewis antigens. HBGAs are present on red blood cells, epithelial and endothelial cells as 
part of the glycocalyx, but can also occur soluble in most bodily fluids, such as saliva, milk or 
blood, except the cerebrospinal fluid. HBGAs are synthesized in a stepwise manner, by 
addition of monosaccharides to precursor molecules by various glycosyltransferases (Figure 
1-7). The variances in activity of these enzymes contribute to the great variety of 
carbohydrates that make up the individual HBGA composition. These glycosyltransferases are 
part of three major gene families, the ABO-, secretor- and Lewis family. The simplest 
antigens are the H antigens, which are specific for blood group O. H antigens are produced by 
two distinct fucosyltransferases, FUT1 and FUT2, which add a fucose in an α-1,2-linkage to 
various precursor disaccharides. 20% of Europeans and Northern Americans are homozygous 
recessive for an inactivating nonsense mutation in the FUT2 gene, making them so-called 
nonsecretors (133). This phenotype is characterized by the lack of ABH antigens on cell 
surfaces and in bodily fluids. The H antigens are substrates for A- or B-glycosyltransferases, 
which convert their substrate to A- or B antigens, by addition of an α-1,3-linked 
N-acetylgalactosamine or galactose, respectively. Fucosylation of N-acetylglucosamine by 
FUT3 converts ABO antigens into Lewis antigens. Differential expression of HBGAs in 
individuals is highly associated with susceptibility towards various infectious diseases and 
noroviruses were the first viral human pathogen for which HBGA dependence was discovered 
(29). It is known that numerous pathogens attach to HBGAs and the interplay between these 
pathogens and this group of antigens is thought to have facilitated the HBGA diversity (78, 
132). 
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Figure 1-7 | HBGA synthesis pathway, at the example of type 1/2 HBGAs. HBGAs are assembled from 
galactose (yellow circle), N-acetyl glucosamine (blue square), fucose (red triangle) and N-acetylgalactosamine 
(yellow square). Nonsecretors lack the FUT2 enzyme and can only synthesize the smallest Lewis antigens. In 
secretor positive individuals, FUT2 fucosylates the precursors, to produce the H-type antigen. A- or 
B glycosyltransferases can modify the H antigen to form A- and B antigens, respectively. FUT3 can add fucose 
to the N-acetylglucosamine, of H-, A- and B type antigens, producing Lewis antigens.  
 
Several studies provided proof that different norovirus genotypes exhibit distinct HBGA 
binding patterns. People with blood group O were shown to be more susceptible towards 
infection with GI noroviruses, whereas individuals with blood group B were partially immune 
against GI infection (78, 115). In contrast, GII noroviruses have a broader binding profile and 
do not discriminate between different blood groups (76). GII.4 genotypes in particular are 
promiscuous concerning the HBGA usage, a fact that could contribute to their prevalence 
(77). It has been suggested that GII.4 not only alters its antigenic landscape to evade herd 
immunity, but also adapts its HBGA binding pattern to allow infection of previously immune 
populations (117). 
The differences in specificity between GI and GII viruses can be explained by the distinct 
binding modes. In both genogroups, HBGA binding exclusively involves residues of the 
P2 domain. However, GI noroviruses detect HBGAs through a binding site located on a single 
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P domain monomer, whereas GII noroviruses contain a distinct binding site for HBGAs at the 
dimeric interface of the P domain dimer, involving residues from both VP1 molecules in a 
dimer (19, 21, 29). This binding site preferentially recognizes α-fucose, thereby explaining the 
broad binding range (29, 201) Furthermore, studies indicated that the secretor status plays a 
crucial role in sensitivity towards norovirus infection: Secretor negative individuals with a 
non-functioning FUT2 allele were resistant to norovirus infection in challenge studies and 
in vitro assays (22, 55, 78, 116). 
Also for other members of the Caliciviridae, HBGA interaction has been reported. For 
example RHDV bound H- and B type antigens (177) and Tulane virus was able to detect 
B type antigens (50). Additionally, MNV and FCV are able to detect sialic acids, which are 
HBGA related ligands, indicating that carbohydrate binding is a common feature within the 
Caliciviridae (198, 203). 
 
1.6. Potential inhibitors for norovirus infection 
So far, no antivirals against norovirus infection have been approved. Potential antivirals could 
target different steps in the viral replication cycle, such as attachment, cell entry, genome 
release, replication and translation, or assembly and release of virions. As many of these steps 
are still poorly characterized in norovirus, attachment to HBGAs has been one of the prime 
targets in past efforts to develop antivirals. A lot of work is done for example on the discovery 
of potentially inhibiting norovirus-specific antibodies. A wide array of different monoclonal 
antibodies (mAbs) have been described to block the VLP attachment to HBGAs in surrogate 
assays (3, 119, 221), and in a recent study, one of those antibodies was shown to be 
neutralizing in cell culture (102). One problem however, is the limited cross-reactivity of 
many antibodies, which often restricts their potential as effective antivirals. In addition to 
antibodies, other compounds, such as citrate (68, 100) or small molecule compounds with a 
cyclopenta‐a‐dimethyl phenanthrene-base structure (233), can interfere with HBGA binding. 
Other targets in the norovirus life cycle have also been studied, such as the RdRp. Compounds 
targeting the RdRp can be divided into nucleoside analogues that bind the active site and 
non-nucleoside inhibitors. One example is 2’ C-methylcitidine, a nucleoside analogue that has 
also been studied in other viruses and was able to inhibit norovirus RdRp (170, 171). 
Moreover, the protease (NS6) also presents a valuable target and therefore also has been the 
subject of numerous inhibitor studies. Rupintrivir, an antiviral originally developed against 
rhinovirus was able to effectively inhibit norovirus protease (172). 
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The only compound that has finished phase II clinical trials is nitazoxanide (NTZ). In these 
phase II clinical trials, treatment with this compound led to a reduced length of the disease 
(174). Nevertheless, other studies claim that NTZ is ineffective against norovirus (88). 
Moreover, the mechanism for norovirus inhibition by NTZ is not identified yet. Additionally, 
several studies suggested that natural compounds could inhibit norovirus, such as theaflavins 
(147) or curcumin (232) but for most of these compounds the inhibition mechanism is 
unknown. Generally, there are several promising candidates, but with most of them only in 
preclinical development, more studies on potential norovirus inhibitors are urgently needed. 
1.6.1.  Norovirus inhibition by human milk oligosaccharides  
Another large group of compounds that has been shown to have an inhibiting effect on 
norovirus are the human milk oligosaccharides (HMOs). HMOs are a family of diverse 
unconjugated glycans that constitute approximately 20% of the carbohydrate content of 
human milk, with up to 20 g/l in colostrum (211). Usually, HMO concentrations in human 
milk are between 5-20 g/l (16), making it the third most abundant compound, after lactose and 
lipids. 
 
Figure 1-8 | Schematic representation of a section of the HMO synthesis pathway. HMOs are assembled 
from glucose (blue circle), galactose (yellow circle), N-acetylglucosamine (blue square), fucose (red triangle) 
and sialic acid (purple diamond). All HMOs are based on lactose. Fucosyltransferases can add fucose to either 
glucose or galactose and produce 2’ fucosyllactose (2’FL) or 3 FL. Lactose can be sialyated, to e.g. produce 
3’ sialyllactose (3’SL) or 6’SL. Addition of N-acetyl glucosamine to lactose forms lactriose, which can further 
be processed to Lacto-N-tetraose (LNT) or Lacto-N-neotetraose (LNnT). Further fucosylation produces Lacto-
N-fucopentaose (LNFP). This figure represents only a small section of the HMO production pathway, as ~150 
different HMOs are known today.  
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So far, ~150 HMOs have been described (96, 195, 227, 228). The wide variety of HMOs is 
produced by specific glycosyltransferases in the mammary gland. These enzymes use lactose 
as acceptor molecule to add various glycosylgroups, as e.g. fucose, galactose, 
N-acetylneuraminic acid or N-acetylglucosamine (95) (Figure 1-8). 
Not every woman is synthesizing the same set of oligosaccharides. Instead, the HMO 
production is dependent on the expression of different glycosyltransferases and therefore is 
comparable to blood group characteristics. Similar to what has been described for HBGAs, 
nonsecretor women do not produce α1-2-fucosylated HMOs, as for example 2’ fucosyllactose 
(2’FL). Therefore, the Lewis blood group and secretor status not only influences the blood 
type, but also the composition of human milk (108). 
Interestingly, HMOs are not digested by infants, instead they pass the digestive tract (48). 
HMOs exhibit prebiotic effects (65), but also have a high potential to function as 
antimicrobials, e.g. by prevention of pathogen attachment to host cells (113, 141). 
It even has been shown that children that were fed with HMOs had a lower incidence of 
diarrhea (140). Therefore, many studies focus on the potential of HMOs as prospective 
antivirals, e.g. for norovirus. HMOs are structurally similar to HBGAs, and can act as cofactor 
decoys, to block binding sites and inhibit cell attachment. In fact, 2’FL was able to bind to the 
HBGA binding sites of both GI and GII noroviruses (i.e. GI.1, GII.10, GII.17) and inhibit the 
attachment to HBGAs in surrogate assays (98, 220). 2’FL is one of the most common HMOs 
in human milk, and studies suggested that it is safe for consumption in infants at least up to 
20 g/l (35). 
1.6.2. Nanobodies and norovirus inhibition  
Antibodies are glycoproteins that are involved in the immune response. Mammalian 
immunoglobulin G (IgG) consists of four polypeptide chains, two identical light (L) chains 
and two heavy (H) chains, forming the typical Y structure (Figure 1-9). The L chains consist 
of two, the H chains of four distinct domains. At the end of each chain is the variable region 
that is responsible for antigen binding. In contrast, camelids, such as alpacas or llamas, or 
cartilaginous fish, are producing immunoglobulins that are lacking the light chain- so-called 
heavy chain-only antibodies (53, 63, 67). The heavy chain comprises two constant regions 
and the antigen-binding domain VHH, connected by a linker region (67). 
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The most variable parts of the VHH domain are the three complementary determining region 
(CDR) loops that are responsible for epitope attachment. Single domain antibodies 
(Nanobodies) are engineered proteins, derived from the antigen-binding domain VHH. 
 
Figure 1-9 | Schematic representation of a conventional antibody (Immunoglobulin G) and a heavy 
chain-only antibody. Both types of antibodies have constant regions 2 and 3 (CH2/3). IgG consists of another 
constant region of the heavy chain (CH1) and of the light chain (CL) and variable regions of both light and 
heavy chains (VL and VH). In contrast, the heavy chain-only antibody only contains a single variable domain, 
termed VHH.  
 
These single domain antibodies have unique qualities and several advantages over 
conventional antibodies. Nanobodies bind epitopes, with high affinities in the nano- to 
picomolar range (124). Usually, Nanobodies have a molecular weight of 12-15 kDa, making 
them markedly smaller than common IgG antibodies (~150 kDa). Therefore, Nanobodies can 
bind to hidden epitopes that would be occluded for the larger antibodies. Moreover, structural 
analysis has shown that often the CDR regions of Nanobodies are longer than the CDR 
regions of antibodies from most other mammals (179), giving them the possibility to bind to 
cavities or clefts (33). Nanobodies are only weakly immunogenic in vivo, and they exhibit 
strong tissue penetration (190). Furthermore, Nanobodies have superior biophysical properties 
compared to conventional antibodies, for example higher solubility and increased stability 
when exposed to high temperature, extreme pH, or protease treatment (46, 109, 212). They 
can also easily be fused to various tags and produced in E. coli in high yields, which lowers 
the production costs substantially (105). 
Due to their versatility, Nanobodies have a wide use of potential applications, as diagnostic 
tools for detection of proteins and microorganisms (159, 209), as therapeutic tools against 
infections (79, 210) or other diseases like Alzheimer’s (110). Nanobodies are also currently 
studied in their function as potential norovirus antivirals. GII.10 specific antibodies have been 
found to broadly inhibit the attachment of VLPs to HBGAs (101), and their efficacy could 
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even be proven in human cell culture (unpublished results). As Nanobodies are considered as 
save for humans, development of norovirus specific Nanobodies could be a promising 
approach for production of norovirus antivirals or prophylaxis. 
 
1.7. Development of a norovirus vaccine – attempts and difficulties 
Next to studies on antivirals, there are increasing efforts to develop a vaccine against 
norovirus. Effective active immunization would have the advantage that it can be 
administered prophylactically to prevent viral infection, disease and spread. A vaccine against 
rotavirus, another gastroenteritis-causing virus, has been developed and implemented with 
great success in many countries. In fact, since this vaccine is in use, norovirus has replaced 
rotavirus as the viral agent that is responsible for most gastroenteritis outbreaks in children in 
many places (20, 72). 
Most of the efforts to develop a norovirus vaccine are based on VLPs. VLPs have been shown 
to be highly immunogenic and safe compared to live attenuated viruses, as they are 
replication-incompetent. Recombinant VLPs are commonly used as effective agent in other 
vaccines, for example against human papillomavirus or hepatitis B (104, 136). 
There are several challenges hampering the development of an effective norovirus vaccine. 
One problem is the high antigenic diversity between the genotypes, therefore protection 
against newly emerging strains could be limited. Moreover, vaccine efficacy might be 
especially low in high-risk populations, namely the elderly and immunocompromised, due to 
impaired immune functions in those patients. 
As GII.4 is the genotype most commonly associated with outbreaks, vaccine development is 
mostly directed towards this genotype. Several vaccine candidates that have entered clinical 
trials use norovirus VLPs in either single formulations or multivalent formulations, with 
VLPs from different genotypes to broaden efficiency. Efforts to produce a norovirus vaccine 
include e.g. a mixture of GI.3 and GII.4 VLPs, with rotavirus VP6 as adjuvant that has 
completed phase I of clinical trials (14, 131), or a single dose, orally administered vaccine 
containing recombinant adenovirus serotype 5 vectors expressing norovirus GI.1 VP1 (92). 
The most advanced norovirus vaccine candidate is currently in production by Takeda 
Pharmaceuticals, and is in phase II clinical trials. This vaccine candidate is bivalent, based on 
VLPs of GI.1 and GII.4, and is administered intramuscularly (153, 208). In order to confer 
immunity against several prevalent GII.4 strains, a consensus sequence was designed (GII.4c), 
	 Introduction		
 15 
from sequences of three different GII.4 isolates (2006a Yerseke, 2006b Den Haag and 2002 
Houston) (153). In first tests, this vaccine was able to induce the production of antibodies that 
were able to detect GI.1, GII.1, GII.3 and GIV.1 noroviruses (153). However, even though the 
vaccine was able to elicit broadly reactive antibodies, the vaccine was only associated with 
modest decreases in severity of the disease. Moreover, neither the duration nor the incubation 
time to symptom onset could be reduced, and the vaccination failed to significantly reduce the 
incidence of the illness (10). Another important factor of an effective vaccine is the duration 
of its protective efficacy. A recent study found that, even though the seroresponse stayed 
above the baseline when compared to the placebo recipients, the antibody titers waned 
strongly over a year (5). 
Binding of noroviruses to HBGAs at the cell surface was proven to be necessary for infection, 
therefore, antibodies that are able to block this interaction have been found to correlate with 
protection against infection (166, 178). One study on mice has shown that immunization with 
GI VLPs did not elicit HBGA blocking antibodies against GII noroviruses (130). 
Furthermore, in a human cross-challenge study, patients were immune to the same norovirus 
genotype, but not to unrelated norovirus strains, implying limited cross-protection after 
infection (230) Conversely, in a recent clinical trial a multivalent VLP vaccine was able to 
raise broadly reactive antibodies (120). 
Overall, the norovirus vaccines that are in testing can potentially elicit virus-specific antibody 
responses, and no adverse effects to the vaccines have been observed. Nevertheless, the low 
levels of efficacy, combined with problems of limited long-term immunity and 
cross-reactivity among genotypes indicate that still a lot of research is needed on the way 
towards a highly efficient norovirus vaccine. One potential solution, inspired by the recent 
progress in the influenza and HIV field, could be to identify and characterize conserved 
epitopes on the norovirus capsid to advance the structure-based design of novel immunogens. 
 
1.8. Structure determination of proteins - cryo-EM and single particle analysis  
Cryo-Electron microscopy (cryo-EM) is a tool to determine the structure of proteins and 
macromolecular complexes, without the need to crystallize the sample. This is especially of 
advantage for large complexes and proteins that are complicated to crystallize. With new 
technological advancements it is now possible to obtain models at near atomic resolution 
(106). In all types of microscopy, the achievable resolution is influenced by the wavelength of 
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the chosen radiation. In electron microscopy, this aspect is removed as limiting factor for 
resolution, as the wavelength of an electron, accelerated by 300 keV, is 0.02 Å. 
Nevertheless, resolution was limited in the past, as samples had to be stained and dehydrated 
in order to provide contrast and limit electron damage. Staining was done by treatment with a 
heavy metal salt solution, such as uranyl acetate. Negatively stained samples are limited by 
the granularity of the stain, leading to a maximum achievable resolution of ~20 Å (148). This 
was overcome when a method was developed to vitrify water in liquid ethane, where the 
water is frozen rapidly to prevent ice crystal formation (28, 45, 204). A further advantage of 
this method is that it keeps the particles hydrated and in a near native state. 
In EM, electrons are used as radiation source that are scattered by the object. Depositing 
electrons in a biological sample however destroys the sample over time. To minimize this 
damage, imaging is done at liquid nitrogen temperatures, leading to a six-fold decrease in 
damage compared to ambient temperatures (45). To further prevent damage and preserve high 
resolution information, the electron dose is kept at a low rate (58). This leads to a low signal 
to noise ratio, as biological macromolecules scatter electrons only weakly. Therefore, imaging 
is performed under slightly defocused conditions. Defocusing introduces differences in the 
scattered and unscattered rays, resulting in visible contrast, but also causes loss of information 
at different spatial frequencies and phase reversals. The influence of microscope 
imperfections and defocusing can be described by the contrast transfer function (CTF). 
During processing of the data, the distortions that are introduced can be corrected 
computationally to obtain the undistorted image and restore the correct phases at all spatial 
frequencies. 
In the single particle approach, first a purified sample is needed, with homogenous, identical 
particles in random orientations on the grid. Then, a large number of projection images of the 
protein are collected, to generate a 3D reconstruction of the 2D projections (Figure 1-10). 
During micrograph acquisition, the images get blurred by beam induced motion, stage drift 
and charging events. To restore high-resolution information, the micrographs are acquired as 
movies and the individual frames are aligned relative to one another. After movie alignment, 
CTF correction is performed. In this step, a model is fitted to the measured CTF of the 
micrograph, to recover CTF parameters and determine the actual defocus of the image. On the 
corrected micrographs, particles are picked either manually or in an automated or 
semi-automated fashion. The first step of sorting is usually 2D classification. Particles are 
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clustered into homogenous subsets, containing the protein in different views and exclude 
broken particles or falsely picked noise. 
 
Figure 1-10 | Workflow for structural analysis using single particle cryo-EM. First, protein is purified and 
vitrified on an EM grid. 2D projections of the protein are acquired at the microscope. These raw images first 
need to be corrected using motion - and CTF correction. Particles are picked from the corrected micrographs and 
2D classification is done, to sort intact from damaged particles or falsely picked noise. For further sorting and to 
generate an initial 3D map of the protein, 3D classification is done. A subset of particles is used for refinement 
of the map, to generate a high-resolution structure of the protein. If the resolution allows, the density can be used 
to build a model of the protein. 
 
In this step, the particle images are compared with class averages and assigned to the class 
with the best cross-correlation. Then a new set of class averages is computed and the process 
is repeated over several iterations. 2D classification is followed by a 3D classification by the 
projection matching technique. In this step, 3D re-projections of the 2D templates are 
calculated and used to match the experimental 2D particles. After sorting, 3D models are 
generated and used as the new templates in the following iteration. For generation of a 3D 
reconstruction from 2D images, one takes advantage of the projection slice theorem: The 
Fourier transform of each 2D projection is a slice through the Fourier transform of the 3D 
object. From the intersection of two 2D transforms in 3D Fourier space one can assign 
relative orientations of the single particles that are needed to build the 3D model. After 
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determination of the relative angles between the 2D class averages, a 3D model can be 
reconstructed, using either a real space- or Fourier space-based model, depending on the used 
processing suite. After a subset of sufficient homogeneity has been selected, these particles 
are refined to high resolution. In the gold standard method, the dataset is separated into two 
independent halves that are refined independently to prevent overestimation of the resolution 
(73). For both datasets, a density is computed. A Fourier shell correlation (FSC) curve is 
generated by calculation of the correlation coefficient within the resolution shells that were 
extracted from the Fourier transforms of the two volumes. In single particle cryo-EM, the 
resolution of the structure is defined as the spatial frequency at a certain FSC cut-off. There 
are different values used, most commonly an FSC value of 0.5, or 0.143, the latter value being 
selected on an attempt to enable comparison of EM and crystallographic models (173). 
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2. Material 
Table 2-1 | Used chemicals  
Chemicals Company 
2’ Fucosyl-lactose Jennewein Biotechnologie GmbH 
A-Trisaccharide Dextra 
Agarose Carl Roth 
Ampicillin Sigma-Aldrich 
BLOTTO Bio-Rad Laboratories 
Blue White Select Screening Reagent Sigma-Aldrich 
Bromphenol blue Alfa Aesar 
Calcium chloride Sigma-Aldrich 
Cesium chloride Sigma-Aldrich 
Dulbeccos Modified Eagle Medium 
(DMEM) 
Gibco 
Dulbeccos Phosphate Buffered Saline 
(DPBS) 
Gibco 
Detection Reagent 1 and 2 (Western Blot) Thermo Scientific 
DMSO Sigma-Aldrich 
DNA loading dye purple (6x) New England BioLabs 
EDTA Thermo Fisher Scientific 
Effectene Transfection Reagent Qiagen 
Ethanol Sigma-Aldrich  
Ethidium bromide BioRad 
Ex-Cell 405 Serum-Free Medium Sigma-Aldrich 
EZ-Link™ Sulfo-NHS-LC-Biotin Thermo Fisher Scientific 
Fetal Bovine Serum Sigma-Aldrich 
GCDCA Sigma-Aldrich 
GelCode Blue protein stain Thermo Fisher Scientific 
Gel loading dye purple 6X New England BioLabs 
Gentamycin Thermo Fisher Scientific 
Glucose Sigma-Aldrich 
GlutaMAX Gibco 
Glycerol Sigma-Aldrich 
H2O2 Sigma-Aldrich 
Hydrochloric acid, 37%, fuming Merck 
Imidazole Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
Isopropyl-β-D-thiogalactopyranosid  Carl Roth 
Kanamycin Carl Roth  
LB agar plates VWR Chemicals 
LB broth (Luria/Miller), granulated Carl Roth 
Lipofectamine 2000 Invitrogen 
Magnesium-Chloride solution, 1M Serva 
Mini-Protean TGX Precast Gels (4-15%) BioRad 
Natriumchloride Carl Roth 
Natriumhydroxide Gruessing 
Ni-NTA agarose Sigma-Aldrich 
o-Phenylenediamine dihydrochloride Sigma-Aldrich 
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Chemicals Company 
Opti-Mem medium Gibco 
PAGE ruler prestained protein ladder Sigma-Aldrich 
PBS 10x powder Medicago 
Penicillin-Streptomycin Sigma-Aldrich 
Phosphate-Citrate buffer tablets Sigma-Aldrich 
Porcine gastric mucin (PGM) type III Sigma-Aldrich 
Puromycin Gibco 
Sf900II SFM (1X) Gibco 
Skim milk powder Sigma-Aldrich 
Sucrose Sigma-Aldrich 
S.O.C medium Invitrogen  
Tetracyclin VWR International 
Terrific Broth (TB-) medium powder Carl Roth 
Trans-Blot Turbo 5x Transfer Buffer BioRad 
Tris-acetate EDTA (TAE) 50x Carl Roth 
Tris-Glycine-SDS 10x Fisher BioReagents 
Trizma hydrochloride solution Sigma-Aldrich 
Trypan blue BioRad 
Tween-20 Sigma-Aldrich 
Uranyl acetate Serva 
β-mercaptoethanol Sigma-Aldrich 
Water, sterile filtered, suitable for cell 
culture 
Sigma-Aldrich 
 
Table 2-2 | Used equipment 
Equipment and Materials Company  
0.6/1 grids, Cu/Rh, 300 mesh Quantifoil 
1.2/1.3 grids, Cu/Rh, 300 mesh Quantifoil 
96-well maxisorp plates Nunc 
Accublock mini Labnet 
Accu-jet pro pipet boy Brand 
Äkta prime plus GE Healthcare 
AVANTI J-26 XP centrifuge Beckman Coulter 
Beckman Optima LE 80K Beckman Coulter 
Beckman MaxE Ultracentrifuge  Beckman Coulter 
Centrifuge 5418 Eppendorf 
Centrifuge 5430R Eppendorf 
ChemiDoc BioRad 
Cell Counting slides, Dual Chamber BioRad 
Dialysis Cassettes (slide-a-lyzer) Thermo Fisher Scientific 
DMi1 Light Microscope Leica 
Ecotron Incubator Infors 
Erlenmeyer Flasks Corning 
Erlenmeyer Flask 500 ml Corning 
Filter Paper No.1 Whatman 
Gradient master 108 Biocomp 
GloMax Explorer Promega 
HiLoad 26/600 Superdex 200 pg GE Healthcare  
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Equipment and Materials Company  
HiLoad 26/600 Superdex 75 pg GE Healthcare 
HiPrep 26/60 Sepahcryl S-500 HR GE Healthcare 
iMark Microplate Absorbance Reader BioRad 
Immunowash Microplate Washer Bio-Rad 
Mini Protean Tetra System Apparatus BioRad 
MultiA grids, Cu/Rh, 300 mesh Quantifoil 
MultiTron incubator Infors 
Nanodrop Lite Thermo Fisher Scientific 
OD600 DiluPhotometer Implen 
Rotor JLA 8.1 Beckman Coulter 
Rotor JA 25.5 Beckman Coulter 
Rotor SW 40 Beckman Coulter 
Rotor SW 56 Beckman Coulter 
Rotor Ti45 Beckman Coulter 
Rotor TLA 55 Beckman Coulter 
Shaker DRS-12 NeoLab 
Stirred Water Bath WB-4MS BioSan 
Stirrer C-MAG HS10 IKA 
Thermomixer Comfort Eppendorf 
Tissue Culture Flask 25 cm2 Falcon 
Tissue Culture Flask 175 cm2 Falcon 
UP200HT Ultrasonic processor  Hielscher Ultrasonics 
Vortex Genie 2 Scientifc Industries 
Xplorer plus multipipettes Eppendorf 
Zetasizer Nano S Malvern 
 
Table 2-3 | E. coli strains 
Name Company 
MAX efficiency DH10Bac Competent cells Invitrogen 
E. coli DH5α (chemically competent) Invitrogen 
E. coli WK6 (chemically competent) Invitrogen 
E. coli DB3.1 (chemically competent) Invitrogen 
E. coli BL21 (chemically competent) Invitrogen 
 
Table 2-4 | Cells for protein expression 
Name Company 
HIGH FIVE TM  Thermo Fisher Scientific 
HEK-293T Sigma Aldrich 
Sf9 Gibco 
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Table 2-5 | Commercial Kits 
Name Company 
QIAprep Spin miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR purification Kit Qiagen 
 
Table 2-6 | Enzymes 
Name Company 
Gateway LR Clonase Enzyme Mix Thermo Fisher Scientific 
Phusion High-Fidelity PCR Master Mix  New England BioLabs 
Restriction enzyme Bsp1407I Thermo Fisher Scientific 
Restriction enzyme BstEII New England BioLabs 
Restriction enzyme PstI New England BioLabs 
T4 DNA Ligase New England BioLabs 
 
Table 2-7 | Antibodies 
Name Company 
Monoclonal HRP-conjugated goat α-His 
antibody 
Sigma-Aldrich 
Monoclonal HRP-conjugated goat α-mouse 
antibody 
Thermo Fisher Scientific 
Monoclonal HRP-conjugated goat α-rabbit 
antibody 
Sigma-Aldrich 
Polyclonal rabbit α-GII.10 VLP antibodies In-house production at DKFZ 
Polyclonal rabbit α-GII.4 VLP antibodies In-house production at DKFZ 
Precision Protein StrepTactin-HRP 
conjugate 5,000× 
BioRad 
 
Table 2-8 | Primers 
Name Sequence (5’-3’) Function 
A6E GATGTGCAGCTGCAGGAGTCTGGAGGAGG PCR Nanobody 
PMCF GTAGTGCGGCCGCTGAGGAGACGGTGACCT PCR Nanobody 
Universal 
Forward 
CGC CAG GGT TTT CCC AGT CAC GAC Sequencing 
Universal 
Reverse 
TCACACAGGAAACAGCTATGAC Sequencing 
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3. Methods 
3.1.  VLP expression and purification 
3.1.1. Cloning of constructs with the Gateway cloning system 
For the production of VLPs, bacmids were produced, containing the recombinant gene for 
VP1 or VP1/VP2, respectively (Table 3-1). The sequences were ordered from Invitrogen, in a 
pENTR221 vector. Using the Gateway cloning system, the desired insert was cloned into a 
pDEST8 vector. 1 µl of pENTR221 plasmid was mixed with 1 µl of pDEST8 plasmid, 6 µl 
water and 1.5 µl LR Clonase II enzyme mix and incubated for 1 h at RT. The reaction was 
stopped with proteinase K (10 minutes (min), 37 °C). 
3-1 | Used norovirus genotypes for VLP production with accession code. 
Genogroup  Name Accession code Protein  
GI.1 West Chester AY502016  VP1 
GI.1 Norwalk Q83884 VP1 
GI.1 Norwalk Q83884/Q83885 VP1/VP2 
GI.2 Funabashi258 AB078335 VP1 
GI.2 Southampton L07418 VP1 
GI.3 Kashiwa645 BD011871 VP1 
GI.4 Chiba AB042808 VP1 
GI.11 #8 AB058547 VP1 
GII.1  Hawaii Virus U07611 VP1 
GII.4 CHDC ACT76142 VP1 
GII.4 Saga AB447457 VP1 
GII.4 Sydney K4LM89 VP1 
GII.4 Sydney K4LM89/K4LB50  VP1/VP2 
GII.4 c n.a. VP1 
GII.4 Yerseke ABL74391 VP1 
GII.10 Vietnam 026 AF504671 VP1 
GII.17 Kawasaki  LC037415 VP1 
 
3.1.2. Production and transformation of chemically competent E. coli 
100 ml of LB media were inoculated with a competent E. coli preculture. Cells were 
incubated shaking at 37 °C until an optical density at 600 nm (OD600) of 0.25-0.3 was 
reached. Following a 15 min cooldown on ice, cells were pelleted for 10 min at 3,300 ×g and 
resuspended in 40 ml ice cold 0.1 M CaCl2. Cells were pelleted again and resuspended in 6 ml 
0.1 M CaCl2 with 15% glycerol. 100 µl of the mix were aliquoted into sterile microcentrifuge 
tubes, flash frozen in liquid nitrogen and kept at -80 °C. 
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E. coli DH5α, E. coli WK6, E. coli BL21, and E. coli DB3.1 were transformed using the heat 
shock method. Aliquots of chemically competent cells were thawed on ice and ~100 ng 
plasmid were added and incubated for 10 min. Heat shock was done at 42 °C for 45 s. After 
addition of 600 µl SOC medium, cells were incubated shaking for 1 h at 37 °C and 1,000 rpm. 
Following the regeneration period, cells were spun down for 2 min at 2,125 ×g, resuspended 
in 200 µl media and plated on LB Agar plates containing ampicillin. The ampicillin was 
added on the plates just prior to plating of the cells. Colonies were grown for ~18 h at 37 °C. 
3.1.3. Transformation of E. coli MAX efficiency DH10Bac competent cells and 
bacmid preparation 
The cloned plasmid (3.1.1) was used for transformation of E. coli DH5α (3.1.2). A single 
colony was grown in 4 ml LB with ampicillin at 37 °C over night. The plasmid was isolated 
with a QIAprep miniprep kit after manufacturers instructions and analyzed on an agarose gel, 
to verify presence of the insert. Positive plasmids were used for transfection of E. coli MAX 
efficiency DH10Bac cells for bacmid production. 
60 µl of E. coli DH10Bac cells were aliquoted and 1 µl of plasmid was added. After 
incubation for 10 min on ice, cells were heat shocked for 45 s at 42 °C. 600 µl SOC medium 
were added and cells were regenerated shaking for 4 h at 37 °C. The cells were plated on LB 
plates with 50 µg/ml kanamycin, 10 µg/ml tetracycline, 6 µg/ml gentamycin and 40 µl 
blue/white select and grown for 28 h at 37 °C. White colonies were used to prepare an over 
night culture in LB with 50 µg/ml kanamycin, 10 µg/ml tetracycline, 6 µg/ml gentamycin. 
Bacmids were isolated using a QIAprep miniprep kit after manufacturers instructions and 
stored at 4 °C until transfection. 
3.1.4. Production of recombinant baculoviruses 
Sf9 cells were transfected with recombinant bacmid DNA encoding the protein of choice, 
using Effectene transfection reagent. Sf9 cells were seeded into a 6-well plate in 2 ml Sf900 
medium. 90 µl EC buffer were mixed with 3.2 µl Enhancer and 8 µl bacmid DNA. 10 µl 
Effectene were added, mixed and incubated for 5-10 min at RT. When the cells were attached 
to the plate, old media was aspirated, and 1 ml of new Sf900 media was added. After the 
incubation, 1 ml Sf900 media was added to the transfection mix and pipetted drop wise onto 
the cells. Plates were incubated for 7 days at 28 °C. The supernatant and the cells were added 
to Sf9 cells in a T75 flask, to expand the baculovirus. After 5-7 days of incubation, the 
baculorvirus-containing supernatant was centrifuged 1057 ×g for 10 min to pellet residual 
cells, sterile filtered and stored at 4 °C. 
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3.1.5. Expression and purification of VLPs  
If not stated otherwise, VLPs were produced using the baculovirus expression system. 
Supernatant of infected Sf9 cells, containing the baculovirus, was used for infection of High 
Five cells (ThermoFisher). 5 days post infection, cells and secreted baculoviruses were 
removed from the cell culture supernatant by two sequential centrifugation steps at 1057 ×g 
for 10 min and at 4,960 ×g for 1 h, respectively. Norovirus VLPs in the supernatant were 
pelleted by ultracentrifugation at 142,032.1 ×g for 2 h at 4 °C. After resuspension in PBS over 
night, the VLPs were subjected to CsCl gradient centrifugation (18-20 h, 4 °C, 121,780.9 ×g) 
for further purification. Afterwards, VLPs were pelleted again for 2 h at 71,680 ×g, and 
resuspended in PBS to remove the CsCl from the solution and concentrate the sample. 
3.1.6. Sucrose density gradient centrifugation  
Heterogeneous VLP samples were further purified using a sucrose gradient. The 15-45% w/v 
sucrose gradient was prepared with a gradient maker (Gradient master 10, Biocomp). 200 µl 
VLP sample were added onto the gradient and centrifuged for 2 h 154,693 ×g and 4 °C. 
3.1.7. Generation of mammalian expression vectors 
The plasmids used for VLP production in HEK-293T cells were provided by Dr. Stefan 
Pusch. The used plasmids were pMXs-puro, pDest-puro and pLEX-puro. All constructs 
contained AttR sequences for cloning with the Gateway cloning system, as described in 3.1.1. 
Empty vectors contained the ccdB gene, which is toxic for E. coli DH5α, so for amplification 
of the empty vectors, E. coli DB3.1 were used. To verify that the insert is in the plasmid, the 
pENTR221, the destination vector and the newly cloned vector were cut with restriction 
enzyme Bsp1407I and after incubation for 2 h at 37 °C, the cut plasmids were separated on an 
agarose gel. Positive clones showed DNA corresponding to the backbone of the destination 
vector and the insert of the pENTR221 vector (i.e. the gene of interest). 
3.1.8. Propagation of HEK-293T cells 
HEK-293T cells were cultured in Dulbeccos modified Eagles medium (DMEM), 
supplemented with 1% glutaMAX, 10% fetal bovine serum (FBS) and 1% 
streptomycin/penicillin, (DMEM complete). Cells were cultured adherent in T175 flasks at 
37 °C and 5% CO2 and passaged when 80-90% confluent. 
3.1.9. Transfection of HEK-293T cells 
The evening before transfection, 1.5x106 cells/well were seeded into 6 well plates and 
incubated over night at 37 °C and 5% CO2. Transfection was done using Lipofectamine 2000 
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transfection agent. 12 µl Lipofectamine and 2 µg plasmid were added to separate tubes 
containing 100 µl Opti-Mem Medium each. After incubation for 5 min at RT, the 
Lipofectamine-containing Opti-Mem was added to the tube containing the plasmid, then the 
mix was vortexed briefly and incubated for 20 min at RT. Following incubation, 1.5 ml 
DMEM complete was added. Media was aspirated from the cells and the media containing the 
transfection mix was added to the cells and incubated at 37 °C and 5% CO2. After 4-6 h, 
media was aspirated and new DMEM complete was added. To obtain a stable cell line, cells 
were propagated in complete DMEM supplemented with 10 µg/ml puromycin starting 24 h 
post transfection, to maintain only cells containing the plasmid. 
3.1.10. Expression and purification of VLPs expressed in HEK-293T cells 
HEK-293T cells were transfected as described in 3.1.9 and grown in complete DMEM 
medium. After 5 days of VLP production, the cell culture supernatant and cells were 
collected. The cells were pelleted by centrifugation at 300 ×g for 10 min and resuspended in 
PBS buffer. The cells were lysed by sonication and resulting cell debris was spun down for 
30 min at 4 °C and 7,500 ×g. VLPs were purified from the cleared cell lysate and the 
supernatant by ultracentrifugation and CsCl gradient centrifugation, as described in 3.1.5. 
3.1.11. MNV virion production 
Murine norovirus CW1 was propagated in RAW 264.7 cells. Cells were infected with the 
virus and grown for 5 days at 37 °C and 5% CO2. Cells and medium were subjected to 
freeze/thaw cycles, and debris was removed by centrifugation for 20 min at 470 ×g. MNV 
virions were concentrated by ultracentrifugation for 2 h at 142032.1 ×g, resuspended in PBS 
over night and further purified in a CsCl gradient (121780.9 ×g, 18-20h). The gradient was 
fractionated and checked for presence of virions in negative stain electron microscopy 
(3.12.1). Fractions containing MNV were pooled and dialyzed into PBS. 
3.2.  Expression and purification of Nanobodies 
3.2.1. Nanobody selection 
Nanobodies were produced by the VIB Nanobody service facility, approved by the ethics 
commission of the Vrije University in Brussels. An alpaca was injected subcutaneously with 
purified VLPs. A VHH library was constructed from isolated lymphocytes and screened for 
VLP specific Nanobodies with a phage display. Three rounds of panning were performed and 
crude periplasmic extracts were analyzed for antigen specific Nanobodies using ELISA. 
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3.2.2. Generation of Nanobody expression constructs 
The Nanobody constructs were obtained from the VIB Nanobody service facility in a pMECS 
vector. For expression, the sequences were subcloned into pHEC6c expression vector. The 
genes were amplified by PCR using PMCF and AGE primers (Table 2-8) that flank the 
Nanobody sequence on the pMECS vector. The amplified fragments were isolated using the 
QIAquick PCR purification kit. Fragments were digested with PFSI and BstEII enzymes for 
1.5 h at 37 °C and cleaned up using the QIAquick PCR purification kit. The digested 
fragments were then ligated into the pHEN6c vector that has been cut with the same 
restriction enzymes. Ligation was done using the T4 ligase for 10 min at RT. 4 µl of the 
ligation mix were subsequently used for transformation of E. coli DH5α (3.1.2). 
3.2.3. Sequencing 
To verify the sequence of the cloned Nanobody constructs, sequencing service of GATC was 
used. Universal forward and universal reverse primers (Table 2-8) were used for sequencing. 
The obtained DNA sequence was analyzed using the Sequencher program. 
3.2.4. Nanobody expression 
E. coli WK6 cells were transformed as described in 3.1.2, using a pHEN6c vector encoding 
the Nanobody of interest with a C-terminal His-Tag. The day before expression, a preculture 
was inoculated in LB media with 100 µg/ml ampicillin and incubated over night at 37 °C and 
250 rpm. The preculture was used to inoculate 1l of TB media supplemented with 100 µg/ml 
ampicillin, 2 mM MgCl2 and 0.1% glucose the following day. Cells were grown at 37 °C and 
250 rpm and growth was monitored by measuring the optical density at 600 nm (OD600). 
Nanobody expression was induced with 1 mM IPTG after reaching an OD600 of 0.6-0.8 and 
cells were grown over night at 28 °C 250 rpm. Cells were harvested by centrifugation for 
15 min at 4960 ×g and stored at -20 °C. 
3.2.5. Nanobody purification 
The cell pellet was thawed and 12 ml TES buffer per liter E. coli culture were added. After 
homogenization, 18 ml TES/4 buffer per liter E. coli culture was added and incubated for 
30 min in batch to extract the Nanobodies from the periplasm. The cells were then 
subsequently centrifuged for 30 min at 39191 ×g and the supernatant containing the 
Nanobodies was incubated with Nickel-NTA (Ni-NTA) resin for 30 min under agitation at 
4 °C. The Nanobodies were purified with a Ni-NTA affinity method. After three consecutive 
rounds of washing with 2 column volumes of 10 mM, 20 mM and 50 mM imidazole buffer, 
the Nanobodies were eluted using 250 mM imidazole buffer. 
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After overnight dialysis into gelfiltration buffer (GFB), the Nanobodies were further purified 
by size exclusion chromatography using a Superdex-200 or Superdex-75 column. The peak 
fractions were pooled, concentrated to 2-3 mg/ml with a centrifugal filter unit with 5 kDa 
cut-off, and stored at 4 °C. 
Table 3-2 | Buffers for Nanobody purification. 
Buffer Ingredients  
TES Buffer  0.2 M Tris-OH (pH 8.0), 0.5 mM EDTA, 
0.5 M Sucrose 
TES/4 Buffer 50 mM Tris-OH (pH 8.0), 0.125 mM EDTA, 
0.125 M Sucrose 
10 mM Imidazole Wash Buffer 20 mM Tris-OH (pH 7.6) 0.2 M NaCl, 
10 mM Imidazole 
20 mM Imidazole Wash Buffer 20 mM Tris-OH (pH 7.6) 0.2 M NaCl, 
20 mM Imidazole 
50 mM Imidazole Wash Buffer 20 mM Tris-OH (pH 7.6) 0.2 M NaCl, 
50 mM Imidazole 
250 mM Imidazole Elution Buffer 20 mM Tris-OH (pH 7.6) 0.2 M NaCl, 
250 mM Imidazole 
Gelfiltration Buffer 25 mM Tris-OH (pH 7.6), 0.3 M NaCl 
 
3.3. P domain expression 
Norovirus P domain was expressed in E. coli BL21 as a maltose binding protein (MBP) 
fusion protein. E. coli BL21 were transformed with a pMalc2x-P plasmid containing the 
P domain gene of interest. The E. coli were cultured in 100 ml LB with ampicillin over night 
and used for inoculation (1:100) of 1 l LB media. The cells were grown at 37 °C until an 
OD600 of 0.4-0.6 was reached. The temperature was lowered to 22 °C and P domain 
expression was induced by addition of 0.75 mM IPTG. The protein was expressed overnight 
and harvested the following day by centrifugation at 4960 ×g for 15 min, at 4 °C. Pellets were 
frozen at -20 °C or used immediately for purification. 
3.4. P domain purification 
Cell pellets were thawed on ice and dissolved in PBS, before lysis of the cells by sonication. 
Lysates were cleared by centrifugation for 30 min at 39191 ×g and 4 °C. His-tagged MBP-P 
fusion proteins were purified from the supernatants via Nickel-NTA affinity chromatography, 
as described in 3.2.5. 
To cleave the MBP-P domain fusion protein, HRV-3C protease was added. The mix was 
dialyzed over night against 10 mM imidazole buffer at 4 °C. To separate MBP-His and 
P domain, the mix was added to Ni-NTA beads the following day and incubated for 30 min at 
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4 °C. The flow through, containing the cleaved P domain, was collected, concentrated, and 
further purified by size exclusion chromatography with a Superdex-200 or Superdex-75 
column. The peak fractions were pooled, concentrated to ~3 mg/ml and stored at 4 °C. 
3.5. Direct ELISA 
Direct binding of Nanobodies or antibodies to VLPs was analyzed by enzyme-linked 
immunosorbent assay (ELISA). In this assay, Nunc maxisorp 96-well plates were coated with 
100 µl VLPs for 1 h at 37 °C. Plates for GI.1 were coated with 5 µg/ml VLPs and 10 µg/ml 
P domain, GII.4 VLPs were used in a concentration of 1 µg/ml. In GI cross-reactivity assays, 
10 µg/ml VLPs were used. Following a blocking step for 1 h at RT with 5% skim milk in 
PBS, serially diluted Nanobodies, usually with a starting concentration of 100 µg/ml in PBS, 
were added to the plate and incubated for 1 h at 37 °C. When using antibodies, starting 
concentrations were at 1:250 if not stated otherwise. Bound Nanobodies were detected using 
horseradish peroxidase (HRP)-conjugated anti-His antibody (1 h, 37 °C) at a dilution of 
1:4,000. Depending on the antibody, bound antibodies were either detected using HRP-
conjugated goat anti-rabbit or goat anti-mouse antibody, at 1:40,000 or 1:1,000 dilution, 
respectively. Plates were developed with o-phenylenediamine and H2O2 (OPD buffer) in the 
dark at RT for 30 min. The reaction was stopped by addition of 6% HCl and signal was 
measured as absorption at 490 nm (OD490) using an iMark plate reader. Between all steps, 
plates were washed three times with PBS containing 0.1% Tween-20 (PBS-T). Deviations 
from this protocol are indicated in the results. 
3.6.  Biotinylation of Nanobodies  
To use Nanobodies for detection in ELISAs, Nanobodies had to be biotinylated. Nanobodies 
were diluted to 1 mg/ml and dialyzed in PBS overnight. 20× molar excess of EZ-Link™ 
Sulfo-NHS-LC-Biotin to the Nanobody was dissolved in PBS and added to the Nanobody 
sample. After 30 min incubation at RT, the mix was dialyzed overnight in PBS to remove 
unbound biotin from the sample. 
3.7. Surrogate blocking ELISA 
Surrogate blocking ELISAs were performed to analyze the potential of compounds to inhibit 
the attachment of VLPs to HBGAs. As surrogate HBGAs, either porcine gastric mucin type 
III (PGM), or saliva samples were used. Saliva samples were collected from adult volunteers; 
boiled for 10 min and centrifuged for 5 min at 8609 ×g to remove residual debris. Samples 
were stored at 4 °C. PGM was used in a dilution of 100 µg/ml in PBS, saliva samples were 
diluted 1:2,000 in PBS prior to coating. 
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Coating was done for 1 h at 37 °C and plates were subsequently blocked with 5% skim milk 
in PBS for 1 h at RT. VLPs were diluted and incubated with serially diluted Nanobodies or 
compounds for 30 min at RT and incubated for 1 h at 37 °C on the plates. For GI.1 inhibition 
experiments, a final concentration of 0.5 µg/ml VLPs was used. For GII.4, final 
concentrations were at 1 µg/ml. Nanobody concentrations for inhibition started at 100 µg/ml, 
for 2’FL the highest concentration was at 250 mM. Untreated VLPs were used as binding 
control on each plate (0% inhibition). PBS without VLPs was used as negative control.  
Following this step, either biotinylated Nanobodies or polyclonal VLP-specific antibodies 
were incubated on the plate for 1 h at 37 °C. Biotinylated Nanobodies were detected using 
HRP-conjugated streptavidin monoclonal antibody in a dilution of 1:5,000, polyclonal 
antibodies were detected using HRP-conjugated anti-rabbit antibody (1:40,000). Deviations 
from this method are stated in the results. For calculation of the inhibition, the absorbance of 
untreated VLPs was used as a reference for 0% inhibition and all values were normalized to 
this value. 
3.8. Dynamic light scattering 
Size and stability of purified VLPs was determined by dynamic light scattering. 10 µl of the 
VLPs (1 mg/ml) were diluted with 1 ml H2Odd prior to measurements. Triplicate 
measurements were performed at 20 °C with a Zetasizer Nano S with 15 measurement cycles 
each. VLPs were pre-incubated with Nanobodies or other compounds for 30 min at RT prior 
to measurements to analyze their effects on VLP integrity. Deviations from this protocol are 
mentioned in the results. 
3.9. SDS-polyacrylamide gel electrophoresis (PAGE) 
Proteins were separated for analysis using SDS-PAGE. Commercially available 4-15% mini 
PROTEAN TGX gels were used. Protein samples were mixed with 5× SDS sample loading 
dye in 1:4 ratio and boiled at 95 °C for 5 min to denature the proteins. After the run, the 
proteins were stained with GelCode Blue safe protein stain and visualized using the BioRad 
Chemidoc. 
Table 3-3 | SDS sample loading dye ingredients. 
Buffer Ingredients  
5× SDS sample loading dye  250 mM Tris–HCl (pH 6.8), 10% (w/v) sodium 
dodecyl sulfate (SDS), 0.2% (w/v) bromophenol 
blue, 43% (v/v) glycerol, 5% (v/v) 
β-mercaptoethanol 
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3.10. Western Blot  
Specific proteins were detected using western blot. First, proteins were separated via 
SDS-PAGE (3.9) before transferring the proteins from the gel to a nitrocellulose membrane 
using a semi-dry method. The gel and the membrane were equilibrated in transfer buffer and 
placed on transfer buffer soaked blotting paper. Using the Trans blot Turbo protocol, the 
proteins were transferred onto the nitrocellulose membrane. After a washing step in 
Tris-buffered saline (TBS), the nitrocellulose membrane was blocked in 5% blotto-TBS with 
Tween (TBS-T) for 1 h at RT. After 3×5 min of washing in TBS-T, the membrane was 
incubated with rabbit-anti GII.4 polyclonal antibody [1:1,000, in TBS-T-blotto (5%)], for 1 h 
at RT. Following another washing step with TBS-T, HRP-coupled goat-anti rabbit antibody 
was added to the membrane (1:40,000 in TBS-T-blotto). After 1 h incubation, development 
solution was added and proteins were imaged with a BioRad Chemidoc. 
3.11. Agarose Gelelectrophoresis 
To analyze the success of PCRs or cloning, the products were analyzed on an agarose gel. 1% 
agarose in TAE (Tris-acetate-EDTA) buffer was used to prepare the gels. Samples were 
mixed 1:6 with loading dye, and the gel was run for 30 min at 135 V. Ethidium bromide was 
added to the running buffer to stain the DNA. After running the gels, the DNA was visualized 
with a BioRad Chemidoc. 
3.12. EM Experiments 
3.12.1. Negative stain EM  
VLPs and virions were checked for size and integrity using negative stain EM. Samples were 
diluted 1:30 and subsequently applied to EM grids. The grids were washed with distilled 
water and stained using 0.75% uranyl acetate. For human infectious virions, samples were 
fixed with 4% glutaraldehyde prior to staining. Samples were analyzed on a Zeiss 900 
electron microscope, operating with an acceleration voltage of 80 keV and images were 
recorded 50,000 × magnification using a CCD camera. 
3.12.2. Sample preparation prior to freezing 
In order to be able to image VLPs or MNV virions in complex with Nanobodies using cryo-
EM, VLPs were incubated with 5× molar excess of Nanobodies to the binding sites for 
30 min at RT prior to sample preparation. 
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For the complexes of VLPs with small molecule compounds, such as GCDCA, 
A-trisaccharide or 2’FL, the VLPs were incubated with 100× molar excess of compound to 
binding sites. 
MNV virions in complex with MgCl2 and CaCl2 were incubated with 10 mM of MgCl2 and 
CaCl2 and incubated at RT for 3 h. 
3.12.3. Sample vitrification for cryo-EM 
Vitrification of the cryo-EM samples was done with a FEI Mark IV Vitrobot. Purified VLPs 
were applied on freshly glow discharged Quantifoil holey carbon support films (R1.2/1.3 or 
R.0.6/1, cu/rh, 300 mesh) and blotted at 12 °C for 18-24 s at 100% humidity, before plunge 
freezing the sample in liquid ethane. Samples were stored in liquid nitrogen until usage.  
3.12.4. Preparation of graphene covered grids 
Graphene covered grids were prepared as described before (134). Briefly, 1:10 diluted 
graphene oxide solution was placed on the grid and blotted away after incubation for 1 min at 
RT, and washed with distilled water. The grids were dried on a blotting paper and could be 
used immediately after preparation. 
3.12.5. Preparation of carbon-covered grids 
For the preparation of carbon-covered grids, first carbon was first evaporated on mica, to 
generate a thin continuous carbon film. This carbon film was floated onto the EM grids and 
dried on filter paper prior to sample preparation. The carbon film was provided by Dr. Dirk 
Flemming. 
3.12.6. Cryo-EM data collection 
Vitrified specimens were imaged with a Titan Krios (FEI) microscope, operating at 300 keV 
acceleration voltage. Micrographs were acquired with a K2 or K3 direct electron detector, 
using DigitalMicrograph Latitude S software. The used direct electron detector and 
magnification with corresponding pixel size for each dataset are noted in Table 3-4, cryo-EM 
structures solved within this thesis are mentioned in Table 3-5. 
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Table 3-4 | Collected cryo-EM datasets. 
Sample name Camera Magnification  Pixel size 
(Å/px) 
Number of 
Micrographs 
GI.1 K2 130,000 1.08 3,082 
GII.4 NSW-2012 K2 64,000 2.27 346 
GII.4 CHDC K3 64,000 1.375 591 
GII.4c K3 64,000 1.369 4,024 
GII.4c (HEK cells) K3 64,000 1.369 483 
GII.4 NSW2012 + 1GFV56 K3 64,000 1.369 529 
GII.4 NSW2012 + 2GFV20 K3 64,000 1.369 303 
GII.4 NSW2012 + 2GFV37 K3 64,000 1.369 373 
GII.4 NSW2012 + 2GFV46 K3 64,000 1.369 246 
GII.4 NSW2012 + 2GFV104 K3 64,000 1.369 773 
GII.4 NSW2012 + 2GFV118 K3 64,000 1.369 153 
GII.17 K2 130,000 1.08 2,316 
GII.17 + A tri K3 64,000 1.375 1,407 
GII.17 + 2’ FL K2 130,000 1.08 3,570 
MNV – 1. dataset K3 64,000 1.375 4,046 
MNV – 2. dataset K3 64,000 1.375 1,588 
MNV + NB5829 K3 64,000 1.369 3,599 
MNV + 10 mM MgCl2 K3 64,000 1.369 611 
MNV + 10 mM CaCl2 K3 64,000 1.369 303 
MNV + NB5829/MgCl2 K3 64,000 1.369 293 
 
Table 3-5 | Cryo-EM structures solved within the study.  
Structure Particle number Resolution in Å  
(0.143 FSC cut-off) 
EMDB ID 
GII.4c T=1 48,971 4.2 EMD-10757 
GII.4c T=3 44,317 8.0 EMD-10756 
GII.4c T=4 118,971 4.2 EMD-10755 
GII.4c T=4 (HEK cells) 10,135 4.5 EMD-10758 
GII.4 CHDC-1974 42,485 6.1 EMD-4549 
GII.4 NSW-2012 T=4 10,548 7.3 EMD-4550 
GII.4 NSW-2012 T=3 391 15  
GII.4 NSW-2012 +1GFV56 24,597 7.4  
GII.4 NSW-2012 + 2GFV20 8,002 6.5  
GII.4 NSW-2012 + 2GFV37 22,566 6.2  
GII.4 NSW-2012 + 2GFV46 10,401 5.7  
GII.4 NSW-2012 + 2GFV104 43,587 4.6  
GII.4 NSW-2012 + 2GFV118 6,390 8.1  
GII.17  35,709 5.8 EMD-10759 
GII.17 + A tri 40,951 7.9  
GII.17 + 2’ FL 55,956 5.8  
MNV 21,424 4.6 EMD-10596 
MNV + NB5829 32,612 4.7 EMD-10597 
MNV + 10 mM MgCl2 2,783 4.3 EMD-10598 
MNV + 10 mM CaCl2 2,637 4.6 EMD-10599 
MNV + NB5829/MgCl2 7,386 4.5 EMD-10600 
	 Material	and	Methods		
 34 
3.12.7. Cryo-EM data processing with Relion 
In a first processing step, the micrograph movies were corrected for drift using the software 
motioncor2 (114), and defocus estimation was done using ctffind4.1 (139), as implemented in 
Relion 2.1 and 3.0 (181). 
An initial set of 1,000 particles was picked manually, to perform 2D classification and 
produce templates for the automated particle picking procedure. After automated particle 
picking, the particles were first sorted in 2D classifications. A subset of particles was used to 
produce an initial 3D model. Using this model as reference, 3D classification was done with 
the particles as another sorting step. A subgroup of particles generating the highest resolution 
structure was used for 3D refinement. For all VLP datasets, icosahedral symmetry I2 was 
imposed on the dataset for 3D classification, initial model generation and 3D refinement. 
3.12.8. Cryo-EM data processing with cryoSPARC 
Alternatively to Relion, datasets were processed with cryoSPARC (163). Analogous to 
processing in Relion, the micrograph stacks were first drift corrected with motioncor2 (114), 
and then CTF correction was done using ctffind4.1 (139). A subset of particles was manually 
picked and templates for automated picking were generated using 2D classification. All 
picked particles were subjected to several rounds of 2D classification, to exclude falsely 
picked particles and noise. With this subset of particles, first a 3D initial model was prepared 
that was then used as starting point for the 3D refinement. cryoSPARC has the opportunity to 
perform homogenous – as well as non-uniform refinement that can correct for intrinsic 
variabilities. For all VLP datasets, icosahedral symmetry I2 was imposed on the dataset for 
3D classification, initial model generation and 3D refinement. 
3.12.9. Focused reconstruction 
When imposing icosahedral symmetry on particles, variabilities in the asymmetric units are 
not accounted for, resulting in a lower resolution in those variable regions. To resolve these 
structural differences, focused refinement was performed in Relion 3.0. First, the dataset was 
processed as described in 3.12.7, until 3D refinement. Following this step, the dataset is 
expanded by symmetry, using the relion_expand_symmetry command, so that each particle is 
assigned 60 orientations, corresponding to the 60 asymmetric units and redundant views in the 
particle. Using spider (54), a cylindrical mask was prepared and positioned in chimera, to 
cover only the region of interest on the particle, i.e. a symmetry axes or single VP1 dimers. 
Using these input files, 3D classification was performed without angular refinement, to 
resolve the structural deviations between the asymmetric units. 
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4. Chapter 1: Characterisation of potential antivirals for GI 
noroviruses, using antibodies, Nanobodies and the HMO 2’FL 
4.1. Summary 
In this chapter, we analyzed the potential of GI.1 specific antibodies, Nanobodies and the 
human milk oligosaccharide 2’FL, to function as norovirus inhibitors. 
In the antibody panel we identified five antibodies that inhibited VLP attachment to HBGA, 
but these antibodies were unable to block other genotypes. 
For the Nanobodies, we discovered two that inhibited VLP binding to HBGAs by aggregation 
(Nano-94), and in a manner that kept particle integrity intact (Nano-7). The binding site was 
occluded, giving proof that such sites on the capsid can represent vulnerable epitopes. A third 
Nanobody, Nano-62, exhibited as similar binding site, but inhibition was only low.  
We also showed that 2’FL was able to inhibit HBGA attachment of several GI genotypes, 
showing its broad specificity. 
Importantly, we found that combination of Nanobodies and 2’FL improved attachment 
inhibition substantially. In the case of Nano-94, the increase could be defined as synergistic. 
Combining cross-reactive with highly efficient compounds could present a treatment 
alternative to combat the issue of low cross-reactivity in potential norovirus treatments. 
4.2. Contributions 
Parts of this chapter (Nanobodies) were a collaborative work: Alexander Hempelmann, Celina 
Geiss, Juliane Graf, Michelle Haas, and Imme Roggenbach expressed and purified the 
Nanobodies, X-ray crystallography was performed by Dr. Turgay Kilic. ELISA experiments 
were performed and analyzed jointly with Alessa Ringel and Kerstin Ruoff and me. Kerstin 
Ruoff and me performed EM and DLS experiments. Dr. Grant Hansman, Kerstin Ruoff, 
Alessa Ringel, Anna Koromyslova and I wrote the manuscript. It has been published as: 
Ruoff K*, Kilic T*, Devant J*, Koromyslova A, Ringel A, Hempelmann A, Geiss C, Graf J, 
Haas M, Roggenbach I, Hansman G. 2019. Structural Basis of Nanobodies Targeting the 
Prototype Norovirus. Journal of Virology 93:e02005-18 
(* = equal contribution) 
Figures in this chapter were taken from this publication and are labeled accordingly.  
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4.3. Results 
Production of GI VLPs 
In order to be able to identify broadly reactive antibodies and Nanobodies, we produced a 
panel of GI VLPs (GI.2 Southampton, GI.2 Fusabashi258, GI.3 Kashiwa645, GI.4 Chiba 
Virus and GI.11 #8). Purified VLPs were mostly a mixture of small and native VLPs, with the 
typical norovirus morphology (Figure 4-1).  
 
Figure 4-1 | Negative stain EM of different GI genotypes. Shown are VLPs from GI.1 West Chester, GI.2 
Southampton, GI.2 Funabashi258, GI.3 Kashiwa645, GI.4 Chiba Virus and GI.11 #8. The scale bar represents 
50 nm. All VLPs exhibit the typical norovirus morphology, but particles varied in size.  
 
Binding abilities of GI specific antibodies 
A panel of 16 antibodies raised against GI.1 VLPs was obtained from virostat inc. These 
antibodies were first tested for their ability to bind GI VLPs in a direct binding ELISA.  
Kashiwa645 Funabashi258 
#8 Chiba virus Southhampton 
West Chester 
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Figure 4-2 | Cross-reactivity of antibodies binding to different GI genotypes. The color scheme represents 
measured OD490 values. All antibodies were able to attach GI.1 VLPs, but binding patterns to other GI VLPs 
varied between the analyzed antibodies.  
 
All of the tested antibodies bound to GI.1 VLPs. The strongest binders were mAb 6D6, 4921, 
2C7 and 8C8 (Figure 4-2). Remarkably, mAb 7A8, 4901, 6C4 and 3A12 were cross-reactive 
with all other GI VLPs. Of these cross-reactive antibodies, mAb 3A12 exhibited the strongest 
overall binding. Conversely, mAbs 8H10, 4921, 4922,4923 and 8C8 were specific to GI.1. 
 
HBGA attachment inhibition of GI VLPs by GI.1 specific antibodies 
In a surrogate HBGA binding assay, the ability of the antibodies to inhibit the attachment of 
VLPs to PGM was analyzed. Prior to these experiments, the VLPs were examined for their 
HBGA binding properties. GI.11 #8 VLPs neither bound saliva A/B/O samples nor PGM, 
indicating that this genotype was a non-binder. Therefore, the inhibition for these VLPs could 
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not be not further tested in the HBGA surrogate ELISA. Conversely, GI.2, GI.3 and GI.4 VLP 
samples were able to bind to PGM. 
 
Figure 4-3 | Inhibitory properties of GI.1 specific antibodies. Out of the panel of 16 antibodies, only five 
were able to inhibit HBGA attachment of GI.1 VLPs in a dose dependent manner. The inhibition experiments 
were performed in triplicates (error bars indicate standard deviation). 
 
Table 4-1 | IC50 values of mAbs inhibiting GI.1 PGM attachment.  
Antibody IC50 (µg/ml) 
8H10 3.39 
4921 5.33 
4922 11.90 
4923 36.98 
8C8 5.46 
 
Five of the 16 mAbs were able to inhibit the attachment of GI.1 to PGM. The best inhibitor 
was mAb 8H10, with an IC50 value of 3.39 µg/ml (Table 4-1 and Figure 4-3). mAb 4921 had 
an IC50 of 5.33 µg/ml, followed by 8C8, at 5.46 µg/ml. mAb 4922 had a ~two-fold lower IC50 
at 11.9 µg/ml, and the lowest inhibition was measured for mAb 4923 at 36.98 µg/ml. The 
inhibiting antibodies were non-cross reactive for other genotypes (Figure 4-2), therefore the 
attachment inhibition could not be tested for other GI genotypes. 
 
HBGA attachment inhibition of GI VLPs by 2’FL 
To further characterize the GI VLPs, the inhibition ability of 2’FL was analyzed. In previous 
studies, 2’FL was able to inhibit the attachment of VLPs to HBGAs in both GI and GII 
genotypes, suggesting a broad activity of this compound (98, 220). 
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Figure 4-4 | Inhibition of GI VLP PGM attachment by 2’FL. 2’FL was able to inhibit the attachment of all 
tested GI VLPs to PGM in an ELISA surrogate experiment in a dose dependent manner. Inhibition for GI.4 
Chiba virus did not reach a plateau. All experiments were performed in triplicates. Error bars indicate standard 
deviation. 
 
Table 4-2 | IC50 values of 2’FL inhibiting PGM attachment of GI VLPs. 
Norovirus genotype  IC50 (mM) 
GI.1 West Chester 18.27 
GI.2 Southampton 23.48 
GI.2 Funabashi258 34.75 
GI.3 Kashiwa645 44.89 
GI.4 Chiba407 Not defined 
 
2’FL was able to inhibit the attachment of all VLPs to PGM, with IC50 values ranging from 
18.27 to 44.89 mM (Figure 4-4 and Table 4-2). For GI.4 Chiba Virus, the inhibition was too 
weak to calculate an IC50 value. Even in this case, a dose dependent inhibition was observed, 
although the curve did not reach a plateau at the tested concentrations. 2’FL is soluble in H2O 
up to 240 g/l, which corresponds to a maximum molar concentration of 491.8 mM. Therefore, 
the concentration could not be increased to a concentration necessary to reach the plateau. 
 
Structural and functional characterization of GI.1 specific Nanobodies  
A Nanobody library was obtained from the VIB Nanobody Service Facility in Brussels, where 
an alpaca was immunized with GI.1 VLPs. Nanobodies were expressed and purified by 
Alexander Hempelmann, Celina Geiss, Juliane Graf, Michelle Haas, and Imme Roggenbach. 
Based on results from preliminary binding ELISA experiments by Kerstin Ruoff, three 
Nanobodies, Nano-7, Nano-62 and Nano-94 were chosen for further characterization. 
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Binding properties of GI.1 specific Nanobodies 
In order to identify, how the Nanobodies were interacting with GI.1 VLPs and isolated GI.1 
P domains, we performed direct ELISAs with Nano-7, Nano-94 and Nano-62 (Figure 4-5).  
 
Figure 4-5 | Nanobodies binding to GI.1. (A) All Nanobodies were able to detect GI.1 P domain in a dose 
dependent manner. (B) All three Nanobodies were able to detect GI.1 VLPs. For Nano-7, the maximum signal at 
the plateau was ~two-fold lower than for Nano-62 and Nano-94. All experiments were performed in triplicates 
(error bars indicate standard deviation), together with Kerstin Ruoff and Alessa Ringel. The figure was adapted 
from (176). 
 
All three Nanobodies bound comparably well to the GI.1 P domain, with similar cut-off 
values. However, for binding of VLPs, only Nano-62 and Nano-94 displayed a similar 
binding pattern, whereas Nano-7 had a ~two-fold lower absorption value at the highest 
concentration. 
 
Figure 4-6 | Cross-reactivity of GI.1 specific Nanobodies. The cross reactivity in ELISA was tested with VLPs 
from GI.2 Southampton, GI.2 Fusabashi258, GI.3 Kashiwa645, GI.4, Chiba Virus and GI.11 #8. The 
Nanobodies were specific to GI.1, no cross-reactivity with any other GI genotype VLPs was observed. All 
experiments were performed in triplicates (error bars show standard deviation).  
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Cross-reactivity binding ELISAs revealed that Nano-7, Nano-62 and Nano-94 were unable to 
bind to VLPs of genotypes other than GI.1. Tested were GI.2, GI.3, GI.4 and GI.11 VLPs 
(Figure 4-6). These results suggested that the binding sites of all three Nanobodies were not 
conserved in other GI genotypes. 
 
Structural analysis of Nanobodies in complex with GI.1 P domain 
The structure for GI.1 P domain in complex with Nano-94, Nano-62 and Nano-7 was solved 
using X-ray crystallography (experiments performed by Dr. Turgay Kilic). Nano-94 bound to 
the top of the P domain (Figure 4-7A), whereas Nano-62 and Nano-7 attached to epitopes 
located at the lower part of the P domain (Figure 4-7B/C). Interestingly, superposition of the 
P domain/Nano-7 or P domain/Nano-62 structure onto the structure of intact VLPs [PDB: 
1IHM (162)] revealed that in context of the whole particle, the Nanobodies would clash with 
the S domains, as well as neighboring P domains (Figure 4-8 and Figure 4-9). 
 
Figure 4-7 | X-ray crystal structures of GI.1 P domain with Nanobodies. (A) GI.1 P domain in complex with 
Nano-7. The binding site of Nano-7 was located at the bottom of the P domain. Two Nanobodies and one 
P domain dimer were forming the asymmetric unit. The Nanobody was held in place by side- and main chain 
interactions from both monomers. (B) X-ray crystal structure of GI.1 P domain bound to Nano-62. The 
asymmetric unit comprised one P domain dimer and two Nanobodies, with binding sites located at the lower part 
of the P domain. Also here, the Nanobody was held by side chain interactions and main chain interactions from 
both P domain monomers. (C) GI.1 P domain in complex with Nano-94. Two Nanobodies were bound per 
P domain dimer. The interaction was formed solely between one Nanobody and a single P domain monomer, as 
the binding site was located at the top of the P domain. All structures were solved by Dr. Turgay Kilic. The 
figure was adapted from (176). 
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When the P domain/Nano-94 complex was superpositioned on the VLP structure, there were 
no clashes with the S domain or neighboring P domains, as it bound to an epitope located at 
the top (Figure 4-10). However, steric hindrance between individual neighboring Nanobody 
molecules was observed at full occupancy. 
 
 
Figure 4-8 | Model of Nano-7 binding to GI.1 VLPs. (A) The X-ray crystal structure of the GI.1 
P domain/Nanobody complex was fitted into the X-ray crystal structure of the GI.1 VLP (PDB: 1IHM). The 
P domain/Nano-7 structure is colored blue and green, respectively. The VLP structure is shown in grey (light 
grey: P domain, dark grey: S domain). (B) A cutout section demonstrates that Nano-7 clashes with neighboring 
P domains and S domains. (C) Close-up view on a C/C dimer shows Nano-7 would clash with neighboring 
P domains in this position. The X-ray crystal structures were solved by Dr. Turgay Kilic, the modeling was 
performed by me. The figure was adapted from (176). 
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Figure 4-9 | Model of Nano-62 binding to GI.1 VLPs. (A) The X-ray crystal structure of the GI.1 
P domain/Nanobody complex was fitted into the X-ray crystal structure of the GI.1 VLP (PDB: 1IHM). The 
P domain/Nano-62 structure is colored blue and cyan, respectively; the VLP structure is illustrated in grey (light 
grey: P domain, dark grey: S domain). (B) A cutout section shows that Nano-62 clashes with neighboring 
P domains and S domains. (C) Close-up view on a C/C dimer shows Nano-62 would clash with neighboring 
P domains in this position. The X-ray crystal structures were solved by Dr. Turgay Kilic, the modeling was 
performed by me. The figure was adapted from (176). 
 
 
Figure 4-10 | Model of Nano-94 binding to GI.1 VLPs. (A) The X-ray crystal structure of the GI.1 
P domain/Nanobody complex was fitted into the X-ray crystal structure of the GI.1 VLP (PDB: 1IHM). The 
P domain/Nano-94 structure is colored blue and orange, respectively. The VLP is shown in grey (light grey: 
P domain, dark grey: S domain). Neighboring Nanobodies would clash at full occupancy. (B) A cutout section 
shows that Nano-94 is binding to the top of the P domain, forming the outermost layer of the capsid/Nanobody 
complex. (C) Model of a close-up top view on a C/C dimer bound with Nano-94. As this Nanobody binds to the 
top, no steric hindrance with neighboring P domains would occur. The X-ray crystal structures were solved by 
Dr. Turgay Kilic, the modeling was performed by me. 
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Attachment inhibition of Nanobodies 
In previous studies it was shown that GII.10 specific Nanobodies could block the attachment 
of VLPs to PGM in a surrogate HBGA binding assay (101). Therefore, we determined if these 
VLPs were able to block the binding of  GI.1 VLPs to PGM in an adapted blocking assay 
(Figure 4-11). 
 
Figure 4-11 | Inhibition of GI.1 VLP HBGA binding by Nanobodies. (A) Nano-7 was able to inhibit the 
attachment of GI.1 VLPs to PGM in a dose dependent manner, with an IC50 value of 0.4 µg/ml. (B) Nano-62 
only exhibited weak inhibitory properties, with a maximum inhibition of 15% at the highest Nanobody 
concentration. (C) Nano-94 blocked the binding of VLPs to PGM, with an IC50 of 9.2 µg/ml. The inhibition 
experiments were performed in triplicates (error bars indicate standard deviation). The experiments were 
performed by Alessa Ringel, Kerstin Ruoff and me. The figure was adapted from (176). 
 
Nano-7 showed the strongest inhibition, with a half maximal inhibitory concentration of 
0.4 µg/ml. Nano-94 also exhibited dose dependent inhibition, with an IC50 of 9.2 µg/ml. 
Despite the binding site similarity of Nano-7 and Nano-62, Nano-62 had only minimal effect 
on PGM attachment, with a maximum inhibition of ~15% at 100 µg/ml Nanobody 
concentration. 
 
The influence of Nanobodies on the GI.1 capsid morphology 
To further characterize the mode of inhibition, we performed DLS and negative stain EM 
experiments on VLPs treated with Nanobodies (Figure 4-12). 
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Figure 4-12 | GI.1 VLPs after Nanobody treatment. (A) In DLS, incubation with Nano-94 (orange) led to an 
increase in hydrodynamic diameter. In contrast, VLPs treated with Nano-7 (green) or Nano-62 (cyan), exhibited 
a comparable hydrodynamic diameter as the untreated VLPs (black). (B) Negative stain EM of VLPs with 
Nanobodies confirmed these results: Nano-94 led to formation of large VLP aggregates, whereas Nano-7 and 
Nano-62 kept the particle morphology intact. DLS measurements and EM images were prepared by Kerstin 
Ruoff and me. The figure was adapted from (176). 
 
The untreated VLPs showed a single peak with a diameter of ~42 nm. Neither Nano-62 nor 
Nano-7 treatment influenced the particle size, and the peaks were comparable to the peak 
exhibited for untreated VLPs. Correspondingly, in negative stain images of the VLPs treated 
with Nano-62 or Nano-7, the VLPs exhibited a morphology that was undistinguishable from 
untreated VLPs. In contrast, incubation with Nano-94 led to a peak shift in DLS to 
~1,000 nm, suggesting particle aggregation or disintegration of the capsid. Negative stain-EM 
confirmed that the addition of the Nanobody led to formation of VLP aggregates. 
 
Combinational treatment of Nanobodies and 2’FL 
Earlier studies suggested that several compounds block HBGA attachment to norovirus VLPs 
by mimicking the binding factor and occupying the HBGA binding site. One example for this 
was 2’FL, which inhibited GI.1 VLP-HBGA attachment with an IC50 of ~50 mM (98). 
Therefore, we wanted to explore, if the combination of two independently working inhibitors 
could improve the blocking potential. For this experiment, the inhibition ELISA was adapted: 
Constant concentrations of 2’FL (10, 20, 30, 40 and 50 mM) were combined with serially 
diluted Nanobodies (Nano-7 and Nano-94) and incubated with GI.1 VLPs, to determine their 
combined blocking potential (Figure 4-13). In both cases, the combination led to enhanced 
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inhibition, suggesting that the compounds did not influence each other negatively. Instead, the 
extent of inhibition increased with higher 2’FL concentrations. We applied the mathematical 
model of Bliss (15, 160), to define if the observed effect was synergistic or additive. In this 
model, an expected value for additivity is calculated from the inhibition values of the two 
compounds alone. If the observed inhibitory effect is more than 20% above this value, the 
compounds act synergistically.  
For combinations with 40 and 50 mM 2’FL (Figure 4-13 D/E/I/J), the effects could not be 
defined as synergistic, as the calculated expected additive effect exceeded 100% inhibition. 
With Nano-94, several values could be defined as synergistic according to our 20% criteria: 
10 mM 2′FL combined with 25, 12.5, and 6.3 µg/ml of Nano-94 (Figure 4-13A) and 20 and 
30 mM 2′FL combined with 12.5 to 3.1 µg/ml of Nano-94 (Figure 4-13B/C). The differences 
between synergistic values and expected additivity were determined as statistically significant 
in all cases by paired t-test and two-way analysis of variance (ANOVA). Combination of 
2’FL with Nano-7 increased inhibition additively at all tested concentrations, but no 
synergistic effects were observed (Figure 4-13F/G/H/I/J). 
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Figure 4-13 | Combinational inhibitory effects of Nano-7 and Nano-94 with 2’FL. Serially diluted 
Nanobodies were combined with constant concentrations of 2’FL. (A-E) The graphs demonstrate inhibition of 
Nano-94 alone (orange circles), 2’FL alone (dashed line), expected values for additivity according to the 
mathematical model of Bliss (black triangles), and the observed inhibition of the combination (blue/orange 
circles). For several combinations of Nano-94 and 2’FL, the effect could be defined as synergistic. (F-J) The 
graphs show inhibition of Nano-7 alone (green circles), 2’FL alone (dashed line), the expected values for 
additivity according to the Bliss model (black triangles) and the observed inhibition of the combination 
(blue/green circles). The observed inhibition values closely matched the expected values for additivity, 
suggesting an additive effect for this combination. Experiments were performed in triplicates; error bars 
represent the standard deviation. Kerstin Ruoff, Alessa Ringel and me performed and analyzed the experiments. 
The figure was adapted from (176). 
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Cryo-EM analysis of GI.1 VLPs 
As mentioned, Nano-7 and Nano-62 bound to seemingly sterically occluded sites on the 
capsid. Therefore, we sought to analyze the structure of Nanobody-bound VLPs more in detail 
using single particle cryo-EM. 
The X-ray crystal structure of an unliganded GI.1 VLP had already been solved in 1999 (162). 
In this structure, the P domains were located on the shell and the hinge region was not 
extended. This structure was in contrast with published calicivirus structures from other 
genotypes, where the P domains were linked to the S domain by an extended hinge region 
(69, 87). As most other VLP structures were solved using single particle cryo-EM, this raised 
the question whether the differential conformations of the P domains were genotype 
dependent, or if they represent two states of the virus. Therefore, our first aim was to 
determine the structure of a native GI.1 VLP using cryo-EM and evaluate the positioning of 
the P domains.  
In the vitreous ice, GI.1 particles tended to aggregate (Figure 4-14A). To circumvent this 
issue, we deposited a carbon layer onto the grids prior to freezing, a procedure, which 
considerably improved particle distribution und uniformity (Figure 4-14B). Similar 
improvements could be observed with graphene oxide covered grids (Figure 4-14C). In 
general, graphene oxide has superior properties compared to carbon, as it is thinner and 
therefore introduces less background signal. However, the amount of deposited graphene 
flakes on the grid was too low to allow efficient data collection on these grids. Therefore, we 
used carbon-covered grids for GI.1 data collection. 
 
Figure 4-14 | Particle distribution of GI.1 VLPs in vitrified ice with different support films. Without 
support film, the VLPs tended to form large clusters. On grids with either graphene oxide or carbon film 
backing, the VLPs were preferentially monodisperse. The scale bar represents 100 nm. 
No support film Graphene oxide Carbon  
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After treatment of the grids with a carbon support film, the particles were preferentially 
monodisperse in the ice (Figure 4-14C). GI.1 particles were not homogenous and two 
differently sized populations of particles were observed. 
The particles with larger diameter were the supposedly native sized T=3 icosahedral VLPs. 
Particles were picked automatically from 3,082 images and sorted in 2D classification. The 
particles appeared to have a distorted shape (Figure 4-15A). Because of the heterogeneity 
within the particles, the 3D structure of those VLPs could not be solved. 
 
Figure 4-15 | 2D classification of GI.1 VLPs. (A) T=3 icosahedral particles showed a blurred, distorted 
morphology. (B) T=1 icosahedral particles showed well-resolved S domains with clearly visible features, and 
low contrast P domains.  
 
Smaller particles were picked and classified separately (Figure 4-15B). 56,732 particles were 
used for 3D reconstruction, which revealed a T=1 icosahedral capsid. The shell of the 
particles was resolved to a nominal resolution of 3.9 Å. GI.1 S domain monomers could be 
fitted unambiguously into the densities and revealed the icosahedral cage of the T=1 capsid 
(Figure 4-16A/B). The closed shell consisted of 60 individual VP1 subunits. The P domains 
could not be resolved in this structure and appeared as smeared densities (Figure 4-16C/D). 
The resolution of the shell indicated that in general the dataset was of good quality and the 
lack of resolution in the T=3 particles and the T=1 P dimers was likely caused by 
heterogeneity within the particles. Surprisingly, the densities corresponding to the P dimers 
appeared to be located at the three-fold axes, instead of the two-fold axes. 
A 
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Figure 4-16 | Structure of the GI.1 T=1 icosahedral particle. (A) Fitted X-ray crystal structures of the GI.1 
S domain (PDB: 1IHM) revealed the icosahedral cage of the particle. The S domain dimers around the five-fold 
axes are colored. (B) Structure at a threshold of 0.3 shows only the shell. Fitted into the structure are the 
S domains of GI.1, as shown in (A). (C) At a threshold of 0.23, a density was visible at the three-fold axes, with 
three spikes extending out to the five-fold axes. (D) At a threshold of 0.15, also densities at the two-fold axes 
were observable. 
 
To improve the resolution of the smeared P domains, we applied focused reconstruction, but 
resolution was still limited. Nevertheless, two different main classes emerged after this 
classification: One with the P domains at the expected position at the two-fold axes with three 
P domain dimers located around the three-fold axes and one where the P domains appeared to 
form a trimeric assembly at the three-fold axes. However, resolution was not sufficient to 
allow detailed analysis of the complex. Nevertheless, this suggests that in this particle the 
P domain might form trimeric complexes instead of the typical dimeric arch like structures. 
Higher resolution information would be required here, in order to characterize this apparently 
trimeric complex in detail. 
  
B 
C D 
A B 
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4.4. Discussion  
Neutralizing antibodies represent one promising class of potential antivirals against norovirus. 
High-risk populations could be treated with passive immunoprophylaxis or immunotherapy to 
prevent acute norovirus outbreaks. Antibodies are currently evaluated for their potential to 
combat different viral infections in clinical trials, such as cytomegalovirus, influenza or 
respiratory syncytial virus (64, 74, 80). 
Numerous antibodies have been described that are able to block the HBGA binding of VLPs 
to HBGAs in surrogate assays (26, 118, 120, 122). The antibodies we tested in our array were 
raised against GI.1 and many of those were able to detect other GI genotypes as well, 
indicating that these cross-reactive antibodies bound to parts of the VLP that are conserved 
between the different genotypes. The tested GI VLPs exhibit amino acid identities ranging 
from 67,16% (GI.3 Kashiwa645 to GI.2 Funabashi258 and GI.2 Southampton) to 99.63%, 
(GI.2 Funabashi258 and GI.2 Southampton). The most sequence differences were located in 
the P2 subdomain. Therefore it is conceivable that the non-cross-reactive antibodies bound to 
the P2 subdomain. Of note, this subdomain contains the HBGA binding site (19, 21, 29). Five 
antibodies were able to block HBGA binding. As these inhibiting antibodies were not cross-
reactive, it is likely that these antibodies bound to the P2 subdomain, thereby blocking access 
to the HBGA binding site on the VLPs. 
Cross-reactivity plays a vital role in determining whether a potential agent could be used as an 
efficient antiviral. This is particularly true for norovirus, where a multitude of strains are 
existing and new strains are emerging constantly (187). Unfortunately, the only inhibiting 
antibodies we discovered were not cross-reactive against other strains and could therefore 
most likely not serve as a potent antiviral against norovirus, especially as GI infections are 
comparably rare. Moreover, blockage potency of the antibodies was relatively low compared 
to other previously described norovirus specific antibodies (26, 118). 
Conversely to the antibodies, the HMO 2’FL showed a broad inhibition profile across all 
tested GI genotypes. Only for GI.4 Chiba virus, inhibition was too low to determine an IC50 
value. In a prior HBGA binding study, it was determined that in contrast to GI.1, GI.2 and 
GI.3 VLPs, GI.4 VLPs were not able to bind synthetic H type 1/2/3, HBGA carbohydrates, 
suggesting differences in the HBGA binding sites of this genotype (185). These differences 
could also translate to a reduced affinity to 2’FL, as it blocks the HBGA binding site.  
In recent years, Nanobodies have been extensively investigated as potential therapeutics (2, 
180). Nanobodies have several advantages over conventional antibodies, such as their stability 
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and small size that could allow them to bind to occluded sites on the viral particle. In our GI.1 
Nanobody study, we characterized three different GI.1 specific Nanobodies. We found that 
two of the Nanobodies (Nano-7 and Nano-62) bound to the P1 sub-region of the P domain. 
Modeling the X-ray crystal structure of the complex on to the intact particle revealed clashes 
with adjacent P domains and S domains, suggesting that in this P domain conformation the 
Nanobodies would be unable to bind. Steric hindrance between Nanobodies was also 
observed for Nano-94 that bound to the top of the P domain. Therefore, it is likely that the 
P domains structurally rearrange upon binding of the Nanobodies to allow full occupancy. 
This could be possible due to the flexible nature of the hinge region. Moreover, the VLPs 
appeared undistorted in EM, suggesting that the intrinsic flexibility allows Nanobody 
attachment to these occluded sites, to prevent disassembly of the particle. Likewise, with GII 
specific Nanobodies (101) and one antibody (69), clashing with the shell has been observed 
when modeling the X-ray crystal structure into the intact capsid. This suggests that the shift of 
P domains is a common occurrence and possible in both GI and GII noroviruses. 
GI.1 and GII.10 VLPs exhibit marked differences in their P domains, with GI.1 P domains 
being lowered and GII.10 P domains being raised (69, 162). It was suspected that these 
differences could be due to the differences in visualizing techniques (X-ray crystallography 
versus cryo-EM) and that the pH and ionic strength of the crystallization conditions could 
contribute to the lowering of the P domains. Because of high heterogeneity in the sample, we 
could not solve the GI.1 structure in cryo-EM to resolve this issue. Nevertheless, recently a 
cryo-EM structure of GI.1 was solved that reported lowered P domains as well, suggesting 
this state could indeed be a feature of GI.1 noroviruses and was not caused by the 
crystallization conditions (82). 
In context of the intact particles, Nano-7 exhibited a lowered maximal detection signal in 
direct ELISAs than Nano-94 and Nano-62. This might be due to steric hindrances in the 
particle that could prevent all binding sites from being occupied. When binding to P domains 
only, steric hindrance would not be a problem, thus explaining the similar detection levels that 
were observed in the binding ELISA using isolated P domains. 
Despite the similarities of the binding sites of Nano-7 and Nano-62, only Nano-7 was able to 
efficiently inhibit the binding of VLPs to HBGAs (Figure 4-11). This suggests that small 
differences in binding can have a strong impact on inhibitory properties. This is also 
highlighted by the fact that Nano-62 bound to a similar binding site as GII specific Nano-26 
(101), a Nanobody that efficiently disassembled VLPs upon binding. Conversely, Nano-7 did 
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not compromise particle integrity. As direct steric interference of the HBGA binding site can 
be ruled out, no clear mode of action could be defined for this Nanobody. However, our 
results indicated that this Nanobody has a very large footprint, burying more residues than any 
other norovirus-specific Nanobody characterized so far. It could be possible that binding to 
that site triggers internal rearrangements within the P domain that allosterically influence the 
HBGA binding site. 
The third Nanobody studied here, Nano-94, had a distinct binding site, located at the top part 
of the P domain. This Nanobody most likely inhibited HBGA attachment by aggregation of 
the capsids. Particle aggregation has previously been observed for GII specific Nanobody 
Nano-32 as well (101). However, in this case, rearrangement of several loops in the P domain 
was observed that altered hydrophobicity of the capsid, which was not observed for Nano-94. 
Furthermore, we showed that combinational treatment of Nanobodies and the HMO 2’FL led 
to improvement in attachment inhibition. Combination of 2’FL and Nano-94 could be defined 
as synergistic for several conditions. This increase in inhibition might occur as follows: 
Nano-94 binding led to inhibition of VLPs, and remaining available binding sites were then 
blocked by 2’FL attachment to the binding site. With the addition of Nano-94, the 
concentration of 2’FL was higher relative to the remaining free binding sites, explaining the 
synergistic effect. For Nano-7 the effect was defined as additive, but as no clear mode of 
inhibition was defined for Nano-7, also the additive effect could not be explained in detail. 
Most likely however, the additive effect was only caused by the increased total concentration 
of inhibitor in the sample. Nevertheless, we could show that the positive effect of combining 
two different compounds is not limited to a single mode of action of Nanobodies and could 
therefore be exploited in a therapeutic setting.  
Nanobodies have shown promising results as treatments against various viral infections, such 
as HIV or influenza (39). One study demonstrated that a rotavirus-specific Nanobody could 
be used to treat human rotavirus induced symptoms in gnotobiotic pigs (214). Generally, 
Nanobodies are considered as safe and of high efficacy and are therefore of great interest as 
potential therapeutics (2, 152, 213). Combining these efficient antivirals with other 
compounds, such as the broadly-reactive compound 2’FL, could provide higher 
cross-reactivity of the antiviral and higher efficacy without increasing the individual dose of 
the active compounds. Different compounds can act together to increase their effects, or work 
independently on different target sites, to maximize the efficacy. For drug discovery, 
synergistic effects of compounds play a pivotal role and are investigated for a broad range of 
	 Chapter	1		
 54 
different viruses, such as dengue virus or hepatitis C (51, 157, 161). Moreover, combined 
activity of antiviral compounds has also previously been shown for rotavirus, another 
gastroenteritis causing virus: Two studies found that plant-derived compounds were able to 
synergistically inhibit replication in in vitro experiments (94, 123). 
So far, 2’FL has been shown to inhibit GI.1, GII.10, GII.4, GII.17 (98, 220) and also GI.2 and 
GI.3 as shown in this study. However, the IC50 values are relatively high. Nevertheless, as 
2’FL is present in mother’s milk with concentrations up to 20 g/l (16), corresponding to a 
molar concentration of ~40 mM. This shows that 2’FL is safe for consumption at high 
concentrations, even for infants. Combinatorial treatment of 2’FL with a more specific, but 
highly efficient compound could improve the degree of inhibition. It could also be possible to 
combine a Nanobody that inhibits the HBGA binding with a differently acting drug class, 
such as an RdRp inhibitor (170, 171), to target different stages of norovirus infection 
simultaneously. This method is employed in several drugs, such as the state-of-the-art HIV 
treatment, where three synergistically acting compounds are used to suppress different stages 
of the viral life cycle (17, 52, 107). Combination of differently acting drug classes can also 
prevent the emergence of escape mutants for specific antivirals, which is especially 
problematic in fast evolving viruses, such as norovirus.  
In summary, we could show that norovirus HBGA attachment inhibition can be 
synergistically improved by combinatorial treatment. As in the case of norovirus, limited 
cross-reactivity between different genogroups is one of the major impediments for the 
development of antivirals, combination treatment could be a remedy and should be considered 
in further studies. 
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5. Chapter 2: Expression of GII.4 VP1 forms T=4 icosahedral 
particles 
5.1. Summary 
In this chapter we solved the structures of VLPs from different GII.4 variants using single 
particle cryo-EM. Surprisingly, we found that all examined GII.4 variants mainly formed 
particles of T=4 icosahedral symmetry. We showed that this is also the case for the vaccine 
candidate GII.4c, which could have implications for vaccine efficacy. Conversely, negative 
stain experiments suggested that the infectious virion has T=3 icosahedral symmetry, 
indicating that GII.4 VLPs mainly adopted a non-native conformation. Moreover, the 
formation of T=4 particles appeared to be independent of the expression system, as 
expression in insect as well as mammalian cells favored T=4 VLP formation. 
5.2. Contributions 
A part of the results in this chapter was published as: 
Devant JM, Hofhaus G, Bhella D, Hansman GS. 2019. Heterologous expression of human 
norovirus GII.4 VP1 leads to assembly of T=4 virus-like particles. Antiviral Research 
168:175-182 
 
Figures were adapted from this publication, as mentioned in the figure legend. All 
experiments were performed by me. Dr. Götz Hofhaus helped with data collection and 
processing; Dr. David Bhella helped with data processing. The paper was written by Dr. Grant 
Hansman and me, and all authors commented on the manuscript. 
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5.3. Results 
Structural analysis of GII.4 NSW-2012 VLPs  
In recent years, structural studies on human noroviruses were mostly focusing on isolated 
P dimers, and information about intact particles was limited. Only two structures, of GI.1 
(162) and GII.10 VLPs (69) were available, both of which were less clinically relevant 
genotypes. In order to gather additional structural information in terms of the intact particle, 
we decided to solve the structure of VLPs representing the clinically prevalent human 
norovirus genotype GII.4. 
 
Figure 5-1 | Sequence alignment of GII.4 VP1. NSW-2012 (JX459908), CHDC-1974 (ACT76142), and GII.4c 
(153) VP1 amino acid sequences were compared in ClustalX (111). The N-terminus (orange), S domain 
(yellow), hinge region (green) P1 subdomain (light blue) and P2 subdomain (dark blue) are marked. The 
S domain exhibited the highest conservation rate, most substitutions were found in the P domain, especially the 
P2 subdomain. Compared to CHDC-1974, NSW-2012 and GII.4c had an amino acid insertion at position 394 
(numbering according to NSW-2012). The figure was adapted from (41). 
 
In our first analysis, we focused on two different GII.4 isolates from 1974 and 2012, termed 
CHDC-1974 and NSW-2012, respectively. Sequence alignment revealed that the genotypes 
had 89% sequence identity. Most substitutions (45 out of 54) were located in the P2 domain, 
whereas the hinge region and the S domain were mostly conserved (Figure 5-1). Additionally, 
NSW-2012 had a single aa insertion at position 394 compared to CHDC-1974. 
 
NSW-2012           1 MKMASSDANPSDGSAANLVPEVNNEVMALEPVVGAAIAAPVAGQQNVIDPWIRNNFVQAP     60
CHDC-1974          1 ..............T...............................I.............     60
GII.4c             1 ..............T.............................................     60
                     ************** ******************************* *************
NSW-2012          61 GGEFTVSPRNAPGEILWSAPLGPDLNPYLSHLARMYNGYAGGFEVQVILAGNAFTAGKVI    120
CHDC-1974         61 .....................S..........S.........................I.    120
GII.4c            61 ..........................................................I.    120
                     ********************* ********** ************************* *
NSW-2012         121 FAAVPPNFPTEGLSPSQVTMFPHIVVDVRQLEPVLIPLPDVRNNFYHYNQSNDPTIKLIA    180
CHDC-1974        121 ...I....................I.........................AH.S.L....    180
GII.4c           121 ........................I...................................    180
                     *** ******************** *************************  * * ****
NSW-2012         181 MLYTPLRANNAGDDVFTVSCRVLTRPSPDFDFIFLVPPTVESRTKPFSVPVLTVEEMTNS    240
CHDC-1974        181 ...............................................T..I......S..    240
GII.4c           181 ...............................................T..I.........    240
                     *********************************************** ** ****** **
NSW-2012         241 RFPIPLEKLFTGPSSAFVVQPQNGRCTTDGVLLGTTQLSPVNICTFRGDVTHITGSRNYT    300
CHDC-1974        241 .........Y.............................A....N......RVGI.HD..    300
GII.4c           241 ..............G......................................A.TQE..    300
                     ********* **** ************************ **** ******       **
NSW-2012         301 MNLASQNWNDYDPTEEIPAPLGTPDFVGKIQGVLTQTTRTDGSTRGHKATVYTGSADFAP    360
CHDC-1974        301 ...V.....N......................L......A.....A.....S...VH.T.    360
GII.4c           301 .........N.............................G...........S...VH.T.    360
                     *** ***** ********************** ****** ***** ***** ***  * *
NSW-2012         361 KLGRVQFETDTDRDFEANQNTKFTPVGVIQDGGTTHRNEPQQWVLPSYSGRNTHNVHLAP    420
CHDC-1974        361 ...S...T...NN..QTG..............DH-.Q.........N...TSG.......    419
GII.4c           361 ...S...S...SN...TG..........V...S...Q.........D....DS.......    420
                     *** *** ***  **   ********** ***   * ********* ***   *******
NSW-2012         421 AVAPTFPGEQLLFFRSTMPGCSGYPNMDLDCLLPQEWVQYFYQEAAPAQSDVALLRFVNP    480
CHDC-1974        420 ...........................N..........SH....................    479
GII.4c           421 ...........................N...........H....................    480
                     *************************** **********  ********************
NSW-2012         481 DTGRVLFECKLHKSGYVTVAHTGQHDLVIPPNGYFRFDSWVNQFYTLAPMGNGTGRRRAV    540
CHDC-1974        480 ................I......PY............................S..K.VL    539
GII.4c           481 ...........................................................L    540
                     **************** ******  **************************** ** *
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Negative stain comparison of different norovirus VLPs 
Negative stain EM revealed that the GII.4 VLP samples were homogenous and exhibited the 
typical norovirus characteristics, with clearly visible spikes on the surface. However, the 
diameters appeared enlarged compared to VLPs from other genotypes. GII.4 VLPs exhibited 
diameters of ~52 nm, whereas e.g. GII.10 and GI.1 VLPs, for which the structure had already 
been solved, had a smaller diameter of ~43 and 38 nm, respectively (69, 162). 
Comparison of different genotypes revealed that in fact, exclusively GII.4 (CHDC-1974, 
Saga-2006, Yerseke-2006 and NSW-2012, both VP1 only and VP1/VP2 VLPs) exhibited 
these larger assemblies (Figure 5-2). All other examined genotypes, from both GI and GII, 
exhibited particle sizes between 40-45 nm. Interestingly, in several cases, smaller VLPs of 
~28 nm could be observed as well. These particles were found for several different genotypes, 
e.g. GI.1, GII.4 or GII.10. 
 
Figure 5-2 | Size comparison of different VLPs. (A) Negative stain EM micrographs of different norovirus 
VLPs. VLPs from GII.4 genotypes exhibit a larger diameter than VLPs from GI or GII.1 Hawaii, GII.10 026 
Vietnam or GII.17 Kawasaki. The GII.4 genotypes are marked in red. The scale bar represents 50 nm. (B) 
Scatterplot of different VLP sizes. 50 single VLPs per genotype were measured in Fiji (182). GII.4 VLPs are 
marked in shades of blue.  
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Single particle analysis of GII.4 NSW-2012 VLPs 
We applied single particle cryo-EM to determine the structure of NSW 2012 VLPs to a 
resolution of 7.3 Å. The particles were separated evenly in the ice and were mainly 
homogenous (Figure 5-3A/B). 364 images were acquired, from which 10,548 particles were 
used for the final icosahedral reconstruction of the structure, which had a resolution of 7.3 Å 
(Figure 5-3C). 
 
Figure 5-3 | Data processing of NSW-2012 VLPs. (A) Representative cryo-EM micrograph of NSW-2012 
VLPs, acquired at 64,000× magnification. The arrows indicate VLPs with 46 nm (blue) nm and 50 nm (green) 
diameters. The scale bar represents 100 nm. (B) 2D classification of T=4 icosahedral particles. (C) FSC plot of 
the icosahedral reconstruction of NSW-2012 VLPs reveals a resolution of 7.3 Å (0.143 FSC cut-off) and 8.2 Å 
(using 0.5 FSC cut-off). The figure was adapted from (41). 
 
Interestingly, NSW-2012 VLPs exhibited T=4 icosahedral symmetry (Figure 5-4A), meaning 
the VLPs were composed of 240 copies of VP1, instead of 180, which would correspond to 
T=3 icosahedral symmetry. The VLPs had an inner and outer diameter of 32 and 50 nm, 
respectively (Figure 5-4B). The shell volume was calculated to be ~12,724 nm3. This is ~2.1× 
the volume of GII.10 VLPs, which represent a typical calicivirus structure (69). With an inner 
diameter of 23 nm, the volume of GII.10 was calculated to be ~5,985 nm3. 
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Figure 5-4 | Cryo-EM reconstruction of NSW-2012 VLPs. (A) The left side shows an intact particle, 
exhibiting T=4 icosahedral symmetry. Symmetry axes are labeled as 2, 3 and 5. The VLPs were composed of 
240 VP1 molecules that formed two types of dimers; A/B and C/D. B, C and D subunits were at the icosahedral 
two-fold axes, whereas A subunits were located around the icosahedral five-fold axes. The right image is a 
cutaway section of the particle, indicating the inner and outer diameter (32 and 50 nm, respectively) and the 
elevation of the P domains (2.1 nm). (B) The S domain associated with the D subunit was forming a cavity and 
flap like structure that was disrupting the shell. (C) For NSW-2012 T=4 VLPs, both A/B and C/D dimers were in 
a bent S domain conformation. For the C/D dimer, an additional connection was visible between S domain and 
the P1 subdomain. The figure was adapted from (41). 
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formed the capsid. This was markedly different from T=3 particles, which were assembled 
from only 60 A/B and 30 C/C dimers. The A subunit was located at the five-fold axes, 
whereas B, C and D subunits alternated around the two-fold axes (Figure 5-4A/B). Close 
inspection of the isolated dimers showed that both A/B and C/D dimers exhibited a similar 
S domain conformation. In both cases, the S domain was in a convex conformation with 
upwards facing S domains (Figure 5-4C). Conversely, in GI.1 only A/B dimers exhibited a 
convex conformation, whereas the C/C dimers were flat (162). 
In both A/B and C/D dimers, the P domains were raised 21  Å off the shell. Therefore, the 
structure more closely resembled the GII.10 structure (69), than the structure of GI.1 (162), 
even though in GII.10 the P domains were raised only 14 Å. 
Another main difference to typical T=3 structures was found in the shell. Usually, the 
S domains form a contiguous capsid, protecting the enclosed RNA genome. In the T=4 
particles the shell was disrupted by a cavity and flap like structure (Figure 5-4B and Figure 
5-5). This feature was located at the two-fold axes and formed by the S domain of subunit D, 
likely a result of the convex C/D dimer. 
For verification of the structure, we modeled the X-ray crystal structures of the GI.1 S domain 
(PDB: 1IHM) and the P domain of NSW-2012 [PDB: 4OOS (189)] into the obtained density 
map (Figure 5-5). The P domains were fitted unambiguously into both A/B and C/D dimers, 
with cross-correlation coefficients of 0.96, suggesting that no large structural rearrangements 
in the P domain occurred between A/B and C/D dimers. For the S domain, the model could be 
fitted into the A, B and C subunits, but for the elevated S domain of the D subunit, it had to be 
shifted upwards to accommodate the formation of the flap like structure. Nevertheless, the 
X-ray crystal structure could be fitted easily into the density, indicating that mainly rigid body 
movement was involved in this structural rearrangement. A connection between the 
C-terminus of the P domain and the S domain was present that appeared to stabilize this 
untypical conformation (Figure 5-4C and Figure 5-5B). 
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Figure 5-5 | X-ray crystal structures of NSW-2012 P domain and GI.1 S domain fitted into the density 
map of NSW-2012 VLPs. (A) Left shows a close-up on the three-fold axis, with GI.1 S domain (PDB: 1IHM, 
cartoon) fitted into A/B and C/D densities. Right shows a close-up on a two-fold axis, with NSW-2012 P domain 
X-ray crystal structure (PDB: 4OOS, cartoon) fitted into A/B and C/D P domain dimers. (B) Close-up on a 
single C/D dimer of NSW-2012. The new connection between S and P domain is visible. The asterisk is 
representing the hinge region that was not visible in either of the X-ray crystal structures. The hinge region was 
visible and connected S and P domain in both C subunit (blue) and D subunit (red). The figure was adapted from 
(41). 
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T=3 icosahedral symmetry of GII.4 NSW-2012 VLPs 
Most of the VLPs in the raw micrographs were homogenous and exhibited the untypical T=4 
symmetry. Notably, a small subset of 391 particles exhibited a smaller diameter, indicating a 
native T=3 icosahedral symmetry (Figure 5-6A). Icosahedral reconstruction of these particles 
revealed that in fact the particles exhibited T=3 icosahedral symmetry (Figure 5-6C). The 
particle had an inner diameter of ~24 nm, and an outer diameter of ~46 nm, corresponding to 
the particle size that has been determined for GII.10 VLPs (69). 
 
Figure 5-6 | Cryo-EM structure of NSW-2012 T=3 icosahedral VLPs. (A) 2D classification of 1,780 
manually picked particles showed two differently sized assemblies. The first class (red circle) contained 391 
particles with a smaller diameter and was used for further refinement. (B) The FSC plot of the T=3 VLPs 
indicates a resolution of 15 Å and 19 Å, using 0.143 and 0.5 FSC cut-off, respectively. (C) The left side shows 
NSW-2012 T=3 VLP structure with symmetric axes labeled (2, 3, 5). The right figure is a cutaway section, 
indicating an inner and outer diameter of 24 and 46 nm, respectively. At this low resolution, the hinge region 
was not resolved, but a large gap between S and P domain suggests that the P domains were raised up from the 
shell. The figure was adapted from (41). 
 
Due to the low number of particles, the structure was only solved to a maximal resolution of 
15 Å (Figure 5-6B). The hinge region was not resolved at this resolution, but a gap between S 
and P domain indicated that the P domains were raised up from the shell, similarly as in the 
T=4 icosahedral particle. Interestingly, it appeared as if the shell was fully closed in this 
particle. However, higher resolution information would be necessary to unambiguously 
answer this question. 
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Comparison of different GII.4 VLP preparations  
Comparison of negative stain images of different GII.4 VLPs preparations revealed that the 
diameter was comparable across all samples, suggesting that the T=4 particles are formed 
reproducibly, excluding batch effects. To eliminate the possibility that the T=4 particles were 
produced due to an error in the expressed VP1 sequence, we cloned and expressed a new 
construct of GII.4 NSW-2012 VP1 and VP1/VP2. However, also in these cases, the diameter 
of the resulting VLPs suggested the formation of T=4 particles. 
In general, our results revealed that VP1 from NSW-2012 mainly formed two types of 
particles, with T=4 and T=3 icosahedral symmetry. Surprisingly, the non-native T=4 
symmetry was highly favored and only ~5% of the population exhibited T=3 symmetry. This 
proportion was found in several different VLP preparations. 
 
Structural analysis of GII.4 CHDC-1974 VLPs 
In order to verify T=4 symmetry as a universal property of GII.4 norovirus VLPs, we 
determined the structure of GII.4 CHDC-1974 VLPs. In raw micrographs the VLPs appeared 
mostly monodisperse and homogenous, with a similar appearance to GII.4 NSW-2012 VLPs 
(Figure 5-7A/B). 42,485 particles were used for the final reconstruction that had a resolution 
of 6.1 Å (0.143 FSC cut-off, Figure 5-7C). 
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Figure 5-7 | Data processing of CHDC-1974 VLPs. (A) Representative cryo-EM micrograph of CHDC-1974 
VLPs, acquired at 64,000× magnification. The scale bar represents 100 nm. (B) 2D classification of CHDC-1974 
VLPs. (C) The FSC plot of the icosahedral reconstruction indicates a resolution 6.1 Å and 7.2 Å using FSC 
cut-off at 0.143 and 0.5, respectively. The figure was adapted from (41). 
 
In general, the structure of the GII.4 CHDC-1974 VLPs closely resembled the structure of the 
newer GII.4 NSW-2012 isolate. 240 copies of VP1 formed 60 A/B and 60 C/D dimers that 
made up the T=4 icosahedral capsid (Figure 5-8A). 
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Figure 5-8 | Cryo-EM structure of CHDC-1974 VLPs. (A) Shown on the left is an intact particle with T=4 
icosahedral symmetry. The symmetry axes are labeled accordingly (2, 3, 5). The VLPs contained 240 subunits of 
VP1 that were assembling into distinct dimers, A/B and C/D. A subunits were located at the five-fold axes, 
whereas B, C and D subunits were alternating at the two-fold axes. On the right is a cutaway section, which 
indicates the diameters of the structure (32 nm inner diameter, 50 nm outer diameter). The hinge region was 
visible and measured 2.1 nm. (B) The cavity and flap like structures were also observed on the CHDC-1974 two-
fold axes. As in NSW-2012, the structure was formed by the D subunit S domain. (C) Both A/B and C/D dimers 
exhibited a bent S domain conformation, with the S domain being slightly less bent in the C/D dimer. Also here, 
an additional connection between S and P domain was found in the C/D dimer. The figure was adapted from 
(41). 
 
The inner diameter was measured to be 32 nm, the outer diameter was 50 nm, and the hinge 
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and flap like structure, although the curvature was slightly less pronounced than in 
NSW-2012 VLPs (Figure 5-8B). Concomitantly, the C/D dimer was less convex than the A/B 
dimer. Nevertheless, the connection between S domain and C-terminus of the P domain was 
still observed (Figure 5-8C). 
 
Figure 5-9 | X-ray crystal structures of CHDC-1974 P domain and GI.1 S domain fitted into the density 
map of CHDC-1974 VLPs. (A) In the left image, the X-ray crystal structure of GI.1 S domain (PDB: 1IHM, 
cartoon) was fitted into the S domain densities at a two-fold axis. On the right, the X-ray crystal structure of 
CHDC-1974 P domain (PDB: 5IYN) was fitted into P domain densities. (B) Detailed view of a single CHDC-
1974 C/D dimer. The new connection between S domain and P1 subdomain is shown. The asterisks are 
representing the hinge regions that are not visible in the X-ray crystal structures and could not be fitted into the 
densities of the C subunit (blue) and D subunit (red) hinge regions. The figure was adapted from (41). 
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The X-ray crystal structure of GII.4 CHDC-1974 P domain (PDB: 5IYN) and GI.1 S domain 
(PDB: 1IHM) were fitted into the density well (Figure 5-9). Similarly to the NSW-2012 
structure, the S domains appeared to be conserved, and only fitting of the D subunit S domain 
the X-ray crystal structure had to be positioned up, in order to fit into the flap-like density. 
 
Vaccine candidate GII.4c VLPs 
A norovirus vaccine candidate, using GII.4c VLPs as immunogen, has recently entered phase 
IIb clinical trials (112, 208). As our experiments suggested that the formation of T=4 particles 
is GII.4 specific, we wanted to determine, whether GII.4c would form T=4 symmetric 
particles as well, as this could have implications on the efficacy of the vaccine. The sequence 
of GII.4c VLPs is a consensus sequence derived from the sequences of GII.4 2002 Houston, 
2006a Den Haag and 2006b Yerseke (153), but also closely matched the sequence of GII.4 
NSW-2012 and CHDC-1974 VLPs, with sequence identities of 94.26% and 92.39% 
respectively (Figure 5-1). 
As for other tested VLPs, GII.4c VLPs were expressed in HighFive insect cells, using a 
baculovirus expression system. In negative stain images, the VLPs exhibited a diameter 
comparable to other GII.4 VLPs, suggesting that also here, T=4 particles were formed. The 
sample appeared to be heterogeneous, with smaller particles present, that most likely were of 
T=1 and T=3 symmetry. In a first test we could show that the VLPs were functional and could 
bind to A and B saliva samples and PGM. 
 
Separation of differently sized GII.4c particles and antigenic differences 
Because of the heterogeneity in the sample, we tried to separate the particles by size in a 
sucrose gradient centrifugation or size exclusion chromatography. Two bands were visible in 
the sucrose gradient, corresponding to T=1 and a mixture of T=3 and T=4 particles, as 
confirmed by negative stain EM. 
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Figure 5-10 | Size exclusion chromatography of purified GII.4c VLPs. The chromatogram exhibits two 
overlapping peaks at 150 and 200 ml flow. Negative stain EM verified that the first peak contained mainly T=4 
icosahedral symmetric particles, whereas the second peak contained the small T=1 icosahedral particles. No peak 
corresponding to T=3 icosahedral particles was observed. The scale bar in the negative stain EM micrographs 
corresponds to100 nm. 
 
Separation using size exclusion chromatography only succeeded to separate T=1 particles 
from the larger particles, only two peaks were visible in the chromatogram (Figure 5-10). 
Negative stain EM confirmed that the first peak mainly consisted of T=1 particles, whereas 
the second peak contained both T=3 and T=4 particles. Unfortunately it was not possible to 
separate T=3 and T=4 particles. 
Therefore, in order to identify if there are antigenic differences between differently sized 
particles, we compared the antigenicity between separated T=1 and T=3/T=4 particles. 
 
Figure 5-11 | Antigenic comparison of GII.4c T=1 and T=4 particles using direct binding ELISA. (A) 
Binding curves of a polyclonal GII.4 specific antibody to T=1 (blue) and T=4 (red) particles. The binding curves 
exhibited a similar plateau value and slope for both VLP types. (B) Antigenic comparison using Nano-26 
indicates a stronger binding to T=1 particles, as shown by a higher plateau value. (C) Antigenic comparison 
using Nano-85 exhibits a similar starting value, but lower affinity to T=4 particles at lower Nanobody 
concentrations. 
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Previous studies revealed that the GII.10 specific Nanobodies Nano-85 and Nano-26 were 
able to bind GII.4 VLPs, with distinct epitopes at the lower part of the P domain (99, 101). In 
a binding ELISA, both Nanobodies had higher binding affinities to the smaller particles than 
to larger assemblies (Figure 5-11B/C). For Nano-26, maximum absorption was measured for 
T=1 particles up to a concentration of 0.4 µg/ml. In contrast, the measured maximum 
absorption value for T=3/4 particles was ~two-fold lower. For Nano-85, the maximum 
absorption was similar for both T=1 and T=3/4 particles at 100 µg/ml. However, for larger 
particles the binding value already declined from this concentration, whereas maximum 
absorption was measured until 0.4 µg/ml Nano-85 concentration for T=1 particles. 
Conversely, binding assays using a polyclonal GII.4 specific antibody revealed no difference 
in binding to either large or small VLPs (Figure 5-11A) and the slope of the dilution curve 
and maximum absorption value were similar.  
 
Structural analysis of GII.4c particles 
Despite the heterogeneity in the sample, we proceeded with determining the structures of the 
VLPs by single particle cryo-EM, as the particles can be separated computationally. Structure 
determination of the differently sized particles was done by collecting a large dataset of 
heterogeneous particles and picking and refining the differently sized assemblies separately. 
In general, the particles were mostly monodisperse with few aggregates of the particles 
(Figure 5-12A). 
We found that 56% of the particles exhibited T=4 icosahedral symmetry and these particles 
were refined to 4.2 Å resolution (Figure 5-12B/C). The particle had an outer and inner 
diameter of 50 and 32 nm, respectively. The particle consisted of 240 copies of VP1 that 
exhibited four quasiequivalent conformations (A, B, C and D). These gave rise to 60 A/B and 
C/D dimers each. As described for GII.4 NSW-2012 and CHDC-1974, the A subunits 
assembled at the five-fold axes, and B, C and D subunits alternated at the two-fold axes. 
The structures closely resembled the structures of GII.4 NSW-2012 and CHDC-1974. 
P domains were raised ~20 Å, and the cavity and flap like structure was present. This revealed 
that also in this structure, both A/B and C/D dimers had a convex S domain conformation 
(Figure 5-13B). 
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Figure 5-12 | GII.4c VP1 assembles in VLPs of various sizes. (A) Cutout of a representative cryo-EM 
micrograph of GII.4c VLPs shows T=4 (black arrow), T=3 (green arrow) and T=1 (blue arrow) particles. The 
scale bar indicates 50 nm. (B) FSC curves indicate resolutions of 4.2 Å for both T=1 (blue) and T=4 (black) 
particles and 8 Å for T=3 icosahedral VLPs (green), using the cut-off of 0.143 (red dashed line, black line shows 
FSC cutoff of 0.5). (C) T=4 icosahedral structure of GII.4c VLPs. The VLP has an inner and outer diameter of 
32 and 50 nm, respectively. These particles comprised 240 copies of VP1 that form A/B and C/D dimers. (D) 
T=3 icosahedral structure of GII.4c VLPs. T=3 icosahedral symmetric particles consisted of 180 VP1 molecules, 
assembling into A/B and C/C dimers. The inner diameter was 23 nm; the outer diameter was measured to be 46 
nm. (E) T=1 icosahedral structure of GII.4c VLPs. The particles were assembled from 60 VP1 proteins and had 
an inner and outer diameter of 13 and 31 nm, respectively. All structures are colored by radius, as indicated by 
the respective color scales. 
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The lowest number of particles (~20%), was found in native sized T=3 icosahedral assemblies 
(Figure 5-12B/D). These particles were only refined to 8 Å resolution. The VLPs consisted of 
A, B and C quasiequivalent conformations that formed 60 A/B and 30 C/C dimers. The 
diameter of 46 nm was similar to what we found for the low-resolution structure of the T=3 
icosahedral GII.4 NSW-2012 VLPs, suggesting these structures are conserved between 
different genotypes. The inner diameter of the particle was 23 nm. Comparison of the 
P domain conformation between T=3 and T=4 particles revealed that both P domains were 
elevated off the shell and, despite the differences in symmetry, the hinge region appeared 
similar (Figure 5-13A). This indicated that the raise of the P domain was not influenced by 
particle symmetry. 
Usually, the S domain of norovirus particles is relatively rigid, which enables determination 
of the S domain to a comparably high resolution. In this structure however, the S domain at 
the three-fold axis was not clearly resolved. Therefore, we applied focused reconstruction on 
this region, for further structural analysis. 
 
Figure 5-13 | Comparison GII.4c VLPs with T=4 and T=3 icosahedral symmetry. (A) Close-up view of a 
single C/D dimer of the T=4 particle (left) and a C/C dimer of a T=3 symmetric particle (right). The X-ray 
crystal structure of GII.4 NSW-2012 (PDB: 4OOS, cartoon) was fitted into the P domain dimers. Both P domain 
dimers were raised up from the shell by an extended hinge region (black arrows) that measured 2.1 nm. (B) 
Close-up view of the two-fold axis of a T=4 icosahedral particle. A flap and cavity like structure, formed by the 
S domain of the D subunit was disrupting the shell. (C) Close-up view of a focused reconstruction class of the 
three-fold axis of the T=3 icosahedral particle. Despite the low resolution, the capsid shell appeared disrupted by 
a cavity and flap like structure, comparably as in the T=4 particle. Here, the flap structure was formed by the 
S domain of a C subunit. 
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Interestingly, we found several classes, in which the S domain exhibited a similar 
conformation to what we found for the T=4 icosahedral particle: Two S domains, associated 
with the C/C dimer, were raised up and forming a flap-like structure that disrupted the closed 
shell (Figure 5-13C). Although resolution was limited, these results indicated that in T=3 
icosahedral particles the shell was not fully closed as well. This is at odds with the results 
from the GI.1 X-ray crystal structure, where the S domains at the three-fold axis were coming 
together to form a fully closed capsid (162), but explains the lower resolution found for the S 
domains.  
Approximately 23% of particles were small particles that exhibited T=1 icosahedral symmetry 
(Figure 5-12E). The particles were assembled from 60 VP1 monomers that form 30 identical 
dimers. For these particles however, we found that only the shell was well resolved, whereas 
the P domains appeared as blurred densities. This density blurring indicated pronounced 
movement of the dimers. Because of this, the hinge region could not be resolved, but a large 
gap existed between P and S domains. This suggested that in this structure the P domains 
were raised. Superposition of the density onto the T=3 and T=4 particles verified this theory. 
Moreover, the superposition of the particles suggested that in the T=1 particle, the P domains 
were separated stronger than in the larger sized assemblies. 
 
 
Figure 5-14 | Non-icosahedral assemblies formed by GII.4c VP1. (A) On the micrograph on the right, 
assemblies larger than T=4 icosahedral VLPs were found (white circle). On the right, a helical assembly can be 
observed. The scale bar represents 50 nm. (B) 2D classification of the helical filaments found in the preparations. 
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Curiously, also other, non-icosahedral assemblies were present in this sample, of which 
unfortunately the structures could not be solved. In some cases, we found assemblies with an 
enlarged diameter (Figure 5-14A). The particles were not uniform in size and shape, 
preventing structure determination using single particle analysis. Helical assemblies were also 
observed in the sample that appeared to be made up of VP1 (Figure 5-14A). However, a high-
resolution structure could not be determined, as the helical raise and twist could not be 
defined and therefore we could only perform 2D classification (Figure 5-14B). 
Overall, these results reveal that also for this engineered GII.4 strain, mostly T=4 icosahedral 
particles were formed, but in general, the samples exhibited T-number polymorphism. 
 
Expression and structural analysis of GII.4c VP1 in mammalian cells  
In order to determine if the unusual size of the VLPs was due to the expression system, we 
wanted to express GII.4 VLPs in a mammalian cell culture system. Transfected HEK-293T 
cells were cultured in DMEM complete with puromycin, to generate a stable VP1 expressing 
cell line. Comparison of supernatant and cell lysate showed that VP1 was expressed, but the 
VLPs mainly remained inside the cells and were not secreted into the medium. We expressed 
both GII.4 NSW-2012 and GII.4c VLPs in HEK-293T cells and examined their morphology 
using negative stain EM. 
VLPs purified from HEK-293T cells exhibited a similar diameter as GII.4 VLPs that were 
expressed in insect cells. In EM, no differences between VLPs expressed in High Five cells 
and HEK-293T cells could be observed, but HEK-293T expressed VLPs were more 
homogenous and no T=1 or T=3 particles appeared to be produced, leading to higher 
homogeneity of the sample. This was the case for both GII.4 NSW-2012 and GII.4c. 
Therefore, further structural analysis was done only on GII.4c VLPs. 
 
	 Chapter	2		
 74 
 
Figure 5-15 | Cryo-EM structure of GII.4c VLPs, expressed in mammalian HEK-293T cells. (A) Cutout of 
a representative cryo-EM micrograph of HEK-293T cell expressed GII.4c VLPs shows a homogenous sample. 
The scale bar represents 50 nm. (B) FSC plot of the icosahedral reconstruction reveals a resolution of 4.5 Å, at 
0143 FSC cut-off (red dashed line, black lines indicates FC cutoff of 0.5). (C) The cryo-EM structure revealed a 
particle of T=4 icosahedral symmetry, assembled from 120 VP1 dimers (A/B and C/D). The particle had an inner 
diameter of 50 nm and an outer diameter of 32 nm. (D) Close-up on a single C/D dimer, fitted with the X-ray 
crystal structure of GII.4 NSW-2012 P domain (PDB: 4OOS, cartoon). The hinge region was extended and 
measured ~2.1 nm (black arrow). (E) Close-up on an icosahedral two-fold axis. As observed in the T=4 particles 
expressed in insect cells, the D subunit S domains are forming a flap like structure, disrupting the continuous 
shell. 
 
To analyze if there were structural differences between VLPs expressed in HEK-293T cells 
and VLPs from insect cells, the structure of GII.4c VLPs from the mammalian system was 
determined using single particle cryo-EM (Figure 5-15A). 10,135 particles were refined to a 
structure of 4.5 Å (Figure 5-15B/C). The structures matched the insect cell produced T=4 
VLP structure closely, with a cross-correlation coefficient of 0.99 and, at that resolution, no 
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visible differences in structure. In both cases, the particle had T=4 icosahedral symmetry, and 
the characteristic cavity and flap- like structure was observable in both densities, with the flap 
being raised equally (Figure 5-15B/D). Moreover, P domains were raised to the same extent 
(Figure 5-15C). This verified that, at least on a structural basis, the expression system did not 
have an influence. 
 
Negative stain analysis of infectious GII.4 virions  
To determine if authentic GII.4 virions assemble into T=4 particles, we measured the diameter 
of infectious virions in negative stain images (Figure 5-16). Unfortunately, the amount of 
virions produced in the cell culture system was not sufficient to allow cryo–EM single particle 
analysis, but virions from stool samples could be imaged using negative stain EM. The virions 
had a diameter of ~44 nm. This size corresponded to the diameter that we found for T=3 
particles (~46 nm), indicating that GII.4 virions likely exhibit T=3 icosahedral symmetry. 
 
Figure 5-16 | Negative stain images of intact GII.4 virions. The diameter of the virions was ~44 nm, which 
corresponded to the diameter of a T=3 icosahedral particle. The scale bar measures 100 nm. The figure was 
adapted from (41). The images were taken by Dr. Anna Koromyslova. 
 
Taken together, our data revealed that GII.4 VLPs tend to mainly assemble into T=4 
icosahedral particles, a structure deviating from the commonly assumed T=3 symmetry for 
caliciviruses. Moreover, intact virions appear to be of T=3 icosahedral symmetry, suggesting 
these larger assemblies are an artifact of VLP production that is unique for GII.4 VLPs. 
Importantly, the vaccine candidate GII.4c mainly forms T=4 particles as well, which could 
have important implications on the vaccine efficacy. 
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5.4. Discussion  
It is commonly assumed that norovirus VLPs are morphologically identical to intact norovirus 
capsids. However, in our study we showed that, when GII.4 VP1 is expressed in insect cells, 
mostly T=4 icosahedral symmetric particles are formed. Moreover, we found that this was the 
case for at least five different GII.4 strains, and for three, GII.4 NSW-2012, CHDC-1974 and 
GII.4c, the structures were solved within this study. 
In a study on RHDV the authors found that an insertion at the N-terminus led to formation of 
T=4 icosahedral particles, but prior to this, no formation of norovirus T=4 icosahedral 
norovirus particles has been described (127). Our data indicates however, that these particles 
are the predominant form in which GII.4 VLPs are occurring. Moreover, this assembly 
remained structurally conserved over time, as GII.4 CHDC-1974 and GII.4 NSW-2012 were 
isolated 38 years apart and have only 89% sequence identity. Our findings were supported by 
a later study, where VLPs of GII.4 Minerva exhibited T=4 icosahedral symmetry (82). 
Conversely, a study on GII.4 Grimsby VLPs, produced in insect cells, revealed a T=3 
icosahedral capsid (24). 
Our results are contradicting the T=3 symmetry that is likely encoded for by the GII.4 virion 
(Figure 5-16). With our experiments using HEK-293T cells, we excluded that formation of 
these particles was caused by differences in post-translational modifications of the protein in 
insect and mammalian cells. Expression in insect cells and mammalian cells mostly differs in 
the obtained glycosylation patterns. In insect cells, the N-linked glycosylation is simpler than 
in mammalian cells, as only simple mannose based structures can be attached. For VP1 of 
norovirus no glycosylation pattern has been observed so far, therefore our observed results 
were not unexpected.  
Formation of native virions includes the encapsidation of RNA, the genome linked protein 
VPg and several copies of VP2, all of which are not included in the empty VLPs. Expression 
of VP1 from other norovirus genotypes in the baculoviral expression system leads to 
formation of T=3 particles (69, 162). Therefore, these factors are presumably not solely 
defining the type of symmetry, but their presence could tilt the scale towards formation of the 
native T=3 capsids. Moreover, for other single stranded RNA viruses it was shown that the 
capsid assembles around its genome (93, 196), suggesting that the absence of the genome in 
the VLPs could play a role in the formation of the non-native capsids. In fact, it recently has 
been shown that bacteriophage MS2 forms T=4 icosahedral particles instead of T=3 particles 
in absence of full-length RNA (38). 
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Due to these observations, we speculate that the formation of T=4 icosahedral particles might 
be sequence-dependent. Sequence comparison of GII.4 NSW-2012, CHDC-1974, GII.4c with 
GI.1 and GII.10, two genotypes which have been proven to have T=3 icosahedral symmetry 
(69, 162), revealed that only 18.5% of the VP1 sequence are conserved between T=3 and 
T=4-forming genotypes. 5% of these amino acids exhibit conservation between the two T=3 
icosahedral genotypes. Therefore, it could be of great interest for further studies to focus on 
these parts of the sequence to characterize, which part of the protein is responsible for the 
formation of these particles. Production of chimeric VLPs from sequences of T=3 and T=4 
producing VP1 could be of value to pinpoint the sequence or domain that is the major 
contributor to the particle size determination. Studies on calicivirus particle size have been 
done before with contradicting results: Experiments on RHDV suggested that the N-terminal 
arm is the determining factor for particle size (6, 127). Conversely, a study on GI.1 came to 
the conclusion that the N-terminus does not influence particle symmetry. Instead, they found 
that deletions at the C-terminus, as well as deletions at the P2 subdomain mediated changes in 
VLP size (11). 
Even though the symmetric difference was the most obvious variation to the previously 
solved structures, the particles also exhibited other distinct structural features, in particular the 
disruption of the closed shell by flap like S domain conformation. This most likely arises as a 
consequence of the bent C/D dimers. Usually in T=3 icosahedral particles, only A/B dimers 
have a curvature of the S domains, whereas C/C dimers are flat, in order to facilitate the 
curvature of a fully closed capsid structure. In our structures however, we found that the C/D 
dimer was bent as well. This could prevent the S domain from forming the necessary contacts 
with the adjacent B and C subunits, leading to the disruption of the shell. Interestingly, we 
found that, at least to some extent, this was also the case for GII.4c T=3 icosahedral particles. 
This was contradicting the results for GI.1, where the C/C dimer was flat and subsequently the 
shell was forming the expected contacts and formed a fully closed capsid (162). Additionally, 
this suggests that the formation of T=3 icosahedral particles does not necessarily rely on the 
alternating assembly of flat and bent dimers. In consequence this also could mean that the 
absence of flat dimers is not responsible for formation of the T=4 particles. If this opening of 
the shell has a biological function within the norovirus life cycle, or if it is a result of the 
heterologous expression of VP1 in an artificial system remains to be determined. 
The result that particles can adopt differently sized particles is, at first glance, not surprising. 
Capsid polymorphism for norovirus (i.e. formation of T=3 and T=1 particles) has been 
described several times, for production of VLPs (222), as well as in vivo (202) and as a result 
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of infection in a human tissue culture system (49). The presence of these smaller VLPs in 
infected patients suggests that they serve a biological function, however their role remains 
elusive so far. Due to spatial limitations, these T=1 particles are most likely not capable of 
encapsidating a complete genome. Moreover, these smaller VLPs have been observed in 
several different genotypes. Conversely, the formation of T=4 particles has only been 
described as a result of heterologous expression of GII.4 VP1 in artificial cell culture systems. 
Therefore, these particles likely constitute an artifact of VLP production. However, this 
artifact is still of importance, as many studies, most importantly the vaccine studies with 
GII.4c, have been conducted under the assumption that the VLPs are identical to virions 
(153). Our results prove that it cannot be automatically assumed that this is the case, and 
careful examination of the particles is essential. Most importantly, we showed that the VLPs 
used in a vaccine candidate indeed mainly form these non-native assemblies. 
For caliciviruses, the most readily accessible epitopes are on top of the P domain, where 
receptor and cofactor binding sites area located. These epitopes should be easily recognized 
on particles of either symmetry. However, P2 subdomain associated regions are often 
hypervariable and under selective pressure, leading to high genetic and antigenic drift. 
Therefore, antibodies against these epitopes would most likely not be cross-reactive to other 
genotypes or strains emerging after vaccination. Conversely, the P1 subdomain exhibits a 
more stable sequence and therefore might constitute a superior epitope for cross-reactive 
antibodies. In fact, different studies described antibodies and Nanobodies that bound to the 
lower part of the P domain, suggesting that these epitopes possibly represent sites of 
vulnerability for caliciviruses (69, 101, 122, 176). 
Our ELISA results suggest that epitopes, which appear occluded in larger virions, could be 
more easily accessible on T=1 particles, due to increased flexibility of the P domains. Higher 
P domain flexibility could be associated with better accessibility to occluded epitopes. 
Therefore the larger, more rigid particles could serve as a suboptimal antigen due to structural 
constraints. A study on tick borne encephalitis virus also demonstrated differences in affinity 
for several envelope specific antibodies, depending on the quaternary structure of the 
assembly (89). However, in our experiments, overall antigenicity was comparable (as 
determined with the polyclonal antibody). This could mean that in general, smaller and larger 
particles are both strongly immunogenic, both being highly ordered repeats of the antigen, but 
elicitation of neutralizing antibodies binding to occluded regions might be not optimal in the 
larger particles. Conversely, it might also be possible, that a mixture of differently sized VLPs 
could elicit a more diverse panel of antibodies, as availabilities of epitopes vary between the 
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particles. Moreover, previous studies proved that the vaccine candidate was in fact able to 
elicit a robust immune response and at least some antibodies were able to detect different 
norovirus genotypes (120, 153). This is in accordance with our results, as the more occluded 
epitopes were still detectable on the larger assemblies, only affinity was reduced. 
Unfortunately, it was not possible to separate T=3 and T=4 icosahedral particles, and 
therefore antigenic comparisons between particle sizes were limited to T=1 and T=4 particles. 
Such experiments between T=3 and T=4 particles could help ensure that vaccination with a 
non-native immunogen is not antigenically problematic. So far, clinical trials indicated that 
the vaccine is only associated with modest levels of protection when compared to placebo 
groups (10). Hence, it is important to rule out the particle symmetry as a hindering factor for 
efficacy. Nevertheless, immune responses to viruses and vaccines are complex and highly 
impacted by the pre-exposure history of the patients (especially in common viruses such as 
influenza or norovirus) (9, 60, 121). Therefore, the moderate efficacy of the vaccine candidate 
could stem from a multitude of other factors as well. 
Taken together, one could speculate that the differences between the native virion and the T=4 
icosahedral vaccine only play a limited role in affecting its efficacy, but clearly more studies 
on this are needed to answer this question. Nonetheless, there are important consequences 
from our studies on these larger particles: Even though particles appear to be morphologically 
similar to typical norovirus genotypes, they could have symmetric deviations; therefore, 
cautious examination of the used particles is of importance. Moreover, further studies are 
required, to specify whether differences in symmetry translate into differences in antigenicity. 
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6.  Chapter 3: Characterization of GII.4 specific Nanobodies  
6.1. Summary  
In this study we characterized a panel of GII.4 NSW-2012 specific Nanobodies. We found 
that most of the Nanobodies were able to inhibit attachment of GII.4 to PGM in a dose 
dependent manner in the micromolar range. We commonly found that Nanobody binding led 
to particle aggregation, thereby preventing attachment of VLPs to HBGAs. Unfortunately 
none of the tested Nanobodies were able to bind VLPs other than GII.4. 
Moreover, we structurally characterized the binding of six Nanobodies using single particle 
cryo-EM. Interestingly, we found that most Nanobodies were binding to the lower part of the 
P domain. In all cases we observed a shift of the P domain to accommodate Nanobody 
binding, highlighting the flexibility of the capsid. 
 
6.2. Contributions 
In total, 33 Nanobodies were produced and characterized, together with Kerstin Ruoff and Dr. 
Charles Sabin. 11 of these, Nanobodies were characterized by me. For cross-reactivity 
studies, I used all 33 available Nanobodies. I performed the cryo-EM structural analysis.  
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6.3. Results 
Production of GII.4-specific Nanobodies 
For initial production of Nanobodies, we employed the service from VIB Nanobody service 
facility in Vrije University Brussels. Alpacas were immunized with GII.4 NSW-2012 VLPs, 
and 100 Nanobody clones were generated. 33 different Nanobodies were expressed and 
characterized, selected to obtain a wide variety of different Nanobodies, based on the 
sequence. I characterized the binding and inhibitory potential of 11 of these Nanobodies.  
 
Nanobody binding to GII.4 NSW-2012 VLPs  
In first tests, we defined the affinity of the Nanobodies for GII.4 NSW-2012 VLPs. In a direct 
binding ELISA, the plates were coated with 2 µg /ml VLPs and the binding of serially diluted 
Nanobodies was measured. 
 
Figure 6-1 | Nanobodies binding to GII.4 NSW-2012 VLPs. All Nanobodies were able to detect GII.4 VLPs in 
a direct binding ELISA. The dashed line shows a cut-off value of 0.15 OD490. 
 
All Nanobodies were able to attach to GII.4 NSW-2012 VLPs, but the tested Nanobodies 
exhibited marked differences in their binding affinities (Figure 6-1). The strongest binders 
were 2GFV53 and 1GFV30, with a maximum OD490 signal measured up to a concentration of 
0.78 µg/ml. Lowest binding was measured for 1GFV14, 1GFV50 and 2GFV74, where the 
cut-off level of OD490 = 0.15 was reached already at 6.25 µg/ml. 
 
Nanobody concentration (µg/ml)
O
D
49
0
0
1
2
3
4
1GFV50
1GFV53
1GFV28
2GFV74
1GFV76
2GFV68
1GFV14
2GFV105
10
0 50 25
12
.5
0
6.
25
3.
13
1.
56
0.
78
0.
39
0.
20
0.
10
0.
05
2GFV27
1GFV30
2GFV37
	 Chapter	3		
 82 
In order to identify, whether the Nanobodies were cross-reactive against other norovirus 
genotypes and different GII.4 isolates, we performed binding ELISAs with VLPs from GI.1 
West Chester, GI.11 #8, GII.1 Hawaii, GII.10 026-Vietnam, GII.17 Kawasaki, 
GII.4 CHDC-1974, GII.4 Saga-2006, GII.4 Yerseke-2006, GII.4c and GII.4 NSW-2012. 
All 33 expressed Nanobodies were tested for cross-reactivity by me. In this analysis, 
triplicates of the highest Nanobody concentration (100 µg/ml) were tested for their ability to 
bind to 2 µg/ml of the different VLPs. 
 
Figure 6-2 | Cross-reactivity of GII.4 Nanobodies. The Nanobodies were analyzed at 100 µg/ml, for their 
ability to bind to GI.1, GI.11, GII.1, GII.10, GII.17, GII.4c, GII.4 CHDC-1974, GII.4 Saga, GII.4 NSW-2012 
and GII.4 Yerseke at 2 µg/ml. The color scheme represents measured OD490 values. Nanobodies were not able to 
bind to GI or GII genotypes other than GII.4. Binding assays were done in triplicates. 
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None of the tested Nanobodies were able to cross-react with other genotypes. Most 
Nanobodies (15) were specific to GII.4 NSW-2012, but some of the Nanobodies were able to 
attach to GII.4 isolates other than GII.4 NSW-2012 (Figure 6-2). Three Nanobodies 
(2GFV108, 2GFV104 and 1GFV56) were able to attach to all tested GII.4 variants. 
Interestingly, we found that five Nanobodies (2GFV8, 2GFV20, 2GFV60, 2GFV83 and 
2GFV112) were binding all GII.4 VLPs except CHDC-1974. 
HBGA inhibition of Nanobodies 
To analyze if the Nanobodies were able to inhibit the attachment of VLPs to HBGAs, a 
surrogate binding ELISA was performed (Figure 6-3). Except 1GFV14, all Nanobodies were 
able to inhibit PGM binding, with IC50 values ranging from 0.74 µg/ml to 6.31 µg/ml (Table 
6-1). The best inhibitor was Nanobody 2GFV68. Interestingly, only 1GFV30 and 1GFV76 
were able to inhibit 100% of binding, up to a concentration of 25 µg/ml and 6.25 µg/ml, 
respectively. Most Nanobodies reached a plateau at 60-80% inhibition, suggesting that even at 
the highest Nanobody concentrations some HBGA binding sites on the VLPs were still 
available. 
 
Figure 6-3 | Inhibition of GII.4 PGM attachment by Nanobodies. In this surrogate HBGA blocking assay, all 
Nanobodies except 1GFV14 were able to inhibit the attachment of GII.4 NSW-2012 VLPs to PGM. In most 
cases, except for 1GFV76 and 1GFV30, we found that the maximum inhibition was only at 60-80%.  
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Table 6-1 | IC50 values of Nanobodies inhibiting PGM attachment of GII.4 VLPs. 
Nanobody IC50 (µg/ml) 
1GFV50 2.70 
2GFV53 0.77 
1GFV28 1.84 
2GFV27 0.76 
2GFV74 2.19 
1GFV30 6.31 
1GFV76 1.41 
2GFV68 0.74 
1GFV14 Not defined 
2GFV37 1.54 
1GFV105 1.34 
 
The influence of Nanobody binding on the structural integrity of GII.4 VLPs 
To further characterize how these Nanobodies inhibit the HBGA attachment, we performed 
DLS and negative stain experiments.  
After incubation of GII.4 NSW-2012 VLPs with Nanobodies, we observed a pronounced peak 
shift in the DLS measurements, indicating an increase in hydrodynamic diameter. These 
results were confirmed by negative stain EM, where in most samples VLPs were aggregated 
after treatment. Nevertheless, the nature of the complexes varied between the Nanobodies. In 
several cases, as for 1GFV50, 2GFV27, 1GFV76 and 1GFV105 the complexes were dense 
and large, whereas other Nanobodies only moderately aggregated the particles (2GFV74, 
1GFV30, 2GFV68) and in some cases, only small aggregates were observed (2GFV53, 
1GFV28, 2GFV37). VLPs incubated with 1GFV14 did not exhibit a peak shift in DLS, and 
VLPs appeared morphologically identical to untreated VLPs in EM. This was in line with our 
inhibition results, since this Nanobody failed to inhibit PGM attachment. These results 
indicated that likely all inhibiting Nanobodies were preventing PGM binding by aggregating 
the particles. 
 
	 Chapter	3		
 85 
 
 
Figure 6-4 | Treatment of GII.4 NSW-2012 VLPs with different GII.4-specific Nanobodies. (A) Negative 
stain EM and (B) DLS measurements of untreated VLPs and VLPs treated with different Nanobodies. Untreated 
VLPs were mostly monodisperse. 1GFV14 treated VLPs did not differ from untreated VLPs, but treatment with 
all other tested Nanobodies led to aggregation of the particles. The scale bar indicates 100 nm. 
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Structural analysis of GII.4-Nanobody complexes 
Despite these results, we decided to structurally analyze some of the Nanobodies in complex 
with GII.4 NSW-2012 VLPs, using single particle cryo-EM. For these experiments, I also 
used Nanobodies that were not characterized by me (2GFV37, 1GFV56, 2GFV20, 2GFV46, 
2GFV54, 2GFV118, 2GFV83 and 2GFV104). In the ice, most particles appeared aggregated, 
but several datasets could be collected where single particles were still observable and only 
weak aggregation occurred (Figure 6-5A). It was possible to pick particles from the smaller 
and more loosely packed aggregates, and for six different combinations, structures could be 
calculated. In several cases, such as 2GFV54 or 2GFV83, grids were prepared, but the high 
degree of aggregation precluded structure determination using single particle cryo-EM. 
 
Figure 6-5 | Cryo-EM data of GII.4 NSW-2012 VLPs with different Nanobodies. (A) Exemplary cryo-EM 
micrographs for NSW-2012 VLPs with Nanobodies. In all cases aggregation occurred, but particles were still 
clearly visible. The scale bar indicates 100 nm. (B) FSC plot indicates resolutions of 7.4 Å for 1GFV56, 6.5 Å 
for 2GFV20, 6.2 Å for 2GFV37, 5.7 Å for GII.4 with 2GFV46, 4.62 Å for 2GFV104 and 8.1 Å for 2GFV118 
using an FSC cut-off of 0.143 (red dashed line; black line indicates FSC cut-off of 0.5). 
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The Nanobodies selected for structural studies exhibited distinct binding patterns: 2GFV37, 
2GFV46, and 2GFV118 bound specifically to GII.4 NSW-2012; 2GFV20 bound all GII.4 
VLPs except GII.4 CHDC-1974, and 1GFV56 and 2GFV104 bound to all tested GII.4 
isolates. 
The highest resolution structure was obtained for GII.4 and 2GFV104, with 4.6 Å. For the 
2GFV118 complex, resolution was only at 8.1 Å (Figure 6-5B). This could be due to the 
strong aggregation that allowed only a small dataset to be acquired, and only few particles 
could be used for final reconstruction of the structure. 
Generally, the Nanobodies did not disrupt the particle integrity and the capsids were still 
present as T=4 icosahedral assemblies with raised P domains. In all structures we found two 
bound Nanobodies per P domain dimer. Interestingly, we found that in all cases the binding 
sites were located at the lower part of the P domain. The binding sites were at the dimeric 
interface of the two P monomers, suggesting that the Nanobodies interacted with both 
P domain subunits. Moreover this suggests that despite their marked differences in VLP 
binding, the epitopes were located in close vicinity. 
 
Figure 6-6 | Cryo-EM structures of GII.4 NSW-2012 with different Nanobodies. In all cases, Nanobodies 
bound to the lower site of the P domains, at all available binding sites of the capsid. All structures are colored by 
radius, as indicated by the color scale.  
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In all complexes except with 2GFV104, the P domains were rotated similarly and the 
Nanobodies were pointing to the center of the three-fold and five-fold axes (Figure 6-6). For 
2GFV104 however, the Nanobodies were bound to a similar position of the P domain, but 
orientation was different: In this case, the Nanobodies were pointing upwards. Moreover, the 
C-terminal part of the Nanobody was connected to the upper part of the P domain. In this 
conformation, the shell was more surface-exposed than in the other complexes. 
Comparison of the GII.4 NSW-2012 apo structure to the complexed structures revealed that in 
all cases, the P domain was rotated in a clockwise direction in respect to the apo structure 
after Nanobody binding (Figure 6-7). Possibly this movement occurred to allow the 
Nanobodies to efficiently bind to all available binding sites. 
 
Figure 6-7 | Close-up on an A/B dimer of the GII.4 NSW-2012 apo structure and GII.4 NSW-2012 in 
complex with different Nanobodies. In all cases, the P domain was rotated as a result of Nanobody binding. 
 
The measured tilts ranged from ~5º for the 1GFV56 C/D dimer, to 18º for the 2GFV20 A/B 
dimer (Table 6-2). This highlights the high flexibility of the hinge region, as the particles still 
remained intact. The rotation of the A/B dimers remained relatively similar between the 
1GFV56 2GFV20 2GFV37 
2GFV46 2GFV104 2GFV118 
GII.4 apo 
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different complexes (ranging from 11-18º), whereas the C/D dimer rotation ranged from 5º up 
to 17º. Moreover, in some cases, such as 2GFV46 or 2GFV104, the P domain was resolved to 
a higher resolution, when compared to the P domain in the apo structure. This indicates that 
Nanobody binding stabilized the P domain conformation in these structures, resulting in a 
higher overall resolution. 
Table 6-2 | Rotations of the A/B and C/D complex dimers, respective to the P domains in the apo structure. 
Nanobody complex A/B dimer rotation  C/D dimer rotation 
1GFV56 12º 5º 
2GFV20 18º 16º 
2GFV37 12º 17º 
2GFV46 12º 10º 
2GFV104 11º 6º 
2GFV118 13º 8º 
 
In all structures, there were no differences observable in the S domains, suggesting that the 
influence of Nanobody binding was restricted to the P domain, while the S domain remained 
rigid. 
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6.4.  Discussion 
Many successful RNA viruses exhibit extensive antigenic diversity. Nevertheless, it is integral 
to retain the structural integrity of the capsid and important sites, such as receptor or cofactor 
binding sites. These conserved sites could be of interest in the development of a potent 
antiviral.  
Nanobodies are of great interest as potential therapeutics. In this study, we analyzed 
Nanobodies raised against the most clinically important genotype of norovirus. GII.4 VLPs, 
as described in Chapter 2, exhibit an unusual symmetry. Nevertheless, the VLPs were proven 
to be highly immunogenic, and a high number of Nanobodies were produced. In former 
studies on Nanobodies [(101) and Chapter 1], usually different inhibition modes were present. 
However in our case, the results indicated that all Nanobodies that were inhibiting PGM 
binding aggregated the particles. Aggregation of VLPs appears to be a common mode of 
inhibition for Nanobodies, as this has also been observed for Nanobodies from other libraries 
[(101) and Chapter 1]. 
Ten out of 11 Nanobodies were able to inhibit GII.4 NSW-2012 binding to HBGAs, with IC50 
values that were comparable to values found in other studies (101, 176). HBGA binding 
facilitates cell attachment in vivo. Therefore the inhibition of HBGA binding is handled as 
correlate for protection (166). Interestingly, we found that for most Nanobodies, 100% 
inhibition was not reached. This could imply that the Nanobodies might not be able to hinder 
the attachment of all VLPs or that sufficient binding sites were unoccupied to still allow 
binding. From preliminary X-ray crystallography data (unpublished data, performed by Dr. 
Charles Sabin) and the cryo-EM results performed within this thesis, we know that most 
Nanobodies had epitopes located at the lower site of the P domain. Only the epitope of 
1GFV76, one of the two Nanobodies that was able to inhibit 100% of the binding in our 
assay, was located at the top of the P domain. Of note, in studies with GI.1 and GII.10 specific 
Nanobodies [(101) and Chapter 1], highly efficient bottom-binding Nanobodies were 
discovered, suggesting that lower efficiency might not be linked to the location of the binding 
site on the P1 subdomain.  
In a cross-reactivity binding assay we found that none of the Nanobodies were able to bind 
VLPs from genotypes other than GII.4. Most of the Nanobodies were specific to GII.4 
NSW-2012, the genotype they were raised against. Nevertheless, several Nanobodies were 
able to bind to all tested GII.4 VLPs, suggesting that they bound to an epitope that is 
conserved only within the GII.4 genotype. As GII.4 infections are by far the most frequent 
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(42, 165), these Nanobodies could be of therapeutic interest, despite their inability to bind 
genotypes other than GII.4. Moreover, the fact that these Nanobodies are able to attach to 
GII.4 isolates that were isolated 38 years apart (GII.4 CHDC-1974 vs. GII.4 NSW-2012) 
suggests that their epitopes are especially conserved. They could therefore represent important 
sites on the P domain. Unfortunately, these cross-reactive Nanobodies showed only moderate 
inhibition in surrogate blocking ELISAs (data not shown, performed by Kerstin Ruoff), 
limiting the usability of these Nanobodies as potential therapeutics. Nevertheless, 
determination of the exact binding site could provide a target for GII.4 genotypes that could 
be exploited in the development of a GII.4 antiviral. 
Interestingly, one group of Nanobodies (2GFV8, 2GFV20, 2GFV60, 2GFV83 and 2GFV112) 
was able to bind all newer isolates of GII.4, but not GII.4 CHDC-1974, suggesting that the 
epitope evolved after isolation of this variant, but is conserved in the newer isolates. 
Using single particle cryo-EM, we solved the structures of six different Nanobodies in 
complex with GII.4 NSW-2012 VLPs. Notably, in all cases the Nanobodies forced the 
P domains in diverse positions. This becomes necessary, as the binding sites were located at 
the bottom of the P domain, and the Nanobodies would likely otherwise clash with 
neighboring Nanobodies or P domains. This suggests that the capsid in general is flexible and 
allows for diverse positioning of the P domain. Binding of a Nanobody to a sterically 
unfavourable position did not lead to capsid disruption, as has been shown e.g. for hepatitis E 
virus (234). Instead, the flexibility of the hinge region allowed the P domain/Nanobody 
complex to adopt different conformations to accommodate Nanobody binding at all epitopes, 
while maintaining the general structure of the capsid. As disruption of the particle is generally 
a non-reversible process, the high flexibility, allowing the particle to remain intact even at 
unfavourable conditions, could ultimately contribute to the high environmental stability and 
infectivity of noroviruses and in particular GII.4 isolates. 
Despite the apparent similarity in binding sites, the binding pattern of the evaluated 
Nanobodies varied substantially. Structurally most diverse from the others was 2GFV104. In 
this case, the Nanobodies were protruding out from the capsid instead of pointing towards the 
center of the five- or three-fold axes. Cryo-EM is an important tool to analyze how the 
Nanobody binding influences the structural integrity of the intact particles. Nevertheless, due 
to limited resolution of the complexes, it would be of great interest to solve the structures of 
Norovirus P domain and Nanobodies using X-ray crystallography. Determining the exact 
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binding sites and interacting amino acids could provide a structural basis for the differences in 
VLP binding. 
In most structures, the P domains were resolved relatively well when compared to the apo 
structure. This indicated that the binding of the Nanobody additionally stabilized the 
P domain and restricted the movement of the flexible hinge region, most likely by steric 
hindrance. Preventing conformational changes in the capsid has been shown to be an effective 
mode of inhibition e.g. in rhinovirus, where binding of WIN compounds stabilized the capsid, 
subsequently precluding the uncoating (167, 191). Nevertheless, inhibition by preventing 
virus particle breathing can only in detail be assessed in neutralization studies, as often these 
structural rearrangements occur only after receptor binding. As no conformational changes are 
necessary in our HBGA binding assay, the influence of the stabilization of the P domain on 
the inhibition could not directly be determined. Neutralization studies using the enteroid 
system could shed further light on this potential mode of inhibition. 
Overall, this study provides additional examples of Nanobodies as efficient inhibitors of 
norovirus attachment, building a mandate for further research into the development of 
Nanobody-based therapeutics. Due to their limited cross-reactivity, the therapeutic potential 
of the Nanobodies characterized in this study might be limited on their own, but in a 
combinatorial therapy with other Nanobodies or active compounds, as described in Chapter 1, 
these Nanobodies could be of therapeutic interest. Moreover, the use of Nanobodies is not 
limited to therapeutic applications. Nanobodies could be of use in laboratory settings or as 
detection tools. Their high specificity and affinity could be exploited in the development of 
norovirus detection kits that are of higher specificity and more cost-effective than the current 
detection kits that use conventional antibodies for detection (40). 
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7. Chapter 4: Structural characterization of GII.17 VLPs 
7.1. Summary 
In this chapter, we solved the structure of VLPs from the currently prevalent genotype GII.17 
Kawasaki. We found that the VLP exhibited T=3 icosahedral symmetry, which is the typical 
structure of caliciviruses. The P dimers were raised from the shell, as observed for other 
calicivirus structures, giving further prove that this appears to be the most common P domain 
conformation. Moreover we attempted to solve the structure of GII.17 in complex with a 
binding factor (A-trisaccharide) and a small molecule inhibitor (2’FL), but the addition of 
these compounds did not induce structural deviations in the capsid. 
 
7.2. Contributions 
All experiments in this chapter were performed by me. Benedikt Wimmer helped with data 
processing for the GII.17 apo structure. 
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7.3. Results 
Single particle analysis of GII.17 VLPs  
Norovirus GII.4 is generally assumed to be the most clinically relevant norovirus genotype. 
However, in the recent years, genotype GII.17 superseded GII.4 in prevalence in some regions 
of the world. Therefore, we wanted to analyze the structure of GII.17 VLPs in detail using 
single particle cryo-EM. 
 
Figure 7-1 | The cryo-EM structure of GII.17 VLPs. (A) Representative raw micrograph of GII.17 VLPs. (B) 
2D classification shows structurally homogeneous particles. (C) The FSC curve indicates a resolution of 5.8 Å at 
FSC cut-off of 0.143 (red dashed line, 0.5 FSC cut-off indicated as black dashed line). (D) Cryo-EM structure of 
GII.17 VLPs exhibited T=3 icosahedral symmetry. The particle is colored by radius, as indicated by the color 
scale.  
 
GII.17 Kawasaki VLPs were expressed in HighFive insect cells and purified from the cell 
supernatant via a CsCl gradient. The purified VLPs appeared as homogenous and 
monodisperse particles in the vitrified ice (Figure 7-1A/B). A dataset of 2,316 images was 
collected. 35,709 particles were refined to a structure of 5.8 Å resolution (Figure 7-1C/D). 
GII.17 VLPs exhibited T=3 icosahedral symmetry, which is typical for the Calicividae 
family. The particle comprised 180 VP1 monomers, dimerizing at the P domain to form the 
characteristic arch-like structures. VP1 dimers can be divided into two classes: A/B and C/C. 
60 A/B dimers were located at the icosahedral five-fold axes, whereas 30 C/C dimers were 
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positioned at the two-fold axes. B and C subunits were alternating at the three-fold axes. The 
VLPs had an inner diameter of ~24 nm and an outer diameter of ~45 nm. 
 
Figure 7-2 | Detailed view of the GII.17 VLP structure. (A) Cutout view of the structure, and (B) top view on 
a three-fold axis, fitted with GI.1 S domain (PDB: 1IHM) and GII.17 P domain (PDB: 5F4O). (C) Extracted A/B 
(red) and C/C (blue) VP1 dimers revealed that A/B dimers had a convex conformation, whereas C/C dimers had 
a flat S domain conformation. 
 
A flexible hinge connected P and S domain and the P domains were rising from the shell. The 
S domain was resolved to a higher resolution than the P domain, which is linked to stronger 
flexibility in the extended P domain, compared to the more rigid S domain. 
Fitting of the X-ray crystal structure of the GII.17 P domain [PDB: 5F4O (188)] revealed a 
cross-correlation coefficient of 0.96 for both A/B and C/C dimers. This indicates that at the 
given resolution there were no, or only small deviations between A/B and C/C P domain 
dimers. As no structure for GII.17 S domain was available so far, the X-ray crystal structure 
of GI.1 S domain (PDB: 1IHM) was used as S domain model. The S domain of GI.1 and 
GII.17 is relatively well conserved, with a sequence identity of 57%. The structure fitted well 
into the density, indicating that the common jelly-roll fold of the calicivirus S domain is 
A 
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conserved in GII.17. Close inspection of the dimers showed that the A/B dimer had a bent 
conformation, whereas the C/C dimer was flat. 
 
GII.17 VLPs in complex with binding factor A-trisaccharide 
So far, little is known about how the norovirus interacts with the cell prior to entry. In viral 
infections, often binding to cofactors or receptors leads to structural rearrangements 
facilitating infection. As for human norovirus no proteinaceous receptor is known, we wanted 
to analyze whether the binding of HBGAs primes the virus for subsequent steps in the 
infection cycle. In a former study it was shown that GII.17 Kawasaki was able to bind 
A-trisaccharide (A-tri), a core antigen fragment in ABO blood group system (98). Therefore, 
we used A-tri as a model to determine if the capsid morphology is influenced by HBGA 
binding. Structurally, A-tri is a branched amino trisaccharide, comprised of a beta-D-
galactose with an alpha-L-fucosyl residue at position 2 and an N-acetyl-alpha-D-
galactosaminyl residue at position 3. From previous studies, the X-ray crystal structure of 
GII.17 P domain in complex with the compound was available (98).  
 
Figure 7-3 | The cryo-EM structure of GII.17 VLPs in complex with A-tri. (A) Representative raw 
micrograph of GII.17 VLPs with A-trisaccharide. (B) 2D classification reveals structurally homogeneous 
particles. (C) The FSC curve indicates a resolution of 7.9 Å at FSC cut-off of 0.143 (red dashed line, 0.5 FSC 
cut-off indicated as black dashed line). (D) Cryo-EM structure of GII.17 VLPs with A-tri show T=3 icosahedral 
symmetry. The particle is colored by radius, as indicated by the color scale. 
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Prior to sample preparation, purified VLPs were incubated with 100× molar excess of A-tri to 
the binding sites. In the vitrified ice, no differences to unbound viruses were detectable 
(Figure 7-3B). Moreover, addition of A-tri did not introduce noticeable background. 
 
Figure 7-4 | The X-ray crystal structure of GII.17 P domain with A-tri (PDB: 5LKC), fitted into the 
cryo-EM structure of GII.17 apo (A) and GII.17 with A-tri (B). The ligands are shown as yellow sticks and 
highlighted by red arrows. Ligands were not covered by density in the unbound structure and covered by density 
in the complexed structure. 
 
After refinement of 40,951 particles, we obtained a structure at 7.9 Å resolution (Figure 
7-3C/D). Comparison of the unbound to the liganded structure revealed that the structures 
appeared identical and no obvious structural rearrangements had occurred. When fitting the 
GII.17-A-tri complex X-ray crystal structure [PDB: 5LKC (98)] into the density, the A-tri 
molecules were covered, whereas at the same threshold they were not covered in the apo 
structure (Figure 7-4). However, at lower threshold also in the liganded structure the A-tri 
ligand was not covered by density. This could imply that not all binding sites were occupied, 
leading to a lower density threshold. Unfortunately, the resolution of the P domains was not 
sufficient to unambiguously define if the small A-tri molecules were present in the structure. 
As the P domains in norovirus are relatively flexible and therefore resolution is limited, we 
applied focused reconstruction on the P domains. However, resolution of the separate classes 
was not sufficient to unambiguously detect the small ligand bound to the receptor site. All 
classes exhibited a comparable tilt and rise of the P domain, suggesting no strong 
conformational differences within the particles. 
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GII.17 in complex with the small molecule inhibitor 2’FL 
In a similar experiment, we wanted to determine, whether the binding of the inhibitor 2’FL 
led to structural rearrangements. 2’FL is known to broadly inhibit attachment of noroviruses 
to HBGAs by occupying the HBGA binding site. 
 
Figure 7-5 | The Cryo-EM structure of GII.17 VLPs with 2’FL. (A) Representative raw micrograph of GII.17 
VLPs with 2’FL shows not obvious differences to unbound particles. (B) 2D classification indicates structurally 
homogeneous particles. (C) The FSC curve indicates a resolution of 5.8 Å with FSC cut-off of 0.143 (red dashed 
line, 0.5 FSC cut-off illustrated as black dashed line). (D) Cryo-EM structure of GII.17 VLPs with 2’FL exhibits 
T=3 icosahedral symmetry and no structural deviations from the apo structure were observable at this resolution. 
The particle is colored by radius, as demonstrated by the color scale. 
 
GII.17 HBGA binding can be inhibited by 2’FL, and the X-ray crystal structure of the 
P domain/2’FL complex was solved in a previous study (98). For structural analysis of the 
capsids with the compound, VLPs were incubated with 100× molar excess of 2’FL to the 
binding site and flash frozen on the cryo-EM grid. As observed with A-tri, liganded VLPs in 
vitrified ice exhibited a similar morphology as the untreated VLPs and no noticeable 
background was introduced by addition of the compound (Figure 7-5A). A dataset with 3,570 
images was collected. From 55,956 particles, we obtained a structure of 5.8 Å resolution 
(Figure 7-5 C/D). However, no large differences were visible when compared to the apo 
structure. The particles exhibited a diameter of 45 nm, with clearly raised P domains. Only 
when fitting the X-ray crystal structure of GII.17 P domain with 2’FL [PDB: 5LKG (98)] in 
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the complexed structure and in the apo structure, a difference was visible: In the complex, the 
2’FL molecules where covered by EM density (Figure 7-6). Conversely, when fitting the 
complex in the cryo-EM apo structure, no density was visible corresponding to the 2’FL 
molecules. Nevertheless, due to the high flexibility and low resolution of the P domain, it was 
not possible to definitely determine, whether the ligand was bound to the capsid. 
 
Figure 7-6 | X-ray crystal structure of GII.17 P domain in complex with 2’FL (PDB: 5LKG), fitted into the 
cryo-EM densities of GII.17 apo (A) and GII.17 with 2’FL (B). Ligands are colored in purple and highlighted 
by red arrows. In the unliganded structure, the ligands were not covered by density, in the complexed cryo-EM 
structure, the 2’FL molecules were covered. 
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7.4.  Discussion  
In this chapter we determined the structure of the VLPs of the newly clinically relevant 
genotype GII.17 Kawasaki. While the structure in general resembled the typical capsid 
morphology, several features were distinct from previously solved structures (Figure 7-7 and 
Figure 7-8). The P domains of the GII structures were raised up from the S domain, whereas 
the P domains of GI.1 Norwalk VLPs rested directly on the shell. Extended P domains have 
previously been observed for RHDV, MNV, vesivirus 2117, sapovirus and FCV (31, 86, 87). 
Due to the extension of the P domain, GII.17 VLPs were notably larger than GI.1 VLPs. 
Similarly, T=3 GII.4 VLPs had a diameter of 46 nm [Chapter 2 and (41)]. The diameter of 
GII.10 was 42 nm, 3 nm smaller than the T=3 structures of GII.17 and GII.4. This fits well 
with the observation that GII.10 had P domains that were raised, but not as pronounced as in 
GII.4 and GII.17 (Figure 7-8). T=4 GII.4 VLPs exhibited a larger capsid size of ~50 nm, with 
an inner diameter of ~32 nm (41). This can be explained by the fact that the GII.4 T=4 capsid 
incorporated 60 subunits more into the capsid than T=3 structures, leading to an overall 
increase in inner and outer diameter. 
 
Figure 7-7 | Cutout sections of different VLP structures. In GI.1, the P domains were resting directly on the 
shell. All GII structures had elevated P domains. The diameter of GII.17 was larger than GII.10, due to stronger 
extension of the hinge region. The structures are colored by diameter.  
 
A common feature of GII.4 and GII.17 VLPs is an extended hinge region connecting P and 
S domain (Figure 7-8). Both GII.4 and GII.17 are clinically relevant, so one can speculate that 
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the outstretched hinge region could confer an advantage during infection. The P domain is 
responsible for host interactions. This elongation could allow for more flexibility, permitting 
more efficient interactions with host cells, thereby increasing infectivity. 
The hinge regions of GI.1, GII.10, GII.4 and GII.17 have a sequence identity of 60-70%. 
Sequence comparison did not provide obvious reasons for the observed structural differences. 
For MNV-1 the P domains were extended as well (86). Comparison with the MNV hinge 
region demonstrated a sequence identity of only 20-30% compared to the human norovirus 
hinge regions, suggesting that the extension of the hinge was not dependent on the sequence. 
Moreover, there were no insertions within the GII genotypes compared to GI.1. In the X-ray 
crystal structure of GI.1, the hinge region formed a loop (162). Therefore, the extension could 
be due to differential intramolecular interactions, forcing the hinge into an extended 
conformation. Since all caliciviruses share the flexible hinge between the P and S domain, it 
could be possible that raised and lowered P domains are not exclusive conformations of 
certain genotypes but rather are different states occurring throughout the norovirus infection 
cycle. Indications that this might be the case have been found for MNV, where P domains 
were collapsed after treatment with the cofactor bile (183).  
Another main difference between the structures was the tilt of the P domains (Figure 7-8). GII 
P domains were similar in appearance, whereas the P dimers of GI.1 were rotated distinctly. 
In the GI.1 structure, the P domains were only connected via a loop at the quasi-three-fold 
axes, exhibiting only few intramolecular contacts between the neighboring dimers. In 
contrast, the GII P domains were tilted and the flatter part of the P domain was pointing 
towards the quasi-three-fold axes. This rotation of the P domains enabled more interactions 
between adjacent P domains, allowing the formation of a stabilizing network. The P1 domains 
were not only involved in intradimeric interactions that facilitated dimer formation, but also 
participated in interdimeric interactions between individual dimers. As this tilt occurred only 
in the structures with raised P domains, it is possible that these interactions are necessary for 
stabilization and prevent the P domains from collapsing onto the shell. Extensive interactions 
between the P domains at the quasi-three-fold axes have also been observed in the structure of 
elevated MNV P domains (86). 
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Figure 7-8 | Close-up on the P domains of different VLPs. For GI.1 VLPs, the P domains were distinctly 
rotated when compared to the GII structures. This was caused by the rotation due to the lowering of the 
P domains onto the shell in this capsid morphology. 
 
Attachment factors are commonly used to concentrate the virus on the cell surface without 
induction of conformational changes. Conversely, true receptors can often promote 
conformational rearrangements in the capsid to prime the virus for cell entry (231). In 
calicivirus, this has also been shown recently, where the addition of the proteinaceous 
receptors fJAM-A to FCV initiated movement of the P domains. Most importantly, receptor 
binding resulted in the formation of a portal vertex of 12 VP2 monomers that is thought to 
enter the host cell membrane and facilitate the genome delivery (32). Interestingly, the 
addition of the cofactor bile salt to MNV virions resulted in a structural rearrangement where 
the P domains were lowered onto the shell from their normally extended position (183). The 
conformational change is thought to initiate infection. This shows that in the case of MNV, 
also cofactors can induce structural rearrangements on the capsid. However, in our case, no 
structural rearrangements were observed after incubation of the VLPs with the cofactor A-tri. 
As the resolution was limited at the P domain, we could not definitively prove that the ligand 
was attached to the binding sites. Nevertheless, it is conceivable that binding of A-tri did not 
induce any major structural rearrangements. So far, the knowledge about how human 
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norovirus enters the cell is scarce. Several important cofactors, such as HBGAs and bile acids 
are known (49, 133), but their roles are not completely clear. A human norovirus host receptor 
still remains elusive. It could be possible that only binding to a receptor triggers the changes 
that are necessary for infection, as observed in FCV (32). HBGAs, such as A-tri, might only 
be important for initial attachment of the virus to the cell, thus no structural changes would be 
necessary at this point. Many viruses, e.g. herpesviruses (184, 229), flaviviruses (7, 25, 56) or 
picornaviruses (81) bind to molecules of the negatively charged glycocalyx as a first step of 
infection, only to concentrate the virus on the cell surface and enhance infection. Moreover, 
not all virus receptors are imposing structural rearrangements on the capsids. In some cases, 
binding to the receptor triggers signaling pathways that in turn enable cell entry (61). Due to 
this high variability of possible virus/binding factor-interactions, more detailed studies on 
which roles the different norovirus binding factors are assuming are urgently needed. 
Additionally, higher resolution information, where the small cofactors are visible would be 
needed to determine unambiguously that the HBGAs did not introduce structural 
rearrangements. 
Another possibility is that rearrangements can only occur in the context of the intact virion 
and not in VLPs only assembled from VP1. In both cases where extensive structural 
rearrangements have been reported for caliciviruses [MNV (183) and FCV (32)], experiments 
were done with intact virions, as opposed to empty VLPs in our experimental setup. 
Additional interactions of VP1 with VP2, or the VPg-linked genome could aid in facilitating 
the necessary rearrangements. 
In former studies, it has been shown that 2’FL was able to inhibit the attachment of VLPs to 
PGM, by acting as a cofactor decoy and blocking the HBGA binding site (98, 220). However, 
it is possible that next to this direct blocking effect, the sugar has additional effects on the 
virus that lead to the loss of HBGA binding ability. In our structure, the P domains appeared 
to be bound to 2’FL, but due to the high flexibility of the P domain and the lowered 
resolution, the ligand could not be placed unambiguously. Nevertheless, it is conceivable that 
binding of 2’FL has no effect on the structural integrity of the virus, as simple blocking the 
binding site would suffice to efficiently inhibit HBGA binding. 
In summary, we found that GII.17 VLPs exhibited the characteristic norovirus morphology. 
P domains were in a raised state, which further indicates that extended P dimers are the most 
common P domain state in norovirus. Moreover, our results suggest that neither the binding 
factor A-tri, nor the small molecule inhibitor 2’FL induced large structural rearrangements on 
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the GII.17 capsid. Whether the human norovirus capsid is primed by structural 
rearrangements to initiate infection is still to be determined. 
 
	 Chapter	5		
 105 
8.  Chapter 5: Structural analysis of MNV in complex with 
Nanobodies and ions 
8.1. Summary 
In this chapter we solved the structure of murine norovirus (MNV) virions alone and in 
complex with a neutralizing Nanobody. In the apo state, MNV appeared as a typical T=3 
icosahedral norovirus, with raised P domains. 
In the complexed structure, the Nanobody forced the MNV P domains into distinct 
conformations to allowed binding at all available epitopes. Incubation of MNV virions with 
divalent cations (Mg2+ and Ca2+) led to a collapse of the P domain onto the shell, a 
conformational rearrangement that seems to enable efficient MNV infection. Importantly, 
binding of the Nanobody appeared to inhibit this structural rearrangement, thereby effectively 
inhibited viral infection. 
8.2. Contributions 
The results in this chapter were gained as a part of collaborative work: Dr. Anna 
Koromyslova and Virginie Malak cloned and purified the Nanobodies and MNV virions. 
Dr. Anna Koromyslova performed the biochemical characterization of the Nanobodies 
(ELISA, cell attachment and entry assays, ITC). Dr. Turgay Kilic and Dr. Charles Sabin did 
X-ray crystallography experiments. I was working on the cryo-EM structures of MNV apo, 
together with Dr. Charles Sabin, and MNV in complex with NB-5829, MgCl2 and CaCl2, and 
NB-5829/MgCl2. All authors analyzed the data, and wrote and commented on the paper that is 
currently under review and published on a preprint server: 
Koromyslova AD*, Devant JM*, Kilic T, Sabin CD, Malak V, Hansman GS. 2020. 
Nanobody mediated neutralization reveals an Achilles heel for norovirus. bioRxiv 
doi:10.1101/2020.02.07.938506:2020.02.07.938506. 
(* = equal contribution) 
 
Figures from this chapter were taken and adapted from this manuscript. 
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8.3. Results 
Prior results: Biochemical and structural characterization of MNV-specific Nanobodies 
MNV is commonly used as a model system for human norovirus, as a reliable cell culture and 
reverse genetics system are available. In this study, we focused on Nanobodies raised against 
MNV virions, to characterize their neutralization potential and define how those Nanobodies 
are inhibiting infection. 
Generally, two types of Nanobodies were found and structurally characterized by X-ray 
crystallography: One type bound to the upper part of the P domain and was able to neutralize 
infection by competing with the cellular receptor CD300lf (150). The second group of 
Nanobodies bound to an epitope at the lower part of the P domain, so no direct interference 
with binding factors or receptors was found (Figure 8-1). Cell culture assays indicated that the 
Nanobodies binding to the lower part of the P domain were most likely affecting post-receptor 
binding steps, but from cell culture assays and ITC measurements alone, no mode of 
inhibition could be determined. 
 
Figure 8-1 | Binding sites of MNV specific Nanobodies. X-ray crystallographic data revealed that NB-5853 
(blue) and NB-5867 (lavender) bound to the top of the MNV P domain. The binding sites of these Nanobodies 
overlapped with the binding sites of the proteinaceous receptor CD300lf (green). NB-5820 (salmon) and 
NB-5829 (pink) were binding to the lower side of the P domain and interacted with both VP1 monomers in a 
P dimer. Also shown is the binding site of the bile acid GCDCA (orange). Dr. Turgay Kilic and Dr. Charles 
Sabin solved and refined the X-ray crystal structures; Dr. Charles Sabin prepared the figure. Figure adapted from 
(103). 
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Dr. Anna Koromyslova, Dr. Turgay Kilic and Dr. Charles Sabin have performed these prior 
experiments. In the following experiments, we used single particle cryo-EM to elucidate the 
mode of inhibition for the Nanobodies binding to the bottom of the P domain. 
 
The structure of MNV virions in an unbound state 
In former studies, the MNV structure has been elucidated using cryo-EM to a resolution of 
~8 Å (87). In order to have higher resolution information to compare how Nanobodies 
influence the structure, we first determined the structure of MNV in an unbound state. In a 
first dataset 4,046 images were collected. 15,770 particles were used for final reconstruction 
with a nominal resolution of 4.1 Å. However, the P domains were only visible as blurred 
densities. Smearing of densities can be caused by incoherent averaging. Therefore, we applied 
focused reconstruction on the VP1 dimers, to resolve this heterogeneity between the single 
VP1 dimers. Indeed, application of focused reconstruction on the P domain dimers revealed 
that 20% of the A/B- and 25% of the C/C dimers showed a lowered P domain morphology, 
instead of the typical elongated hinge region and subsequently elevated P domain (Figure 
8-2). 
 
Figure 8-2 | Comparison of raised and lowered P domains on the MNV capsid. The classes were separated 
by focused reconstruction on the P domain dimers. Shown are two representative classes of raised and lowered 
P domains of a C/C dimer (grey) fitted with the X-ray crystal structure of MNV (PDB: 3LQ6, blue cartoon).  
P domain 
raised 
P domain 
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Comparison of different P domain conformations indicated that upon collapse of the hinge 
region, the P domain dimers were rotated by ~104º relative to the extended P domain 
conformation. 
To confirm that this was not due to two separate populations of virions, one with only lowered 
and one with only extended P domains, a heterologous refinement was performed in 
cryoSPARC, where two distinct starting models are presented [GI.1 – lowered P domains 
(162) and MNV- raised P domains (87)], to facilitate the separation of two distinct classes. 
Both obtained structures were similar, with well-resolved S domains and fuzzy P domains. 
This suggested that the two conformations indeed were present on the same particles. 
 
Figure 8-3 | Cryo-EM processing of MNV virions. Left shows a raw micrograph of the virions (scale bar 
represents 100 nm), the middle figure is the central section of the reconstruction, revealing that the P domains 
are of lower resolution than the shell. The FSC curve (right) indicates a resolution of 4.6 Å at 0.143 FSC cut-off. 
Figure adapted from (103). 
 
The sample we used for this first structure determination was stored for several months at 
4 ºC. As so far, only raised P domains were reported for MNV (87) we decided to repeat the 
experiment with a freshly purified MNV sample. Also here, particles were well distributed in 
the ice and a dataset with 1,588 images was collected (Figure 8-3).  
 
Figure 8-4 | Cryo-EM structure of the MNV virion. The capsid is shown in whole (left) and in cutout section 
(right). The P domains were all extended. Nevertheless, the P domain resolution was lower than for the 
S domain. Due to the icosahedral reconstruction, the RNA (red) could not be resolved. 
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From the raw data, no obvious differences were observed compared to the first dataset. 21,424 
particles were used for the final reconstruction that had a resolution of 4.6 Å, and P domains 
that appeared to be all raised (Figure 8-3 and Figure 8-10 left). Subsequent focused 
refinement on both A/B and C/C dimers confirmed that all P domains were indeed in a raised 
state. This result suggested that during the long storage, the virions used in the first 
preparation became unstable, causing a proportion of the P domains to collapse onto the 
particles. As both samples were purified in the same way and stored in PBS, effects due to 
differences in the buffer or purification method could be excluded. 
 
Figure 8-5 | Model of top and bottom Nanobodies bound to the MNV capsid. The X-ray crystal structure of 
P domain and Nanobody (cartoon, P domain in blue, NB-5853 turquoise, NB-5867 lavender, NB-5820 salmon, 
NB-5829 purple) was fitted into the cryo-EM density of the MNV virion. In all cases, Nanobodies were clashing 
with adjacent Nanobodies at full occupancy at both three-fold (left) and five-fold (right) icosahedral axes. 
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Bottom Nanobodies 
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Fitting of P domain/Nanobody X-ray crystal structures onto the apo cryo-EM density revealed 
clashes at full occupancy: For both, top (NB-5853 and NB-5867), and bottom binding 
Nanobodies (NB-5820 and NB-5829), the Nanobodies were clashing with adjacent 
Nanobodies when all binding sites were occupied, suggesting that in this capsid conformation 
not all epitopes were available (Figure 8-5). Consequently, this would indicate that either, 
Nanobodies were not able to bind to all available binding sites due to space restraints, or that 
the Nanobody binding forced structural rearrangements onto the capsid to facilitate the 
occupation of all epitopes. 
 
The structure of MNV in complex with NB-5829 
To further define how the Nanobodies were neutralizing the MNV infection, and if and how 
the Nanobody binding influenced the virion structure, we wanted to determine the structures 
of virions in complex with Nanobodies. Binding of Nanobodies with epitopes overlapping the 
CD300lf binding site (NB-5853 and NB-5867) led to aggregation of the particles, so no 
single-particle analysis could be performed. 
 
Figure 8-6 | Cryo-EM processing of MNV virions in complex with NB-5829. Left shows a raw micrograph of 
the complexes (scale bar represents 100 nm), the middle figure is the central section of the reconstruction. The 
FSC curve (right) indicates a resolution of 4.7 Å at 0.143 FSC cut-off. Figure adapted from (103). 
 
Virions bound to the bottom-binding Nanobody NB-5829 however, were still separated in the 
ice and a dataset of 3,599 images was collected and analyzed (Figure 8-6). 32,612 particles 
were used for the final icosahedral reconstruction of 4.7 Å resolution (0.143 cut-off). Even 
though the S domains were resolved well, the P domains appeared as smeared densities and 
were of lower resolution than the S domain, again indicating structural differences within the 
P domain dimers on the capsid (Figure 8-7).  
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Figure 8-7 | The cryo-EM structure of MNV virion in complex with NB-5829. After icosahedral 
reconstruction, additional densities at the P domains were visible, indicating bound Nanobodies. The structure is 
colored by radius, as indicated by the color scale. The P domains were of lower resolution than the shell, 
suggesting movement of this domain. Figure adapted from (103). 
 
By applying focused reconstruction on the P domain/Nanobody complexes, we found that 
indeed all classes had two Nanobodies bound to the P domain dimers. This indicated that also 
in context of the intact particle, two Nanobodies had bound per dimer (Figure 8-8A). Overlay 
of the complexed X-ray crystallography structure indicated a good fit. This revealed that the 
Nanobodies bound to the same binding site and in the same manner on the virions as they did 
to isolated P domains. 
Moreover, we found that the P domains exhibited several different rotations, relative to the 
S domain, with up to 31º tilt between different A/B dimer conformations and 34º tilt between 
C/C dimer conformations (Figure 8-8B). These differences could result in incoherent 
averaging of the P domains and smearing of the P domain densities, as observed in the 
icosahedral reconstruction of the particles. In contrast, in the apo structure a tilt of only 2º in 
A/B- and 12º in C/C dimers was measured, indicating the Nanobody attachment did not 
stabilize the P dimer. Instead, it led to stronger structural deviations within the single P dimers 
on the capsid. Moreover, when compared to the apo structure, we found that the P domains 
were rotated by ~70º. These results indicated that the Nanobodies were forcing the P domains 
in new and diverse positions, most likely to accommodate the binding of Nanobodies to all 
binding sites. This movement of the P domain upon binding of the Nanobody highlights the 
high flexibility of the capsid, in particular of the hinge region connecting S and P domains. 
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Figure 8-8 | Focused reconstruction of P domains in complex with NB-5829. (A) Representative classes of 
A/B and C/C dimers after focused reconstruction. The densities have the X-ray crystal structure of MNV 
P domain (grey cartoon) and NB-5829 (purple cartoon) fitted. (B) To compare the of P domain tilt, two focused 
reconstruction C/C dimer classes were overlaid (light blue and dark blue). P domains are shown in side view (left 
panel), cutout section (middle panel) and top view (right panel). The P domains showed strong tilt of the 
P domain between the different classes, up to 34º. Conversely, the shell remained rigid. Figure adapted from 
(103). 
 
The influence of MgCl2 or CaCl2 on the MNV capsid morphology 
All these results however, did not aid in elucidating the exact mechanism of neutralization. 
Recently, it was proven that binding of an important cofactor, bile salt, induced structural 
rearrangements in the MNV capsid: The P domain collapsed onto the shell, thereby causing a 
rotation of the P domains (183). Even though it is not yet known why this movement is 
important, infectivity is decreased in the absence of bile, suggesting that this structural 
rearrangement facilitated infection. Interestingly, in ITC experiments done by Dr. Anna 
Koromyslova, we found that the addition of CaCl2 to MNV P domain had the same effect on 
Nanobody binding as the addition of bile salt. 
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Figure 8-9 | Cryo-EM processing of MNV virions in complex with Ca2+ and Mg2+. Left shows raw 
micrographs of the virions (scale bar represents 100 nm), the middle figures are the central sections of the 
reconstructions. In these structures, both P and S domain were well resolved. The FSC curve (right) indicates 
resolutions of 4.6 and 4.3 Å for MNV with Ca2+ and Mg2+, respectively (0.143 FSC cut-off). Figure adapted from 
(103). 
 
Therefore, we went on to determine the structure of the capsid in complex with Ca2+ and Mg2+ 
in order to analyze potential structural rearrangements of the capsid as a result of ion binding 
(Figure 8-9).  
Two datasets for MNV virions incubated with 10 mM CaCl2 or 10 mM MgCl2 were collected 
and data was processed using icosahedral reconstruction. The structures were solved to 4.6 
and 4.3 Å resolution, respectively. In both structures, the P domains were clearly resting on 
the shell, and were remarkably similar to the structure of virions in complex with bile salts 
(183). This suggests that the different compounds induced the same conformational changes 
(Figure 8-10). Moreover, the P domains were resolved to a higher resolution than in the apo 
structure. This suggests that the lowering of the P domain onto the shell stabilized the 
structure and reduced the movements of the P domains that, in the apo structure, prevent the 
averaging of the P domains to a high resolution.  
Resolution (1/Å)
FS
C
0.0 0.1 0.2 0.3 0.4
0.0
0.2
0.4
0.6
0.8
1.0
Resolution (1/Å)
FS
C
0.0 0.1 0.2 0.3 0.4
0.0
0.2
0.4
0.6
0.8
1.0MNV + MgCl2 
MNV + CaCl2 
	 Chapter	5		
 114 
 
Figure 8-10 | Comparison of the unbound MNV structure with the ion bound MNV capsids. (A) Intact 
capsids show that the ions induced a collapse of the P domain onto the shell that subsequently led to a 
stabilization of the structure. Addition of CaCl2 and MgCl2 had an equal effect on the capsid. (B) Cutout sections 
of the capsid show the elongated hinge region in the apo structure, compared to the collapsed structures, where 
the hinge was folded into a loop. Consequently, the gap between the P and S domain that is present in the 
unbound structure is absent in the collapsed form. (C) Close-up on a single VP1 dimer, fitted with the X-ray 
crystal structure of MNV P domain (PDB: 3LQ6) shows how the C’D’ loop was folded down in the apo 
structure and in an upwards conformation upon ion binding. For the apo structure, a representative focused 
reconstruction class is shown, as in the icosahedral structure, resolution was limited in the P domains The loop is 
highlighted by a red arrow. The structures are colored by radius, according to the color scale. 
 
Comparison of collapsed and extended P domains showed that, when collapsing, P domains 
were moving 114º in a clockwise direction (Figure 8-10B). Moreover, we found that the C’D 
loop, which was in a closed conformation in the apo structure, was in an opened conformation 
in the lowered state (Figure 8-10C). This loop movement is thought to facilitate the binding of 
the receptor to the P domain, as in a closed conformation, affinity of the receptor to the 
P domain was only low (145).  
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The cryo-EM structure of MNV in complex with both Mg2+ and NB-5829 
Superposition of the MNV P domain/NB-5829 X-ray crystal structure onto the lowered-state 
capsid density indicated that in this conformation, the Nanobodies would clash with 
neighboring Nanobodies and adjacent P domains (Figure 8-11). 
 
Figure 8-11 | Model of NB-5829 binding to lowered P domains. As a model, MNV in complex with Mg2+ was 
used (grey density), to fit the X-ray crystal structure of the P domain/Nanobody complex (cartoon, P domain in 
blue, NB-5829 in purple). In this state, the Nanobody would clash with neighboring P domains. Figure adapted 
from (103). 
 
This finding suggested that Nano-5829 binding prevented the structural rearrangement from 
the raised- to the lowered-state capsid, thereby inhibiting infection. To confirm this, we 
incubated virions with NB-5829 for 30 min at RT and then added 10 mM MgCl2 and 
determined the structure of the complex (Figure 8-12). 
 
Figure 8-12 | Cryo-EM processing of MNV virions in complex with NB-5829 and Mg2+. Left shows a raw 
micrograph of the virions (scale bar represents 100 nm), the middle figure is the central section of the 
reconstruction, showing that the S domain was more sharply resolved than the P domains. The FSC curve (right) 
indicates a resolution of 4.5 Å at 0.143 FSC cut-off. Figure adapted from (103). 
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The structure was solved to a resolution of 4.5 Å and bound to NB-5829 at all available 
binding sites (Figure 8-13). The structure closely resembled the structure of the 
virion/NB-5829 complex, suggesting that after addition of the Nanobody, the ions could 
either not bind at all or at least could not induce the lowering of the P domain onto the shell. 
 
Figure 8-13 | Cryo-EM structure of MNV virion in complex with NB-5829 and Mg2+. (A) Intact particle 
shows additional densities at the P domains at all possible binding sites, indicating bound Nanobodies. The 
structure is colored by radius, according to the color scale. (B) Close-up on a P domain dimer in side view and 
top view. The P domains were raised up from the shell by an elongated hinge region. Overall, the structure 
closely resembled the structure of MNV in complex with only NB-5829. Figure adapted from (103). 
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8.4. Discussion  
MNV is a popular system to study norovirus. Being segregated in the same genus, it is more 
closely related to human norovirus than other available model systems, such as FCV or 
Tulane virus, that are of the Vesivirus and Recovirus genus, respectively. Moreover, as cell 
culture- and reverse genetics systems are readily available (219, 225, 226), the viral life cycle 
can be studied more closely. 
Recently, CD300lf has been identified as the cellular receptor for MNV (150) and the 
discovery of this receptor has explained the inhibition modes for several already described 
antibodies (86, 97). The receptor-binding site is located at the P2 subdomain, the outermost 
part of the P domain (90). This domain harbors binding sites for cofactors, such as bile acids 
(91). Nanobodies and antibodies that bind to the upper part of the P domain often interfere 
with the binding of cofactors or the receptor, as has been shown for the top binding 
Nanobodies NB-5853 and NB-5867 that interfere with CD300lf binding. 
For the Nanobodies binding to the lower part of the P domain, the mode of inhibition was 
unclear, as the receptor was still able to bind to the capsid. Many details about the norovirus 
infection cycle are still unknown. Nevertheless, many studies in the recent years have shed 
light on at least certain aspects of the infection. It is known that cofactors, such as bile salts or 
cations, improve infection (49, 66, 91, 150, 183). Studying the cryo-EM structure of MNV 
with bile salts revealed that the P domains were collapsed instead of elevated, as they are in 
an unbound state (183), and our study confirmed that this is the case also when cations were 
added. In fact, our structures were closely matching the MNV capsid after bile salt addition, 
suggesting that cations and bile induce the same structural rearrangements. Moreover, our 
results have, unknowingly, been confirmed in another study, where the cryo-EM structure of 
MNV was solved in a buffer that contained both MgCl2 and CaCl2. In the study, collapsed 
P domains were reported, but the reason was unclear to the authors. Nevertheless, our findings 
imply that the structural rearrangement they observed was caused by the presence of MgCl2 
and CaCl2 in the buffer (192). 
Taken together, this indicates that the lowering of the P domains onto the shell is an essential 
conformational change to enable infection. Our data suggests that NB-5829 inhibits the 
P domain rotation and collapse onto the P domain, thereby effectively preventing infection 
(Figure 8-14). The fact that several compounds induce this conformational rearrangement 
highlights its importance, but raises the question if the presence of all compounds is required 
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for efficient infection, or if it is redundant and the presence of one type of molecule is 
sufficient to enable infection. 
To date it is not known why the collapse of the P domain is important for infection. Therefore, 
we cannot with certainty pinpoint the exact stage of the viral entry mechanism that is 
inhibited. A cryo-EM structure of a complex of MNV, bile salts and CD300lf indicated that 
due to spatial restraints it is unlikely that all binding sites can be covered by the receptor, even 
though the clashes were reduced compared to binding to the apo structure (183). It could 
therefore be possible that the P domain movement opens up more potential binding sites for 
the receptor, thereby increasing the effective valency of the viral particle. However, we 
cannot exclude that this structural change is needed for a later step in the infection cycle, e.g. 
cell entry or RNA release, and that by binding of the Nanobody not the receptor binding, but 
another, later stage of infection is prevented. 
  
Figure 8-14 | Model for mode of inhibition of the neutralizing Nanobody NB-5829. Without inhibitor, 
divalent cations, such as Mg2+ or Ca2+, or bile acids induce structural rearrangements of the P domain, in turn 
leading to the collapse of P domain onto the S domain. When NB-5829 is bound to the capsid, P domain collapse 
is prevented. The particle is still able to attach to the receptor CD300lf, but most likely, a later step in the 
infection cycle, such as cell entry or RNA release is impaired, subsequently inhibiting infection.  
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The intracellular concentration of Ca2+ is 20,000x lower than outside the cell (30), thus it is 
possible these that structural rearrangements also allow the virus to detect whether they are 
outside or inside a cell. Considering the high concentration of ions and bile salt outside of the 
cell compared to inside, it is conceivable that the collapsed form is required for cell entry. Our 
finding that ions lead to structural rearrangements are not entirely surprising, as structural 
dependence on Ca2+ has been shown for a number of non-enveloped viruses. For rotavirus, 
VP7, a protein of the rotavirus capsid, is able to bind Ca2+, and upon chelation of the ions, the 
protein undergoes antigenic changes that prevent binding of monoclonal antibodies (43). In 
high calcium environments, VP7 is arranged in a trimeric assembly that dissociates under low 
calcium conditions. This structural rearrangement was shown to facilitate capsid uncoating 
in vitro (44, 175). This is only one of many cases, where divalent cations play a role in capsid 
assembly and loss of the ions translates into capsid destabilization (18, 44, 169).  
It is still unknown whether our findings can be translated into human norovirus infections. For 
human norovirus, both raised and lowered state P domains have been reported, but only in 
different genotypes and a comparable structural rearrangement has not been observed so far 
(69, 82, 162). Therefore, it remains to be determined if a P domain collapse plays a vital role 
in the infection cycle of human noroviruses, or if this is a feature unique to MNV. For several 
genotypes, the addition of bile acid could enhance infection in vitro (49), suggesting that bile 
plays a role in human norovirus infection as well. However, so far the exact role is yet to be 
determined. Bile acid was able to attach to different human norovirus P domains (91). 
Moreover, addition of the bile acid GCDCA was able to restore HBGA binding in a supposed 
non-binder genotype, by inducing structural modifications on the P domain (91). These results 
suggested that the bile acids have the capacity to directly interact with the virus, possibly 
influencing cell attachment. Nevertheless, structural studies in context of human norovirus 
particles with bile have not been done so far. Conversely, another study found that bile acids 
influence cellular mechanisms of the host cells to provide optimal conditions for norovirus 
infection, suggesting an indirect influence of the cofactor (144). Future studies, both in cells 
and on capsids, will have to clarify the role of bile acids as a cofactors in the infection cycle 
of human norovirus. 
So far it is also not known how exactly the binding of the ions/bile salt to the upper part of the 
P domain leads to the collapse of the hinge region. The regions are distant from each other, 
but are connected through a stretch of residues. Therefore, it is possible that long-range 
interactions are causing the hinge region to ultimately collapse and lower the P domain onto 
the S domain. 
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Surprisingly, we found that also on the unliganded capsid, lowering of the P domain is 
possible, apparently without the addition of external triggers. Moreover, this was not the case 
for the whole capsid but only few P domains, suggesting that both states can be present on the 
same capsid. As so far, P domains were observed only either all elevated or all lowered, this is 
a new feature that certainly will have to be studied in more detail. This sample had neither 
bile nor ions added, therefore this result could entail that other factors could trigger the 
collapse of the P domain as well. 
Epitopes at the bottom of the P domains are more conserved and therefore, antibodies and 
Nanobodies binding to this region are more likely to be cross-reactive. In fact, even though 
the lower part of the P domain is less accessible; it appears to be relatively strongly 
immunogenic. Various different antibodies and Nanobodies have been reported to bind to the 
lower part of the P domain, and many of those have been proven to effectively inhibit 
norovirus (69, 99, 101, 176). Therefore, the lower part of the P domain might represent a 
vulnerable part of norovirus, independent of the genogroup. Of note, despite the similar 
binding epitopes, antibodies and Nanobodies were inhibiting with remarkably different 
mechanisms: GII.10 specific Nano-26 and Nano-85 for example bound to the lower part of 
the P domain of different norovirus VLPs, thereby effectively destroying the particles (99, 
101). GI.1 specific Nano-7 also bound to a lower part of the P domain, but here, no clear 
inhibition mode could be defined, as the particles remained intact and not aggregated. 
Nevertheless, HBGA binding was abolished effectively upon binding of this Nanobody (176). 
Conversely, another GI.1 specific Nanobody, Nano-62, bound an epitope close to the Nano-7 
binding site, but was not able to inhibit the attachment of VLPs to HBGAs, suggesting that 
not all epitopes at this site of the domain are vulnerable. 
In summary, we have identified a potential intermediate conformation in the norovirus entry 
pathway, while simultaneously providing an explanation how Nanobodies can prevent those 
structural rearrangements to inhibit infection. We confirmed that in an unbound state, the 
P domains of MNV are elevated and found that a P domain collapse could be induced by 
addition of divalent metal ions. This movement can be blocked by addition of a Nanobody 
that is binding to the lower part of the P domain, and this interaction effectively inhibited 
MNV infection. This highlights the importance of this movement for infection and could 
inform the future development of antivirals by targeting this essential entry pathway 
intermediate. 
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